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Samar Hussein Binkheder 
BIOMEDICAL LITERATURE MINING AND KNOWLEDGE DISCOVERY OF 
PHENOTYPING DEFINITIONS 
Phenotyping definitions are essential in cohort identification when conducting 
clinical research, but they become an obstacle when they are not readily available. 
Developing new definitions manually requires expert involvement that is labor-intensive, 
time-consuming, and unscalable. Moreover, automated approaches rely mostly on 
electronic health records’ data that suffer from bias, confounding, and incompleteness. 
Limited efforts established in utilizing text-mining and data-driven approaches to automate 
extraction and literature-based knowledge discovery of phenotyping definitions and to 
support their scalability. In this dissertation, we proposed a text-mining pipeline combining 
rule-based and machine-learning methods to automate retrieval, classification, and 
extraction of phenotyping definitions’ information from literature. To achieve this, we first 
developed an annotation guideline with ten dimensions to annotate sentences with evidence 
of phenotyping definitions' modalities, such as phenotypes and laboratories. Two 
annotators manually annotated a corpus of sentences (n=3,971) extracted from full-text 
observational studies’ methods sections (n=86). Percent and Kappa statistics showed high 
inter-annotator agreement on sentence-level annotations. Second, we constructed two 
validated text classifiers using our annotated corpora: abstract-level and full-text sentence-
level. We applied the abstract-level classifier on a large-scale biomedical literature of over 
20 million abstracts published between 1975 and 2018 to classify positive abstracts 
(n=459,406). After retrieving their full-texts (n=120,868), we extracted sentences from 
their methods sections and used the full-text sentence-level classifier to extract positive 
sentences (n=2,745,416). Third, we performed a literature-based discovery utilizing the 
positively classified sentences. Lexica-based methods were used to recognize medical 
concepts in these sentences (n=19,423). Co-occurrence and association methods were used 
to identify and rank phenotype candidates that are associated with a phenotype of interest. 
We derived 12,616,465 associations from our large-scale corpus. Our literature-based 
associations and large-scale corpus contribute in building new data-driven phenotyping 
definitions and expanding existing definitions with minimal expert involvement. 
Josette Jones, RN, Ph.D, Chair 
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CHAPTER ONE: INTRODUCTION 
 
1.1 Background 
Adverse drug events (ADE) are a big concern in health care, leading to significant 
costs, morbidity, and mortality (Eriksson, Werge, Jensen, & Brunak, 2014; "U.S. Food and 
drug administration. Preventable Adverse Drug Reactions: A Focus on Drug Interactions," 
2018). It has been estimated that over 2 million serious ADE are reported yearly ("U.S. 
Food and drug administration. Preventable Adverse Drug Reactions: A Focus on Drug 
Interactions," 2018). In the first quarter of 2017, the U.S. Food and Drug Administration 
(FDA) reported around 297,010 serious outcomes and around 44,693 deaths due to ADEs 
(Somnath Pal, 2017). The annually estimated cost to manage ADEs in the United States is 
up to 30.1 billion dollars due to hospitalizations, prolonged hospital stays, and prescriptions 
to treat ADEs (Sultana, Cutroneo, & Trifiro, 2013). The Institute of Medicine has defined 
an ADE as an unintended drug-related “injury caused by medical management”, and they 
note that most ADEs can be prevented (Homsted, 2000). Furthermore, polypharmacy, 
where a patient is taking more than one drug, increases the risk of drug reactions ("U.S. 
Food and drug administration. Preventable Adverse Drug Reactions: A Focus on Drug 
Interactions," 2018). Serious adverse events should be reported to the FDA, such as death, 
life-threatening, hospitalization, disability, permanent damage, or birth defects ("U.S. Food 
and drug administration. What is a Serious Adverse Event?,"). 
Pharmacovigilance is “the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 
problems” (Organization, 2002). One of the main objectives of pharmacovigilance is the 
early detection of novel and underreported adverse events and drug correlations (Rave 
Harpaz, Haerian, Chase, & Friedman, 2010) as a part of post-marketing drug discovery. A 
sub-domain of pharmacovigilance is pharmacoepidemiology that aims in quantifying 
ADEs in a large population (de Vries & de Jong-van den Berg, 2001). Aims of 
pharmacovigilance and pharmacoepidemiological research includes: early detection of 
ADEs as well as identification of contributing risk factors and its quantitative aspects (de 
Vries & de Jong-van den Berg, 2001). Post marketing surveillance is important to detect 
both anticipated and unanticipated adverse effects (Czaja et al.). Studies show that early 
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discovery of post-marketing ADEs (R. Harpaz et al., 2013) and identification of causes is 
necessary to decrease the occurrence harmful events (Tache, Sonnichsen, & Ashcroft, 
2011). Post-marketing research provides the opportunity to study factors that contribute to 
the risk of ADE in general population, such as pharmacokinetics in patients with organ 
impairment, drug’s dose and frequency, and genotype (Sultana et al., 2013). 
There are two major sources for mining ADE-drug associations: spontaneous 
voluntary reporting and electronic health records (EHRs). FDA Adverse Event Reporting 
System (FAERS) is an example of a spontaneous voluntary reporting system where health 
professionals, consumers, and manufacturers send reports of adverse events. EHRs have 
become an emerging source for pharmacovigilance, which is similar to FAERS, support 
hypothesis generation in areas like drug-adverse effect associations (Castro et al., 2014). 
Unlike the challenges of voluntary reporting of suspected ADEs (e.g. bias and 
underreporting), EHRs longitudinal data is capable of providing measurements of drug’s 
harm in actual patients (Eriksson et al., 2014) using medications in real-world settings 
(Castro et al., 2014) contributing to advancement of the medical knowledge ("U.S. Food 
and drug administration. Preventable Adverse Drug Reactions: A Focus on Drug 
Interactions," 2018). However, it also can add some challenges when conducting EHR-
based studies for ADEs or any phenotype. 
 
1.2 Problem Statement 
Even though EHR secondary research helped in advancement of the overall 
population health, it accompanied with several challenges. To conduct an EHR-based 
study, one of the earliest stages in EHR mining is the identification of a cohort of specific 
cases (Q. Li et al., 2014) which needs a phenotyping case definition. These phenotyping 
case definitions might not be readily available for all conditions, especially when dealing 
with large-scale phenotypes. Furthermore, conventional methods to create new case 
definitions require experts’ knowledge or to use existing case definitions require literature 
evidence and reviews. Either of these methods can be time-consuming and labor-intensive. 
Within the EHR setting, incorrectly identified phenotypes cases can result in unreliable and 
biased results (Macdonald, Kilty, & van Walraven, 2016). Therefore, we have identified 
the lack of availability of phenotyping definitions for many cases of interest or their 
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inconsistencies (Hansen et al., 2013; R. L. Richesson, Hammond, et al., 2013) as a 
knowledge gap, which creates a barrier when a researcher needs to identify cases for EHR-
based research. 
With this, there is a need to develop informatics approaches and data-driven 
approaches to define cases (Lasko, Denny, & Levy, 2013) on large-scale settings (Rubbo 
et al., 2015). Utilizing biomedical literature, there is a need to discover and understand the 
repeatable patterns and relationships of phenotypes that help in building new phenotyping 
case definitions and support existing definitions (Overby et al., 2013; Rasmussen et al., 
2014). Such health informatics tools help to utilize literature-based phenotype definitions 
information for future applications (Kirby et al., 2016; Rasmussen et al., 2014) and to 
support the knowledge-discovery of unknown relationships across these phenotypes. 
Based on our research interest, the cases of interest for this work are primarily 
derived as phenotypes with an evidence to be an ADE (Duke et al., 2012; H. Y. Wu, Zhang, 
Desta, Quinney, & Li, 2017). However, several other phenotypes were included because 
some are considered confounding, risk factors, or other clinical concepts. In other words, 
our proposed approach is generalizable to not only ADE cases, but also to other phenotypes 
and diseases. 
 
1.3 Overview of the Dissertation 
This dissertation presents an informatics approach for mining phenotyping 
definitions in the biomedical literature. We developed a text-mining pipeline combining 
rule-based and machine-learning methods to automate retrieval, classification, and 
extraction of phenotyping definitions’ information from literature. To our knowledge, there 
is no existing work for mining literature-based phenotyping definitions. To achieve this 
goal, we proposed three Aims. 
Aim 1. Develop a corpus for annotating phenotyping case definitions in published 
literature. An annotated corpus is needed for building and evaluating text-mining tools. As 
a starting point, we created a list of phenotype of interest to collect abstracts and full texts. 
These phenotypes were ADEs that were selected from an observed ADE evidence in 
previously published in-vitro Pharmacokinetics (PK), in-vivo PK, and clinical 
Pharmacodynamics (PD) studies. Moreover, we analyzed the presentation of phenotyping 
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case definitions in the biomedical literature to identify sections where this information can 
be located. A new annotation schema is developed to manually annotate a corpus on a 
sentence level. One of the major goals for developing the annotated domain-specific corpus 
is to serve as a gold standard for developing text-mining tools (J.-D. Kim, Ohta, & Tsujii, 
2008) that is accomplished in Aim 2. 
Aim 2. Automated extraction of sentences with phenotyping case definitions from 
biomedical literature. These ADE terms served as the building block for developing our 
dictionary and lexica, corpus, and text-mining pipeline. For building the lexica, a 
comprehensive dictionary was developed using standard terminologies reflecting major 
entities, including clinical diagnoses, procedures, and drugs. This dictionary can assist in a 
number of text-mining tasks, such as named entity recognition (NER), information 
retrieval, and information extraction. Moreover, we developed a text-mining pipeline that 
will be composed of two levels of classification. First, Abstract-level classifier to retrieve 
abstracts with relevant studies describing phenotyping definitions. Second, Full-text 
sentence-level classifier to classify sentences within methods sections of the full text with 
that show evidence of phenotyping case definitions. These classifiers will utilize 
informatics approaches of text-mining, machine learning, and rule-based. The validated 
classifiers are applied on a large-scale literature and further information extraction and 
knowledge discovery is performed in Aim 3. 
Aim 3. Perform a discovery-based study to evaluate and validate literature-based 
phenotyping case definitions of selected phenotypes. In this Aim, we will utilize sentences 
with evidence of phenotyping case definitions from the large-scale screening of literature 
as well as the lexica and dictionary (from Aim 2). We aimed to use a data-driven approach 
to prioritize the co-occurrence of terms for a phenotype of interest in literature. Moreover, 
an approach was proposed to rank the sentences for each ADE of interest based on its 
significant associated terms. Lastly, we will compare, validate, and evaluate the results of 






Figure 1 Theoretical model for the dissertation 
 
1.4 Significance 
First, to facilitate the utilization of EHRs for clinical research. Here we consider 
ADEs as an example of that we use in this dissertation. Studies showed that experimentally 
validating large numbers of drugs-ADEs associations is not feasible and the use of multiple 
resources that together would be able to derive true supportive evidence of these 
associations (Banda, Callahan, et al., 2016). Spontaneous voluntary reporting, such as 
FAERS, have been widely used for signal detection of ADEs. However, the spontaneous 
voluntary reporting suffers from some limitations, such as bias in reporting, lack of 
causality ADE-drug relationship, incomplete data, and duplicated reports. For example, 
ADEs signal scores from FAERS data by themselves do not provide causal ADE-drug 
relationship when used by itself. Instead, FAERS data provide advantage for mining ADE-
drug associations in initial stages of ADE-drug discovery as a guiding resource rather than 
hypothesis generation. Therefore, it is necessary to utilize other resources, such as 
biomedical literature and EHRs, to generate ADE-drug causal relationships and hypotheses 
(R. Harpaz et al., 2012). EHRs are a potential resource to support translational research 
and hypothesis generation in areas of drug safety (Yao, Zhang, Li, Sanseau, & Agarwal, 
2011), and to better understand health outcomes. However, there are several requirements, 
which majorly is the availability of phenotyping case definitions for building the 
appropriate cohort of cases, which we are addressing in this work. 
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Second, to support the biomedical research towards high-dimensional drug 
interactions in EHRs. Here we extends our example of ADEs research on the need to 
support high-dimensional discovery, which is necessary as a part of pharmacovigilance 
research in which the identification of ADEs during the post-marketing stage (Banda, 
Evans, et al., 2016). However, there are still limitations where existing studies mostly work 
on a small scale of associations (Duke et al., 2012), and tend to use traditional methods to 
identify associations of single drugs and single ADE phenotypes (L. Li, 2015). On the other 
hand, clinical trials are capable of capturing multiple phenotypes, but they suffer from low 
sample size and lack “real world” factors that contribute to the efficacy of drugs. Some 
examples of mining high-dimensional ADE-drug associations (L. Li, 2015) are the 
identification of six novel DDIs that increased the risk of myopathy (Duke et al., 2012). 
Another example is the identification of 171 novel drug interactions associated with eight 
(L. Li, 2015; Tatonetti, Fernald, & Altman, 2012). Therefore data mining approaches are 
capable of expanding the dimensions of associations in health records (L. Li, 2015). This 
expansion requires also scaling up the phenotyping process and their definitions by using 
data-driven and data mining approaches. 
Identifying health outcome of interest (HOI) is still a concern in observational 
studies (Fox et al., 2013). For example, Zhang et al. have developed a statistical model to 
identify high-dimensional myopathy-drug associations in EHR. Myopathy definition was 
adopted from literature and were mapped to the concept IDs of Observational Medical 
Outcomes Partnership (OMOP) Common Data Model (CDM) (Zhang et al., 2015). 
However, when dealing with large number of ADEs, there is a need to more scalable 
methods for defining ADEs in EHRs. Accurate definitions are critical in building cohort of 
patients experiencing ADEs and should be matched with study’s goals. De Bie et al. in 
their drug safety surveillance study defined several ADE phenotypes of interest, such as 
acute liver injury and upper gastrointestinal bleeding, using iterative process that was 
initiated by using clinical criteria published in the literature. Diagnosis codes, laboratories, 
and clinical notes were used to define these ADE phenotypes (de Bie et al., 2015). De Bie 
et al. stated that their cohort selection has affected the estimation of statistical power of 




“The extrapolation of relevant safety outcomes from adults to children does 
not always work and that it is very important to choose age appropriate 
events and definitions when setting up EHR-based pediatric surveillance 
systems” (de Bie et al., 2015). 
 
In the following sections, we identified the challenges associated with developing 
or using standard phenotyping definitions. 
Third, developing new phenotyping definitions is complex. Such development 
process generates several potential challenges that elaborate in the complexity and 
inconsistency of the phenotyping definitions. The first challenge is that the development 
of a new case definition is a long, time-consuming, and labor-intensive process (Lasko et 
al., 2013; Park & Choi, 2014). A multidisciplinary team works on developing and 
designing phenotyping definitions for mining EHR data where manual review, multiple 
iterations, and validation can be also needed (Carroll, Eyler, & Denny, 2011). Further, such 
a process requires an extensive manual review of EHR charts. For example, Hsu et al. 
developed an algorithm to identify chronic rhinosinusitis (CRS) cases and controls using 
ICD-9 International Classification of Diseases, Ninth Revision (ICD-9) and Current 
Procedural Terminology (CPT) codes. They validated the algorithm using manual chart 
review as the reference standard (Hsu, Pacheco, Stevens, Smith, & Avila, 2014). As a part 
of the manual chart review, the authors identified the need of reviewing the encounter notes 
and CT sinus results, which was held by two reviewers and took a length of 40 hours for 
reviewing only 200 cases. Therefore, such algorithm development process cannot be 
scalable to a bigger set of phenotypes or ADEs (Hsu et al., 2014). Even though several 
Natural Language Processing (NLP) tools have been developed in the medical domain, 
clinical narrative is the most challenging part of the phenotype definition development 
because it requires extensive human involvement (Park & Choi, 2014). Therefore, using 
common terminologies and expanding dictionaries can support newly developed NLP tools 
for mining ADE phenotypes in EHR. 
The second challenge, the multiple cycles of communication during the 
development process of case definitions can be time-consuming, inflexible, and error-
prone. One traditional way of developing new definition is expert-driven, an iterative 
process that requires multiple cycles of communication between the clinical researcher and 
the data analyst. The clinical researcher usually uses the phenotype definition in a human-
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readable format. On the other hand, the data analyst’s role is to convert the phenotype 
definition from the human-readable format into the computable format. However, 
mismatches between the desired definition and the computable definition are highly 
possible (Xu et al., 2015). Communication challenges can also arise due to the 
multidisciplinary nature needed for developing the phenotype definition where it requires 
input from different medical professionals, such as geneticists, clinicians, informaticians, 
and epidemiologists (Mo et al., 2015). Therefore, creating a source that supports scientific 
collaboration for these definitions will be imperative. 
The third challenge, after the development process, many case definitions lack 
portability across different institutions, which can affect phenotyping definitions’ 
generalizability.  One of the important aspects for any phenotyping definition is portability 
across different EHR systems and/or institutions, especially when applying complex 
selection criteria. The nature of phenotyping definitions across different studies can be 
highly diverse and inconsistent, which is a recognized problem between different 
institutions (Christley, Duffy, & Martin, 2012; Rubbo et al., 2015). Definition portability 
facilitates comparing, sharing, validating, assessing, and disseminating of phenotyping 
definitions (Simonett et al., 2015). The validation step across multiple institutions is 
important to ensure that the definition is performing well across different populations 
(Liao, Ananthakrishnan, et al., 2015). A major player to the lack of portability is the lack 
in consistency between different EHR systems in recording clinical data (Malinowski, 
Farber-Eger, & Crawford, 2014). This can be also true in clinical data that are presented in 
the biomedical literature, as clinical researchers tend to report the same clinical terms 
differently. In addition, Hsu et al. stated that definition generalizability can be affected by 
variations in clinical use of standardized codes between different individuals, centers, or 
specialties (Hsu et al., 2014). Therefore, it is recommended to share phenotyping 
definitions to improve portability and generalizability (Overby et al., 2013). Properly 
documenting published phenotyping definitions in the literature can have an important role 
in discovering the patterns that can cause lack of portability across different phenotyping 
definitions. 
Fourth, literature-based phenotyping definitions are critical, but still not scalable. 
Reporting phenotyping case definitions is very inconsistent in studies where it can even 
 
9 
lack some broad or basic description (Yao et al., 2011). The variation of these definitions 
and lack of their availability can inhibit the research of ADEs (Christley et al., 2012; Rubbo 
et al., 2015). The variation in textual descriptions of the phenotyping defining is one of the 
biggest challenges of implementing existing phenotyping definitions. Inconsistency can be 
due to the fact that there is no internationally agreed standard that assists in conducting and 
reporting phenotyping definitions as well as its validation studies (Rubbo et al., 2015). This 
can result in an inconsistent implementation and interpretation of the definitions because 
of variation in concept granularities and ambiguities. Several factors contributed to the 
variations and inconsistencies of definitions that were published in observational studies 
including the increase use of EHR data and other data sources, and the use of standard 
codes (e.g. ICD- codes) (Shankar-Hari et al., 2016). These definitions can differ across 
different studies depending on study purpose and design. For example, Shankar-Hari et al. 
conducted three studies to develop a new definition for identifying septic shock, which was 
called to review by Society of Critical Care Medicine (SCCM) and the European Society 
of Intensive Care Med (ESICM) in January 2014. In their systematic review, 44 studies 
were identified. They stated that septic shock definitions in the literature reported different 
cutoffs and combinations for the following phenotypes “blood pressure, fluid resuscitation, 
vasopressors, serum lactate level, and base deficit” (Shankar-Hari et al., 2016). Their final 
consensus definition for septic shock was: 
 
“Adult patients with septic shock can be identified using the clinical criteria 
of hypotension requiring vasopressor therapy to maintain mean BP 65 
mmHg or greater and having a serum lactate level greater than 2 mmol/L 
after adequate fluid resuscitation” (Shankar-Hari et al., 2016). 
 
Therefore, harmonization of phenotyping definitions that were already published 
in the literature can be very effective in generating stronger phenotype definitions. 
The process of searching literature for evidence-based EHR-phenotyping 
definitions lack scalability, and can be difficult, slow, and time-consuming. However, there 
is evidence that “repeatable patterns within phenotyping algorithms exist” (Rasmussen et 
al., 2014). Using a systematic approach to learn the repeatable patterns in phenotyping 
definitions can be a strong starting point for advancing the process of their development 
and our understanding of these definitions (Rasmussen et al., 2014). Moreover, using 
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systematic approaches can improve the consistency and validity of the phenotyping 
definitions that are generated from different institutions (Overby et al., 2013). A rare 
condition called drug-induced liver injury (DILI) is an example of a case definition with 
such semantic challenge (Overby et al., 2013). Overby et al. addressed the challenge of 
harmonizing the DILI definition between two institutions, Columbia University (CU) and 
Mayo clinic. They reported that there was significant differences in DILI phenotyping 
definitions between CU and Mayo clinic. These differences are reflected by the final scope 
or goal of the study. For example, unlike DILI definition used in CU that used “DILI caused 
by any medications”, the DILI definition that Mayo clinic used was narrowed by 
medications selection as “DILI caused by a medication preparation of interest to Drug 
Induced Liver Injury Network (DILIN)”. The final harmonized definition selected the 
narrowed criteria used by Mayo clinic. They reported that factors influencing these 
differences could be due to the baseline population size, data access characteristics, and 
multiple interpretations of EHR phenotyping definitions (Overby et al., 2013). 
Literature-derived evidence can be established through extraction of evidence from 
unstructured text using combination of text-mining and data mining approaches, for 
example, extraction pairs of biological entities (Ananiadou, Kell, & Tsujii, 2006). Don R. 
Swanson describes knowledge discovery and hypothesis generation from literature as 
 
“assembling pieces of a puzzle to reveal an unnoticed, unintended, but not 
unintelligible pattern. The fragmentation of science into specialties makes 
it likely that there exist innumerable pairs of logically related, mutually 
isolated literatures”  (Swanson, 1988). 
 
In 1988, Swanson discovered a relationship between migraines and magnesium 
deficiency by identifying 11 factors common between the two conditions, which are 
 
“type A personality, vascular tone and reactivity, calcium channel blockers, 
spreading cortical depression, epilepsy, serotonin, platelet activity, 
inflammation, prostaglandins, substance P, and brain hypoxia” (Swanson, 
1988). 
 
Consequently, Swanson generated a hypothesis that supplementing food with 
magnesium can improve migraines. Unlike traditional manual literature, text-mining 
supports scalable and high-throughput research, and is capable of discovering unknown 
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associations and patterns hidden in unstructured text. Biomedicine is a “data-rich but 
hypothesis-poor science”. Accelerating knowledge discovery and hypotheses generation 
by using data-driven methods followed by experimental data validation is needed 
(Ananiadou et al., 2006).  With this, our goal in this work is to use large-scale evidence 
extracted from literature to support knowledge discovery of patterns that can assist in 
defining phenotypes in the EHRs. This can assist in the future by combining biomedical 
literature-derived knowledge with EHR to advance scientific research as well as novel 
discoveries and hypotheses generation (Ananiadou et al., 2006; Rebholz-Schuhmann, 




This work is the first, based on our knowledge, to use text-mining approaches to 
mine phenotyping definition published in the biomedical literature. Therefore, it is 
innovative in several ways. 
Development of a novel foundational informatics approach for annotating and 
mining phenotyping definitions in the literature. In this work, we analyzed the major 
patterns of phenotyping case definitions’ modalities, such as data sources, standardized 
codes, clinical, and laboratory information. This was supported by using existing 
terminologies and ontologies as well as proposing new keywords that characterize these 
phenotyping definitions. Based on the analysis of features and ontologies, we developed a 
new annotating schema to manually annotate these definitions. The gold standard corpora 
can assist in training and testing classifiers to automate the extraction of the definitions’ 
information and to eliminate the barriers of collecting these definitions. The schema, the 
corpora, and the classifier will contribute in the field of text mining of the biomedical 
information. 
A literature-based large-scale screening of evidence-based phenotyping definitions 
is capable of performing an advanced information retrieval and extraction. Consequently, 
it will introduce a new resource with a large collection of phenotyping definitions. Due to 
the fact that there is limited research in the area of validation of phenotyping algorithms in 
the literature (C. Barber, D. Lacaille, & P. R. Fortin, 2013), researchers need to conduct a 
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series of literature reviews to validate them (C. Barber et al., 2013). Therefore, the 
collection of definitions will enable research to improve, use, and validate these definitions 
as well as discover variability patterns in different definitions. 
An approach to prioritize phenotype concepts derived from large-scale corpus that 
assist in defining phenotypes and identify novel associations. Unlike previous work that 
relied on abstracts rather than full texts (Botsis & Ball, 2013), in this work we proposed 
using full texts for more comprehensive retrieval of information. According to our 
knowledge, this is the first work that uses full texts for mining published phenotyping 
definitions. 
With this, we believe that this work will lay as the foundation of literature-based 
mining phenotyping case definitions information in the field of health informatics. 
 
1.6 Description of the Chapters 
In section 1.2, we proposed three Aims to perform our literature mining and 
discovery-based study of phenotyping definitions. This dissertation is composed of five 
chapters, including this chapter (Chapter 1). Each of following chapters (two, three, and 
four) has introduction, background, methods, discussion, and results. Chapter five is the 
conclusion chapter. The description of each chapter is as the following: 
Chapter 2—this chapter is titled as “A corpus for annotating phenotyping 
definitions sentences in biomedical literature”. To address Aim 1 of this dissertation, the 
following tasks are performed in this chapter: selection of phenotypes, abstracts and full 
texts collection and selection, construction process of corpus, and annotation process as 
well as inter-annotator agreement evaluation. 
Chapter 3—this chapter is titled as “An automated text-mining approach of 
phenotyping definitions in the biomedical literature”. This chapter covers Aim 2, with the 
following tasks: building lexica and dictionary, corpus used for training and building the 
model, information retrieval and extraction, classifiers performance evaluation, and a 
literature large-scale screening pipeline. 
Chapter 4—this chapter is titled as “Discovery study to represent and validate 
literature-based phenotyping definitions”. This chapter covers Aim 3 that further extend 
the information extraction. In this chapter, we performed co-occurrence analysis on the 
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positively classified sentences, DICE coefficients for ranking phenotypes and sentences 
and for building network graphs, and validation of literature-based co-occurrence across 
three sources. 
Chapter 5—this is the discussion and conclusion chapter. It connects the results 
chapters of this dissertation and provides a discussion of the implication of this work. 
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CHAPTER TWO: A CORPUS FOR ANNOTATING SENTENCES WITH 
INFORMATION OF PHENOTYPING DEFINITIONS IN BIOMEDICAL 
LITERATURE 
 
In Chapter 1, we introduced the problem that phenotyping case definitions are not 
available for all phenotypes of interest. There are several efforts for generating phenotyping 
definitions, but the efforts in both literature-based mining and knowledge discovery of 
phenotyping definitions are still limited. Our aim is to develop an automated approach to 
mine these definitions in the literature. However, the state-of-art text-mining methods are 
based on a labeled corpus (Dogan, Leaman, & Lu, 2014; Shatkay & Craven, 2012). 
Therefore, the goal of this Aim is to build corpora and guidelines to annotate phenotyping 
definitions in the biomedical literature. These corpora are used in the following chapters. 
 
2.1 Introduction 
The current direction is moving towards the utilization of electronic health records 
(EHRs) for clinical research, including ADE discovery (Chiang et al., 2018; Czaja et al.; 
Yeleswarapu, Rao, Joseph, Saipradeep, & Srinivasan, 2014; J. Zhao, Henriksson, Asker, 
& Bostrom, 2015). EHR-based studies, in general, rely on defining a phenotype in a 
population in order to advance the knowledge of a disease or an adverse event (Glicksberg 
et al., 2018; R. L. Richesson, Hammond, et al., 2013). In terms of EHR-based research, the 
term “phenotype” can refer to observable patient characteristics inferred from clinical data, 
such as biomarkers and diseases (Hripcsak & Albers, 2013, 2017; R. L. Richesson, 
Hammond, et al., 2013; Shivade et al., 2014). An accurate phenotyping definition is critical 
to establish a cohort of patients for EHR-based research (Glicksberg et al., 2018; Gurwitz 
& Pirmohamed, 2010; Kirby et al., 2016; R. L. Richesson, Hammond, et al., 2013), 
including cross-sectional, and association studies (Banda, Seneviratne, Hernandez-
Boussard, & Shah, 2018). Utilizing either structured or unstructured data (Banda et al., 
2018; Hripcsak & Albers, 2017; W. Q. Wei & Denny, 2015), there are several methods 
that can be used for EHR phenotyping, including natural language processing (NLP), rule-
based systems, statistical analysis, data mining, machine learning, and hybrid systems 
(Banda et al., 2018; Shivade et al., 2014). Depending on the phenotype of interest as well 
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as study’s research question, standard queries for defining a phenotype can consist of any 
of the following: logical operators, standardized codes, data fields, and values sets 
(concepts derived from vocabularies or data standards) (R. L. Richesson, Hammond, et al., 
2013). With this, the goal is to develop the annotation guidelines that are able to capture 
such information about phenotyping case definitions. 
There are two types of methods for developing a phenotyping definition either 
developing new case definitions, or utilizing existing case definitions' information that are 
already available in different sources. Traditional phenotyping relies on expert knowledge 
and these definitions might change overtime (Hripcsak & Albers, 2017). This task is 
challenging due to complexity of EHRs and heterogeneity of patient’s records (Banda et 
al., 2018). Furthermore, it is also a labor-intensive process where a multidisciplinary team 
is needed with team members includes biostatistician, clinical researcher, EHR 
informatician, and NLP expert (Liao, Cai, et al., 2015). One example of expert-driven 
definitions is a study that identified patients with chronic rhinosinusitis (CRS) for a better 
understanding of the “prevalence, pathophysiology, morbidity, and management” using 
EHR data. Their team developed an algorithm to define CRS cases using ICD-9 diagnosis 
codes and Current Procedural Terminology (CPT) codes. The process took several 
iterations until they achieved predictive positive value of 91%. Further, they stated that 
manual review of notes and sinus CT results took two reviewers 40 hours, which is not 
scalable to larger number of patients or notes. Not to mention, their CRS definition has 
only been tested on one site and its performance is not known in other centers (Hsu et al., 
2014). This creates further difficulties when creating new definitions. Lessons learned from 
The Electronic MEdical Records and GEnomics (eMERGE) Network (Gottesman et al., 
2013) showed that the process of developing, creating, and validating a phenotyping 
definition for a single disease is time consuming and can take around 6-8 months. 
Consequently, the eMERGE network developed Phenotype KnowledgeBase (PheKB) 
(Kirby et al., 2016), which is a phenotype knowledgebase collaborative environment that 
allows collaborating and commenting between groups of researchers who were invited by 
a primary author. PheKB (Kirby et al., 2016) uses an expert-driven approach where new 
phenotyping definitions are generated by multi-institutional input and available publicly 
for use. PheKB provides a library of definitions for several phenotypes and incorporates 
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several data modalities, majorly including standard codes, laboratories, medications, and 
NLP. 
Another method relies on deriving phenotyping definitions from existing data 
sources, such as EHR and biomedical literature. Some of these were addressed manually 
using systematic reviews (Claire Barber, Diane Lacaille, & Paul R. Fortin, 2013; Fiest et 
al., 2014; Leong et al., 2013; Lui & Rudmik, 2015; Macdonald et al., 2016; Pace, Peters, 
Rahme, & Dasgupta, 2017; Souri et al., 2017) or automatically using computational 
approaches. Systematic reviews have a big role in the medical knowledge. However, with 
the massive amount of information, there is still a need to use automated approaches to 
extract medical knowledge; for example, the rate of published clinical trials articles is over 
20,000 per year while around 3000 systematic reviews were indexed in MEDLINE yearly. 
Overall, systematic reviews are time-consuming and labor-intensive (Cohen et al., 2010). 
On the other hand, the automated approaches for mining phenotypes in the literature were 
mostly focused on extracting phenotype terminologies (Collier et al., 2015; Henderson, 
Bridges, Ho, Wallace, & Ghosh, 2017; D. Zhao & Weng, 2011) in studies without the 
defined scope of EHR-based studies. Some of these studies (Botsis & Ball, 2013; D. Zhao 
& Weng, 2011) have addressed only one phenotype at a time and utilized abstracts rather 
than full text. Unlike full texts that are richer in information, abstracts are not sufficient for 
the granularity of phenotyping definitions information. Furthermore, such approaches 
might not be generalizable especially when working on a large-scale set of phenotypes. In 
“Automating case definitions using literature-based reasoning” (Botsis & Ball, 2013), 
Botsis and Ball (Botsis & Ball, 2013) have developed a corpus and a classifier to automate 
extraction of “anaphylaxis” definitions from literature. However, Botsis and Ball (Botsis 
& Ball, 2013) only relied on abstracts rather than full text that provides more rich 
information. In addition, the classifier was developed for only one condition "anaphylaxis". 
Even though they focused on some cues of phenotyping definitions e.g. signs and 
symptoms, they did not consider other cues of phenotyping definitions (e.g. standardized 
codes and laboratory measures) (Botsis & Ball, 2013). Therefore, this effort did not address 




With the goal of minimizing human involvement, we realized that there is a lack of 
phenotyping tools (Shivade et al., 2014) addressing or automating the extraction of existing 
definitions from scientific literature. There is a strong motivation for this research, to our 
knowledge; there is no existing corpora that address our information needs. An example of 
developing corpus for phenotypes is PhenoCHF (Noha Alnazzawi, Thompson, & 
Ananiadou, 2014; N. Alnazzawi, Thompson, Batista-Navarro, & Ananiadou, 2015), an 
annotated corpus by domain experts for phenotypic information relevant to Congestive 
Heart Failure from literature and EHR. The PhenoCHF corpus data was derived from i2b2 
(the Informatics for Integrating Biology at the Bedside) discharge summaries dataset 
(Uzuner, 2009) and five full text articles retrieved from PubMed that covered the 
characteristics of Chronic Heart Failure (CHF) and renal failure. However, PhenoCHF 
focused only on one condition, CHF, and it was built on a small set of only five full text 




2.2.1 Phenotyping definitions 
Different institutions view a phenotyping case definition differently. For example, 
Strategic Health IT Advanced Research Projects (SHARP), which is a collaboration effort 
(academic and industries partners) to advance the secondary use of clinical data. It views a 
phenotyping definition as the 
 
“inclusion and exclusion criteria for clinical trials, numerator and 
denominator criteria for clinical quality metrics, epidemiologic criteria for 
outcomes research or observational studies, and trigger criteria for clinical 
decision support rules, among others” (Chute et al., 2011). 
 
On the other hand, eMERGE phenotyping definitions extends to include practices 
as the 
 
“algorithmic recognition of any cohort within EHR for a defined purpose. 
These purposes were inspired by the algorithmic identification of research 




Further practices that eMERGE used in developing phenotyping definitions include 
other data modalities, such as diagnostics fields, laboratory values, medication use, and 
NLP-based (Chute et al., 2011). Here, we summarize definitions from different 
perspectives for defining a phenotyping case definition, which are: 
 
“The identification of patients’ cohort in the EHR by defining an inclusion 
and exclusion criteria performed for structured data and unstructured 
clinical text” (Pathak, Kho, & Denny, 2013). 
 
“An EHR-based cohort that only select subset of patients who fulfill the 
pre-defined phenotype” (Yu et al., 2015). 
 
“EHR-based research is concerned about cohort selection that is the 
identifying cases and controls for a phenotype of interest. A phenotype 
definition is developed from combining multiple EHR data, such as billing 
codes, medications, narrative notes, and laboratory data” (Carroll et al., 
2011; Liao, Cai, et al., 2015; Roden & Denny, 2016). 
 
“The process of deriving a cohort of a phenotype of interest using either 
low-throughput or high-throughput approaches” (R. L. Richesson, Sun, 
Pathak, Kho, & Denny, 2016). 
 
“The identification of cohort utilizing risk factors, clinical or medical 
characteristics and complications” (R. Richesson et al.; Yadav, Steinbach, 
Kumar, & Simon, 2018). 
 
2.2.2 Applications of phenotyping definitions 
The aim of this section is only to provide some overview about study designs in the 
biomedical research where phenotyping case definitions can be used. A phenotyping case 
definition can be applied to several types of studies, such as cross-sectional, association, 
and experimental (Banda et al., 2018). For example, pharmacovigilance, predictive 
modeling, clinical effectiveness research, and risk factors studies are considered use cases 
for the association case-control or cohort studies. More examples are shown in (Banda et 
al., 2018). Different study designs require different cohort designs as well as definitions 
where one phenotype can be defined in different ways depending on the study needs and 




“patients with type 2 diabetes or far more nuanced, such as T2DM patients 
with stage II prostate cancer and urinary urgency without evidence of 
urinary tract infection” (Banda et al., 2018). 
 
There are two major types of studies in the biomedical domain: primary research 
that directly collect data and secondary research that relies published information or 
sources of data. The focus of this section is on the primary research since it is the used 
research for EHR-phenotyping. Primary research has observational, also called 
epidemiological studies, and interventional studies, also called experimental studies 
(Thiese, 2014). Study designs for observational study designs are ecological, proportional 
mortality, case-crossover, cross-sectional, retrospective and prospective cohort. Each of 
these has its own strengths and weaknesses. Examples of some of the primary studies that 
we cover in this work (Thiese, 2014): 
 Ecological study design: Generally, called retrospective, and it is used to estimate 
a prevalence of a disease or an ADE in a population. The grouping is based on 
geographical locations or temporal associations. 
 Proportional mortality ratio study (PMR): Identify relationships between exposure 
and outcomes. E.g. cardiovascular deaths among different ethnic groups. 
 Cross-sectional studies, also prevalence studies: Samples are selected based on 
exposure without knowing their outcome. 
 Case-control study design: Samples are identified based on the case status. This is 
the optimal study design for rare diseases. 
 Retrospective and prospective cohort study design: Cohort studies is to identify 
patients based on the exposure and observe the development of the outcome of 
interest either for the future or for the past. Prospective is the gold standard for 
observational studies. 
New research, such as pharmacovigilance, is moving towards the emergence of 
electronic health information, machine learning, and NLP (Sarker & Gonzalez, 2015). 
EHRs provide complementary data with some flexibility with extended periods tracking, 
large sample size, and data heterogeneity (Yadav et al., 2018). The availability of a cohort 
can create several opportunities for data mining and modeling such as risk models, adverse 
event detection, measuring the effect of intervention, and building evidence-based 
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guidelines (Yadav et al., 2018). Cohort identification can be accomplished by using 
phenotyping definitions, which classify patients with specific disease based on EHR data, 
can be manually developed by experts or machine learned.  A phenotyping definition 
shared some major features, such as logic, temporality, and the use of standard codes 
(Newton et al., 2013). Furthermore, examples of data categories that are commonly used 
across institutions are age, sex, race, ethnicity, height, weight, blood pressure, inpatient and 
outpatient diagnosis codes, laboratory tests, and medications (Newton et al., 2013). On the 
other hand, there are some challenges with cohort identification process that vary 
depending on the study type. The phenotyping process is more sophisticated than creating 
simple code (Banda et al., 2018). Several factors can contribute to their complexity, 
including the used methods and confounding. For example, when defining acute or less-
defined phenotypes, one critical step is addressing confounding using matching of gender 
and age. These confounders are relatively easy to address, but others, such as co-diseases, 
might be more difficult. In some of the studies, Castro et al. were not able to identify 
methods for matching controls in EHR data. Case-control studies may inherent some 
limitations in detecting comorbidity such as insufficient controls, identification of correct 
confounders, and matching process. Literature-based comorbidity associations derived by 
clinical-expert is considered as a reference standard to compare the performance of the 
matched controls. However, the study reported that those clinical-expert driven 
associations between a list of PheWAS disease groupings and inflammatory bowel disease 
(IBD) generated some disagreement among gastroenterologists. Instead, Castro et al stated 
that their goal is to compare matching algorithms methods in order to identify clinically 
meaningful comorbidity associations (Castro et al., 2014). 
 
2.2.3 Medical corpora for text mining 
Text mining application mostly relies on supervised learning requires a corpora that 
is a collection of text annotated by experts. This is due to the challenges of recognizing 
terms as the example provided by Rodriguez-Esteban R for: “the text “early progressive 
multifocal leukoencephalopathy” could possibly refer to any, or all, of these disease terms: 
“early progressive multifocal leukoencephalopathy,” “progressive multifocal 
leukoencephalopathy,” “multifocal leukoencephalopathy,” and “leukoencephalopathy””. 
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Such annotations based on expert knowledge can be used to train machines, for example, 
on recognizing biomedical terms in text (Rodriguez-Esteban, 2009). An annotated high-
quality corpus requires experienced annotators and comprehensive guidelines (Dogan et 
al., 2014). The manually annotated corpus can serve as a gold standard for building 
automated systems including statistical, machine learning, or rule-based (H. Gurulingappa 
et al., 2012). Examples of annotated biological corpora, are GENIA for annotating 
biological terms (J. D. Kim, Ohta, Tateisi, & Tsujii, 2003), BioCreative1 for annotating 
biological entities in literature e.g. genes and proteins (Krallinger et al., 2015), and 
BioNLP2 that is a collection of corpora, such as Colorado Richly Annotated Full-Text 
Corpus (CRADF)3 and Protein Residue Corpora4, for annotating biological entities. Other 
usages of an annotated corpus is as curated data to create literature-based knowledgebase, 
such as MetaCore5 and BRENDA86 for enzyme functional data (H. Gurulingappa et al., 
2012). However, these are mostly restricted to specific domains such as biological domain 
which annotates information, such as gene names, protein names, cellular location or 
events (e.g. protein-protein interaction) (H. Gurulingappa et al., 2012). Availability of 
corpora in the medical domain is even more limited than biological domain. One of the 
major reasons is that medical domain confronted with data availability and ethical issues 
of using electronic medical records (H. Gurulingappa et al., 2012) , including privacy and 
confidentiality and Health Insurance Portability and Accountability Act (HIPAA) 
regulations (Ozair, Jamshed, Sharma, & Aggarwal, 2015). Examples of biomedical corpora 
are Text Corpus for Disease Names and Adverse Effects for annotating diseases and 
adverse effects entities (Harsha Gurulingappa, Klinger, Hofmann-Apitius, & Fluck, 2010), 
CLinical E-Science Framework (CLEF) for annotating medical entities and relations (e.g. 
drugs, indications, findings) in free text of 20,000 cancer patient records (Roberts et al., 
2009), and Adverse Drug Effects (ADE) corpus7 for annotating ADEs entities (H. 










Gurulingappa et al., 2012). None of the available corpora serves our needs for this task to 
annotate contextual cues of defining a phenotype in observational studies on sentence-level 
annotations from full texts, such as the presence of codes, laboratory tests, and type of data 
used. 
With this, our aim is annotating a corpus that capture sentences with not only 
phenotype concepts, but also contextual cues of a phenotyping definition that are presented 
in the literature. We believe that EHR-based studies will provide relevant information for 
defining phenotypes. An annotation schema is developed, and it serves as a foundational 
approach for annotating phenotyping definitions-related information in the literature. Both 
the corpus and the guidelines are designed based on extensive textual analysis of sentences 
to reflect phenotyping definitions information and cues. Ten dimensions are proposed to 
annotate the corpus at the sentence-level. Furthermore, after identifying the presence or 
absence of the ten dimensions, the level of evidence for each sentence was generated 
automatically using rule-based approach to ensure consistency and accuracy of 
annotations. All sentences in the methodology section were extracted from full text 
research papers. To the best of our knowledge, there is no existing corpus that is publicly 
available for annotating sentences with contextual cues of phenotyping definitions from 
biomedical full texts. 
 
2.3 Methods 
The procedure of a corpus construction consists of documents selection and 
sentence-level annotation (Verspoor et al., 2013). The documents selection starts with 
selection of phenotypes of interest that can assist in searching for abstracts. After that, 
abstracts collection prepared and full texts of selected abstracts were downloaded for the 
sentence-level annotation. For the sentence-level annotation, ten dimensions are proposed 
to annotate sentences with cues of a phenotyping case definition e.g. biomedical terms, and 





2.3.1 Selection of Phenotypes 
Our group is primarily interested in ADEs (Duke et al., 2012; H. Y. Wu et al., 
2017). Therefore, we identified our phenotypes of interest based on our previous work of 
literature-based discovery (Duke et al., 2012; H. Y. Wu et al., 2017) that have identified 
drug-drug interactions (DDIs)  due to interactions among five Cytochrome P450 (CYPs) 
enzymes, including CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A. These CYPs 
have a significant role in drug metabolism leading to several DDIs (Ogu & Maxa, 2000; 
J.-F. Wang & Chou, 2010). Furthermore, text-mining technology were used to extract DDI 
evidence and their corresponding ADEs from biomedical literature. DDIs were identified 
with evidence in all types of DDI studies, including clinical pharmacodynamics (PD), 
clinical pharmacokinetics (PK), and in vitro PK studies (H. Y. Wu et al., 2017). Among 
those clinical PD abstracts with 986 drugs pairs, we explored ADEs from those abstracts 
containing substrates of five major metabolizing enzymes above mentioned. The drug-
enzyme relationships were collected from Flockhart table1 and FDA. As a result, a list of 
ADEs (n = 673) was used as the primary list of phenotypes. All the ADE terms for those 
substrates were Medical Dictionary for Regulatory Activities terminology (MedDRA) 
(Brown, Wood, & Wood, 1999) preferred terms (PT). 
To narrow down our phenotypes of interest, we identified ADEs that showed 
evidence of drugs-ADEs linkage in Side Effect Resource (SIDER) database (Kuhn, 
Letunic, Jensen, & Bork, 2016) and found that 398 ADEs were successfully linked to the 
side effects in SIDER database. At the end, expert reviews were performed by two experts 
who are Lang Li, Ph.D., and Sara Quinney, Pharm.D., Ph.D. to finalize the list of 
phenotypes of interest. They excluded ADE terms that are did not meet our lab research 
interests, such as terms related to infections and cancer. The final list of phenotypes of 
interest is 279 ADEs (Appendix 1). Figure 2 shows the process of the selection of 
phenotypes. 
 





Figure 2 Flowchart of selection of phenotypes 
 
2.3.2 Abstracts and full texts collection and selection 
To search the literature for observational studies, we consulted a medical librarian 
to assist in building search queries to ensure the highest coverage. A review study reported 
that due to the broad nature of phenotyping studies, it can be difficult to perform one search 
that is capable of capturing all EHR phenotyping studies (Banda et al., 2018). Therefore, 
we collected our abstracts based on two search criterions: 
First, we searched PubMed database to identify observational studies of our 
phenotypes of interest. The searching query consist of [an ADE phenotype of interest term] 
combined with a set of keywords that were tested to retrieve relevant observational studies 
(see Table 1). We did not put restrictions on the year of publication and the searched was 
performed on November 2017. The total number of retrieved abstracts without duplications 
was 1323 abstracts. One reviewer manually reviewed each abstract to select articles that 
met the inclusion criteria described in Table 1. It also shows the exclusion criteria that was 
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applied to exclude abstracts. A total of 800 abstracts met our inclusion criteria. From the 
800 abstracts, a subset of 57 abstracts were randomly selected for full-text sentence-level 
annotation task (PMIDs in Appendix 2). 
 
Table 1 Abstract Inclusion-Exclusion criteria 
Searching Query [A phenotype of interest term] AND electronic health record (code OR codes 
OR algorithm* or "case definition" OR "phenotyping" OR "case identification" 
OR claim OR administrative) 
 
Inclusion Criteria 1. Abstracts should satisfy each of the following: English, full text available 
and original research. 
2. The primary source of data is EHR or EMR. Some accepted terms: Registry, 
administrative data. 
3. The article should use observational data (population-based, surveillance, or 
cohort/cases) either retrospectively or prospectively. 
4. Clearly describe a case definition or algorithm according to any of the 
following criteria: coding algorithms (SNOMED, ICD9/10, CPT, LOINC, 
RxNorm, UMLS, READ), laboratory, natural language processing (NLP), or 
inclusion and exclusion criteria. 
 
Exclusion Criteria 1. Review articles 
2. Non-human studies 
3. Nurses/practitioners as primary population of the study 
4. Not real-world data: e.g. simulation data 
5. Tools, systems, or reporting systems that do not address phenotyping or 
descripting phenotyping definition. 
 
Second, we used abstracts from a previous search that was performed by two 
reviewers. The used search queries were more generalized such as “electronic health record 
AND myopathy” (all queries are presented in Appendix 3). The downside of these queries 
is that it generates large number of abstracts that can be time-consuming and labor-
intensive to review all of them. The reviewers collected some relevant abstracts from these 
search queries. From these collected abstracts, we randomly selected 29 abstracts. The 
query searches with PMIDs are showed in Appendix 3. 
With this, the total number of abstracts derived from the two search criterions is 86 
abstracts. We achieved this number based on our goal to reach around 4000 sentences from 
methods sections. We downloaded their full texts and we tokenized them into sentence 
tokens using a package called Perl::Tokenizer as preparation for the annotation process. In 
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addition, we manually fixed sentences that were tokenized improperly. After that, we 
extracted sentences within methods sections. 
 
2.3.3 Corpus construction 
The annotation guidelines were developed based on textual analysis of the cues in 
sentences with a phenotyping definition information that were inspired by major data 
modalities of phenotyping definitions used in PheKB (Kirby et al., 2016). We performed 
sentence-level annotations with three major categories for each sentence, which are: 
inclusion, intermediate, and exclusion. The sentence-level annotations’ categories were 
derived based on the availability of ten dimensions that are shown in Table 2 with their 
descriptions and examples. Furthermore, some of these dimensions have sub-dimensions. 
The detailed annotation guidelines is available in Appendix 4. The annotation construction 
is as the following: 
First, inclusion category includes sentences that show evidence of at least one of 
the dimensions that characterize a phenotyping definition (Table 2). We identified five 
dimensions for the inclusion category, which are “Biomedical & Procedure”, “Standard 
codes”, “Medications”, “Laboratories”, and “Use of NLP”. The proposed dimensions are 
represented as either keywords or more complex as events where co-occurrence of more 
than one keyword occurs. For example, “Standard Codes” dimension is represented by the 
presence of any keyword relative to “Standard Codes”, such as ICD9, SNOMED, or a 
diagnostic code. On the other hand, “Biomedical & Procedure”, “Medications”, 
“Laboratories”, and “Use of NLP” require an event presence such as co-occurrence of two 
keywords that were identified for each dimension. A sentence is categorized as positive for 
the inclusion category if it shows evidence of any of these five dimensions (Table 2), which 
we called inclusion conclusion (INC) is true (Table 3). 
Second, intermediate category includes sentences that do not show direct evidence 
of a phenotyping definition, but it can assist by providing supporting evidence for 
phenotyping. We identified two dimensions for the intermediate category, which are “data 
Entities” and “Study Design or Institutional Review Board (IRB)”. Since different studies 
have different research questions and designs, intermediate category can assist in capturing 
data types information that matches the study’s goals (Yadav et al., 2018). A sentence is 
 
27 
categorized as positive for the intermediate category if it shows evidence of any of the two 
dimensions (Table 2), which we called intermediate conclusion (ITC) is true (Table 3). 
Third, exclusion category includes sentences that are out of the scope of a 
phenotyping definition or phenotyping. A sentence is categorized as positive for the 
exclusion category if it shows evidence of any of the three dimensions (Table 2), which we 
called exclusion conclusion (EXC) is true (Table 3). 
Finally, the final decision is the overall sentence-level of evidence derived from 
INC, ITC, and EXC. We note that some sentences can have evidence of more than one 
dimension which determines final sentence-level conclusions (INC, INT, EXC) in Table 
3. We used rule-based approach to produce four final sentence-level decisions, which are 
Positive, INTERMEDIATE_I, INTERMEDIATE_II, and Negative. The goal is to create 
an accumulative evidence in each sentence based on the presence of any of the three 
conclusions (INC, ITC, EXC). This help to ensure consistency, accuracy, and quality of 
the annotations. Table 3 shows the criteria of the seven rules (R1, R2, R3, R4, R5, R6, and 
R7). R8 final decision where all the three conclusions (INC, ITC, EXC) are false was 







Table 2 Sentence-level annotation’s categories, dimensions, and sub-dimensions 
1. Inclusions category (n = 5) Description Examples 
1.1. Biomedical & Procedure Evidence of defining a phenotype when 
biomedical and procedure entities co-occur with 
phenotyping definition cues. 
“dyslipidemia was defined as total cholesterol greater 
than 220 mg/dl…” (PMID:20819866). This sentence 
provides an evidence of defining a disorder called 
dyslipidemia. The association of the disorder term with 
the word “defined” satisfies this dimension. 
1.2. Standard Codes Evidence of using standard terminologies that are 
commonly used in clinical setting. Examples of 
these standard coding classifications and/or 
terminologies are ICD-9/10, SNOMED CT, and 
CPT codes. 
“a primary or any secondary discharge diagnosis 
(International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9-CM] code) of 
myoglobinuria (791.3)” (PMID:15572716) provides an 
evidence of the use of ICD-9-CM code. 
1.3. Medications Evidence of the use of medication for defining a 
phenotype. 
“the use of a lipid-lowering medication” (PMID 
20819866). 
1.4. Laboratories Evidence of using quantitative values reflecting 
clinical measurable values (i.e. laboratory tests 
values, vital values, procedures, clinical). 
“Dyslipidemia was defined as total cholesterol greater 
than 220 mg/dl”. (PMID:20819866) reported the use of 
“total cholesterol” test, and the value that the study 
used to define Dyslipidemia. 
1.5. Use of Natural Language 
Processing (NLP) 
Evidence of NLP use accompanied with any of 
the following entities: biomedical, procedure, 
and/or medications. 
“Example of a Clinical Note Represented as a “Bag of 
Words” Note ID 45893484-02 34695234-01 HF status 
positive negative Covariate #1 "heart" 3 1 Covariate #2 
"pulmonary"“  (PMID:17567225) 
2. Intermediate category (n = 2)    
2.1. Data entities Evidence of information relevant to data entities 
used in study or phenotyping definitions. Some 
examples when describing a database used, 
clinical data, and/o electronic health records 
(EHR). 







2.2. Study design or IRB Evidence of information about study design or 
the IRB. For example, an evidence of the method 
used as “Gold standard”. 
“STUDY DESIGN: Retrospective chart review.” 
(PMID: 11388131). 
3. Exclusion category (n = 3)   




3.1.4. Patient direct contact 
3.1.5. Provider or researchers 
(excluding patients) 
3.1.6. Performance 
3.1.7. Quality of Care 
Evidence of information about other study 
methodological details that is not supportive for 
defining a phenotype directly. 
“All patients were members of the managed care 
system and incurred a significant financial advantage 
from having their prescriptions filled within the 
system.” (PMID16765240) – (Sub-dimension: 
Financial) 
 
Note: additional examples in the annotation guidelines 
in the appendix 





Evidence of computational or statistical 
information that is not supportive for 
phenotyping definitions. 
“We used logistic regression models with generalized 
estimating equations to adjust for race, year, race x year 
interactions, age, and sex.” (PMID16567608) ) – (Sub-
dimension: Statistics) 
3.3. Exclusion 3- Insufficient 
evidence: 
3.3.1. Insufficient evidence 
Sentences that do not show any evidence in any 
of the nine dimensions. 
“As reported previously, administratively-assigned 
race/ethnicity is highly concordant with genetic 














Table 3 Level of evidence of a sentence with a phenotyping definition (Rule-based final decisions) 
Rule  Rule description Level of evidence  Final Decision Number of Sentences 
R1 If INC= True and 
ITC= False and 
EXC = False 
The sentence shows strong evidence of a phenotyping definition.  
Positive 1222 (30.77%) 
R2 If INC= True and 
ITC= True and 
EXC = False 
The sentence shows strong evidence of a phenotyping definition.  
R3 If INC= True and 
ITC= True and 
EXC = True 
The sentence shows strong intermediate evidence of a 
phenotyping definition due to the presence of any of the Exclusion 
criteria. 
 
INTERMEDIATE_I 701 (17.65%) 
R4 If INC= True and 
ITC= False and 
EXC = True 
The sentence shows strong intermediate evidence of a 
phenotyping definition due to the presence of any of the Exclusion 
criteria. 
 
R5 If INC= False and 
ITC= True and 
EXC = False 
The sentence shows weak intermediate evidence of a 
phenotyping definition due to the absence of any of the Inclusion 
criteria, but presence of any of the intermediate criteria. 
 
INTERMEDIATE_II 914 (23.01%) 
R6 If INC= False and 
ITC= True and 
EXC = True 
The sentence shows weak intermediate evidence of a 
phenotyping definition due to the absence of any of the Inclusion 
criteria, but the presence of any of the intermediate criteria. 
 
R7 If INC= False and 
ITC= False and 
EXC = True 
The sentence shows no evidence of a phenotyping definition.  




2.3.4 Annotation process 
In order to produce a high-quality corpus, it is recommended that the corpus is 
annotated by more than one annotator (Artstein, 2017). Here, two annotators with a 
biomedical informatics background (Samar Binkheder, M.S., Heng-Yi Wu, PhD) carried 
out the annotation process. Both annotators have degrees in biomedical informatics, are 
familiar with the medical standard terminologies, and are familiar with text-mining. They 
designed the annotation guidelines iteratively through several meetings and manual 
analysis of textual patterns of a phenotype definition. When both annotators were satisfied 
with the final version of the annotation guidelines, they started the annotation of the corpus. 
For each dimension of the ten dimensions (Table 2), if the dimension is present, the 
annotator annotates it as 1, otherwise, it is 0. The development of an annotation guidelines 
is critical to ensure the consistency and quality of the annotations. The process can start by 
a draft, and then refined iteratively until final draft is satisfied (H. Gurulingappa et al., 
2012). During the guideline’s development process, subsets of the corpus were annotated 
until the annotators were satisfied with the guidelines. After that, the full corpus was 






Figure 3 Iteration process of developing the annotation guidelines and the final 
annotation 
 
After finalizing the guidelines, both annotators annotated all sentences of the corpus 
following the final proposed annotation guidelines. The annotation process was divided 
into several rounds starting from annotation of subset of sentences 400 (first round). After 
that, the number of sentences for each round were 1000, 1300, and 2700. After each 
annotation round, there were “consensus sessions” that each took around 1-4 hours where 
annotators discussed and resolved any disagreements. Moreover, a third Ph.D. annotator 
addressed disagreements in annotations between annotators if they did not achieve a 
consensus. The goal was to identify areas of disagreements as well as areas to achieve our 
100% gold standard. 
 
2.3.5 Inter-annotator agreement (IAA) 
The inter-annotator agreement is to assess the reliability of the annotations. There 
are several benefits for the manual annotation by multiple people, such as to generate 
correct annotations, validate and improve the scheme guidelines, resolve ambiguities in 
data, and evaluate valid interpretations (Artstein, 2017). Further, the written annotations 
guidelines scheme help in generating consistent and reproducible annotations (Artstein, 
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2017). Therefore, to measure the agreement between annotators, we used three measures 
of agreement: percent agreement, overall percent agreement (Wilbur, Rzhetsky, & 
Shatkay, 2006), and Cohen’s kappa (McHugh, 2012). These measures vary in their 
approaches, but they all aim at producing the best possible reliable and correct annotations 
as there is no reference for the annotation of some of the sources (Artstein, 2017). The 
percent agreement and Cohen’s kappa (McHugh, 2012) were calculated for each dimension 
using R packages (‘irr’1 for percent agreement and ‘fmsb’2 for kappa). For example, if the 
two annotators annotate a dimension as 1, it means an agreement. On the other hand, if one 
annotator annotates a dimension as 1 and the other as 0, it means disagreement. The overall 
percent agreement (Wilbur et al., 2006) was calculated over the ten (10) dimension on a 
sentence-level (Table 2) as the following: 





2.4.1 Corpus description 
PubTator3, a web-based tool for annotating biomedical entities, including diseases, 
genes, mutations, and chemical (C.-H. Wei, Kao, & Lu, 2012). We uploaded our PMID list 
(n = 86) and run the annotation analysis. Table 4 presents the results from PubTator for the 
disease terms that were found in more than one abstracts. Disease terms that appeared in 
single abstracts and terms for other entities (genes, mutations, and chemical) are shown in 
Appendix 5. 
 






Table 4 Phenotypes appeared in more than one abstract in our corpus 
Term Number of abstracts 
Diabetes 16 
Hypertension 11 
Diabetes mellitus 8 










Type 2 diabetes 3 





Myocardial infarction 2 
Pulmonary embolism 2 
Rhabdomyolysis 2 
Rheumatoid arthritis 2 




We annotated the corpus using our annotation guidelines with ten dimensions 
(Table 2). The total number of sentences in this corpus was 3971 sentences that were 
extracted from 86 full texts methods sections. Table 5 shows the number of annotated 
sentences in for each category and dimension. “Biomedical & Procedure” dimension 
showed the highest number of annotated sentences with around 1449 (36.5%). “Data 
entities” and “EXC2 – Computational and statistical evidence” were both over thousand 
annotated sentences with 1370 (34.5%) and 1314 (33.1%), respectively. The number of 
annotated sentences for “Medications”, “Standard codes”, and “Laboratories” dimensions 
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from inclusion category were 593 (14.9%), 385 (9.7%), and 246 (6.2%). The number of 
annotated sentences for “Use of NLP” dimension were the lowest with 49 (1.2%). 
 
Table 5 Corpus description and inter-annotator agreement 
Category 




# of sentences 
(%) per 
dimension 
Percent Kappa Kappa 
95% CI 
Inclusion 1923 out of 3971 (48.4%) 
Biomedical & Procedure 1449 (36.5%) 95.00% 88.96% 0.87 - 0.90 
Standard codes 385 (9.7%) 99.47% 97.01% 0.95 - 0.98 
Medications 593 (14.9%) 99.09% 96.44% 0.95 - 0.97 
Laboratories 246 (6.2%) 99.70% 97.42% 0.95 - 0.98 
Use of NLP 49 (1.2%) 99.65% 83.54% 0.74 - 0.92 
Intermediate 1851 out of 3971 (46.6%) 
Data entities 1370 (34.5%) 96.71% 92.59% 0.91 - 0.93 
Study design and/or IRB 780 (19.6%) 98.00% 93.56% 0.92 - 0.94 
Exclusion 2273 out of 3971 (57.3%) 
EXC1 – Irrelative evidence 733 (18.4%) 97.27% 91.05% 0.89 - 0.92 
EXC2 – Computational 
and statistical evidence 
1314 (33.1%) 96.84% 92.83% 0.91 - 0.94 
EXC 3 – Insufficient 
evidence 
359 (9.0%) 95.96% 78.72% 0.75 - 0.82 
 
Table 3 shows the rule-based final decisions which are “Positive”, “Intermediate 
I”, “Intermediate II”, and “Negative”. The positive indicated the highest level of evidence 
of defining a phenotype while the negative indicated no evidence of defining a phenotype. 
The number of sentences with “Positive” are 1222 (30.77%). “Intermediate I” is the 
sentences that showed strong intermediate evidence were 701 (17.65%) sentences of the 
corpus. “Intermediate II” are the sentences that showed weak intermediate evidence were 
914 (23.01%) sentences of the corpus. Finally, the number of negative sentences 
represented in our corpus was 1134 (28.55%) sentences. 
 
2.4.2 Inter-annotator agreement 
For inter-annotator agreement, the calculations were based on annotation of each 
dimension (Table 2 & Table 5). We used the overall sentence-level percent agreement 
(inspired by Wilbur et al. (Wilbur et al., 2006)), percent agreement, and Kappa. The overall 
sentence-level percent agreement was high with 97.8%. The percent agreement and kappa 
measures results are shown in Table 5. Generally, all dimensions showed high agreement 
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on both percent agreement and kappa. For the dimensions of the inclusion category, the 
“Biomedical & Procedure” showed around 95% percent agreement, and almost perfect 
kappa with 88.96%.  For the “Standard codes”, “Medications”, and “Laboratories” 
dimensions, they all showed over 99% percent agreement and over 96% kappa. For the 
“Use of NLP” dimension, it showed over 99% percent agreement and 83.54% kappa. For 
the dimensions of the intermediate category, they showed high agreement on percent 
agreement with over 96%, and kappa with over 92%. Finally, for the dimensions of the 
exclusion category, both “EXC1 – Irrelative evidence” and “EXC2 – Computational and 
statistical evidence” showed high agreement on percent agreement with 97.27% and 
96.84%, and kappa with 91.05% and 92.83%, respectively. The “EXC 3 – Insufficient 




In this work, our goal was to develop an annotation approach and an annotated 
corpus that is capable of supporting future text-mining tasks such a literature-based 
discovery of phenotyping case definitions. In terms of selection of phenotypes, we chose 
to select a set of phenotypes based on our group research interests, which were mostly 
ADEs (n = 279). We utilized these phenotypes to search the literature for abstracts and we 
included 86 abstracts to build the sentence-level corpus from their full texts’ methods 
sections. Annotation approaches were based on evaluating the presence of our proposed 
ten dimensions in a sentence (Table 2) and the final decisions were derived based on a set 
of seven rules (Table 3). Our focus in annotating the corpus is to develop a generalized 
approach to capture contextual features of phenotyping rather than focusing on specific 
entities. The two annotators worked in developing the annotation guidelines iteratively; 
after finalizing the guidelines, the whole corpus was annotated. For inter-annotator 
agreement, we used three measures for evaluation: overall sentence percent agreement 
(inspired by Wilbur et al. (Wilbur et al., 2006)), percent, and kappa agreement. Overall, the 
results for the inter-annotator agreement were high and the overall sentence-level percent 
agreement was high with 97.8%. One observation with the “EXC 3 – Insufficient evidence” 
dimension showed “substantial agreement” (see Table 2 for interpretation of Kappa in 
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(Viera & Garrett, 2005)) that was the lowest kappa score among all dimensions. This 
dimension indicates sentences with lack of evidence in any of the other nine dimensions. 
Overall, we annotated 3971 sentences extracted from methods sections of 86 articles and 
the inter-annotator agreement showed that the annotations and guidelines are valid. 
Annotating a larger number of articles might generate more contextual patterns of 
a phenotyping definition in EHR-based studies. However, we also believe that we have a 
comprehensive coverage for several study types of studies. Here we report the study design 
terms as they appeared in our corpus and it here as it appears it the text: 
 Observational Study 
 Longitudinal study 
 Cohort Study (retrospective cohort, prospective cohort, Nonrandomized 
retrospective cohort study) 
 Case-Control Study 
 Retrospective Study (retrospective cohort, nonexperimental retrospective, 
Nonrandomized retrospective cohort study, retrospective validation) 
 Cross-sectional Study 
 Comparative Study 
 Descriptive Study 
 Validation Study 
 Prospective Study (prospective cohort study) 
 Genome-Wide Association Study 
 Epidemiology and/or Surveillance Study 
 Follow-up Study 
With the multi-study coverage, we believe that our corpus was sufficient to capture 
wide range of contextual cues representing a phenotyping case definition in the biomedical 
literature. 
 
2.5.1 Sentence-level annotation and dimensions selection 
Our decision in this work is to focus on the sentence-level annotations rather than 
entity-level annotations. There are several reasons for this decision. First, we believe that 
a phenotyping definition is best represented as full sentences rather than single concepts or 
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terms. Entity-level annotations can be accomplished in future steps with the goal of text 
summarization. Second, we aimed to utilize a generalizable approach that serves as a 
foundational basis for annotating a phenotyping definition. The selection of ten proposed 
dimensions (Table 2) was based on identifying phenotyping definition contextual cues that 
were observed in published literature (Botsis & Ball, 2013; Kirby et al., 2016; Shivade et 
al., 2014; Yadav et al., 2018)  as well as during our manual annotation process (Figure 3). 
Third, based on our analysis, contextual cues of a phenotyping definition are not only 
reliant only on biomedical concepts, but also it can be extended to other cues, such as 
“defined”, “inclusion criteria”, “exclusion criteria”, and “eligibility”. To our knowledge, 
contextual cues of phenotyping definitions in the literature that surround biomedical and 
medication entities were not studied previously. 
 
2.5.2 Error analysis 
We performed an error analysis on sentences where annotators had disagreements. 
We found that recognizing abbreviated terms was slightly challenging and it appeared 
problematic in seven dimensions shown in Table 6. Thus, it can be hard to determine if an 
abbreviated term is a biomedical, procedure, or medication. For example, the term ICD can 
mean “implantable Cardiac Defibrillators” or “International Classification of Diseases”. 
Therefore, we addressed this to the best of our abilities by returning to the full text article. 
In addition to the abbreviation challenge, we observed that natural human error could also 
generates some disagreements during the annotation process. For example, one of the 
annotators missed some keywords that were noticed during the consensus sessions. Such 
mistakes were not intentionally made. Furthermore, there was an ambiguity in some of the 
terms that the same term has more than one meaning. In this case, understanding the context 
around the text is necessary and helped in addressing this problem. Overall, annotating 
phenotyping definitions’ events e.g. a co-occurrence of more than one keyword, is 
challenging because they require the presence of more than one pattern. Table 6 provides 




Table 6 Error analysis of the annotation disagreements 




"Events that occurred during follow-up were 
identified from hospitalization records, and 
ARIC and CHS study" (PMID25104519) 
Standard codes "Finally, the Apollo Data Repository provided 
data for ICDs" (PMID26961369) 
Medications "‘‘common’’ side effects, e.g. headache, to 
judge the relevance of side effects associated 
with AZA." (PMID24177317) 
Use of NLP "From this cohort, we identified 15,761 
patients with HPI” (PMID25567824) 
Data “Cohort with HPI data” (PMID25567824) 
EXC1 – irrelevant 
evidence 
"190 patients completed the SCID 
assessment"(PMID25827034) 
EXC2 – Computational 
and statistical evidence 
"The MCMC method" (PMID21931496) 
One of the annotators 
missed keywords or/and 
criteria 
Use of NLP "The algorithm uses non-negated terms 
indicative of HF" (PMID17567225) 
Data "If data on weight and height were available” 
(PMID21862746) 
EXC1 – irrelevant 
evidence 
- EXC1 – irrelevant evidence (financial): 
"until termination of insurance coverage." 
(PMID12952547) 
- EXC1 – irrelevant evidence (Ethical): 
"To protect patient confidentiality, all 
personal identifiers are deleted” 
(PMID21051745)  
- EXC1 – irrelevant evidence (Location of 
the study): "We randomly sampled 
outpatient clinical encounters from 
October 1, 2003 through March 31, 2004 
at VA Maryland (VAMHCS) and at VA 
Salt Lake City (VASLCHCS) Health 
Care systems." (PMID20976281) 
EXC2 – Computational 
and statistical evidence 
"Characteristics were measured during the 
one-year baseline period (i.e., before time 
zero)." (PMID20112435) 
Without co-occurrence 
Use of NLP 
 
"Humedica derives NLP items from text 
entries that correspond primarily to terms in 
two large dictionaries, SNOMED and 
MedDRA" (PMID26725697) 
NLP terms did not co-occur with 
biomedical/procedure/medication concept 







"Only acute conditions occurring during the 
first 24 hours of hospital admission were 
considered." (PMID24734124) 
The term “condition” by itself can have 
different meaning not relevant to disease. 
However, when the word "condition" is not 
supported with other keyword indicating it is 
a medical condition. 
Study design or IRB "The nucleotide reference for this allele is 
guanine. 4." (PMID26221186) 
The term “reference” does not indicate gold 
standard reference. 
EXC2 – Computational 
and statistical evidence 
"More points mean a higher risk of 
hyperkalemia." (PMID20112435) 
Neither Biomedical nor 





"We created a binary variable for marital 
status, where “single” included those patients 
classified as divorced, single, widowed, or 
separated." (PMID25091637) 
Not clear statement of 
using standard codes 
 
Standard codes "Outcomes were evaluated by 
administratively coded data” 
(PMID26370823) 
Assigning terms as 
Biomedical & Procedure 






"The most recent fasting lipid profile in 
patients with dyslipidemia and glycosylated 
hemoglobin level in patients with diabetes” 
(PMID11388131) 
Spelling and short forms 
 
Medications "Asthma meds refilled regularly." 
(PMID12952547) 
Biomedical/Procedure/Me






"reports KD=9100 for bupropion and 
KD>10 000 for mirtazapine (vs 200 for 
nefazodone)." (PMID22466034) 
“More than or less than” 
value, but not directly 




"≥2 years of observation before period of 
interest; n = 50." (PMID23449283) 
Adding new keywords for 
the dimension 
EXC2 – Computational 
and statistical evidence 
Example of new keywords describing 
“EXC2”, are: risk score, inter-rater variability, 
custom-designed data entry template, 
predictor variable, Tukey multiple comparison 
test, Web-accessible, teleconferences, 
propensity-matched, machine-implementable 
rule, Illumina Omni1_- QUAD, Illumina 





2.5.3 Limitations of the study 
This work does not stand without limitations. The manual corpus annotation is 
time-consuming and labor-intensive. Only two annotators annotated the corpus; therefore, 
we tested the annotations with more than one measurement of agreement (overall percent, 
percent, and kappa). Both annotators were familiar with biomedical informatics concepts 
and text-mining approaches, but we note that some were more challenging than others. The 
results inter-annotator agreement showed high agreement indicating reliable annotations 
and guidelines. Generally, more annotators with clinical expertise could assist more during 
the task of annotations. In addition, automatic entity recognition to recognize biomedical 
entities can also improve the annotation process and decrease the time of annotation. As 
mentioned previously, the scope of this work is on capturing patterns of contextual cues 
surrounding a phenotyping definition. 
For “Use of NLP” dimension, we decided to only annotate the presence or absence 
of NLP in a sentence with the goal to use it as a part of phenotyping. Going beyond this 
scope would complicate the annotation task, require detailed and full annotation of NLP 
methodology, and require a bigger corpus. Therefore, the number of sentences of this 
dimension is comparably lower than other dimensions. In addition, our aim in this work is 
to establish a foundational approach. 
 
2.5.4 Applications of the corpus 
To date, PheKB (Kirby et al., 2016) library provides around 50 definitions only for 
some phenotypes. A study of best practices for phenotyping of adverse events found that 
the re-utilization of existing definitions is crucial (Wiley, Moretz, Denny, Peterson, & 
Bush, 2015). This only works for case definitions that have been already published in the 
literature. Therefore, this work aimed to support the re-usability of published definitions 
(R. L. Richesson, Hammond, et al., 2013) by analyzing their contextual cues. Specifically, 
for using case definitions to establish EHR-based research, such drug safety surveillance. 
Availability of these definitions can also assist in the validation of them in several 
institutions to ensure cohort consistency (R. L. Richesson, Rusincovitch, et al., 2013). The 
ten dimensions in our annotation guidelines provide a foundational understanding of the 
basic contextual cues that represent a phenotyping case definition in the literature. 
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Therefore, we believe that this corpus can serve as a baseline for developing either 
automatic or manual approaches to annotate a larger corpus size and advancing our 
proposed guidelines. Furthermore, our main aim of developing this corpus is to use it for 
text-mining applications to automate mining of phenotyping definitions publish in the 
literature. 
In conclusion, clinical research, such as drug discovery, is moving toward the use 
of EHRs that provides information about patient’s variations, including comorbidities and 
co-medications. The corpus and annotation guidelines can serve as a foundational 
informatics approach for annotating and mining literature-based phenotyping definitions. 
Ten dimensions are proposed characterizing major contextual patterns and cues of a 
phenotyping definition in published literature. This is a step towards research to advance 





CHAPTER THREE: AN AUTOMATED TEXT MINING APPROACH OF 
PHENOTYPING DEFINITIONS IN THE BIOMEDICAL LITERATURE 
 
In Chapter 2, we proposed an approach to annotate phenotyping definitions in 
published literature. In addition, we used our proposed annotation guidelines to create a 
corpus of annotated sentences from full texts. The main motivation behind developing the 
corpus is to develop a text-mining technology. In this chapter, we build an information 
retrieval (IR) and extraction (IE) systems for facilitating the use of published literature-
based phenotyping definitions. In addition, we applied these systems on a large-scale 
literature. Similar to Chapter 2, we are using adverse drug reactions (ADEs) as our 
phenotypes of interest that can be used in many tasks, such as building lexica and 
dictionary. The final product of this chapter is a large collection of phenotype definitions-
related abstracts and sentences. We note that our used approaches for mining ADE 
phenotype definitions-related abstracts and sentences can be generalized to other 
phenotypes and are not limited to ADEs. 
 
3.1 Introduction 
A major public problem is that many drug side effects appears in public, including 
deaths and hospitalizations, after the release of the drug to the market. These side effects 
reported to reach millions, where “5% hospital admissions, 28% emergency visits, and 5% 
hospital deaths” (Sarker & Gonzalez, 2015). Furthermore, the estimated cost is about 
seventy-five billion dollars yearly (Sarker & Gonzalez, 2015). There are several sources 
that have been used to conduct post-marketing ADE-based research, such as spontaneous 
reporting systems, electronic health records (EHRs), social media, and biomedical 
literature (Davazdahemami & Delen, 2018). Research shows that FDA Adverse Event 
Reporting System (FAERS) data has limitations where it either underestimates or 
overestimates some ADEs (Sarker & Gonzalez, 2015). On the other hand, repurposing of 
EHR for pharmacovigilance and clinical research (Newton et al., 2013) has increased 
where a number of approaches can be used for phenotyping (Banda, Callahan, et al., 2016; 
Newton et al., 2013; X. Wang, Hripcsak, Markatou, & Friedman, 2009). For example, 
several studies have used EHR for ADE signal detection and used literature for its 
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validation (Iyer, Harpaz, LePendu, Bauer-Mehren, & Shah, 2014). The use of EHR 
provides several advantages, including “large scale, reduced cost, repeated observations, 
and the ability to observe rare events” (Mo et al., 2015). Furthermore, EHR for secondary 
use purposes mining is important because it offers a rich resource of accumulated clinical 
& patient’s data on variable disease levels, it provides opportunities for analyzing ADEs, 
and it supports answering of clinical research questions (Chiu & Hripcsak, 2017; Yadav et 
al., 2018). Examples of patient’s data in EHRs that are collected routinely in clinical 
practice are diagnoses, laboratory tests, billing records, medications, and medical history 
which can be either in structured (e.g. ICD9 codes) or unstructured format (e.g. clinical 
notes) (Chiu & Hripcsak, 2017). In contrast, EHR use generates new challenges. 
The use of EHR does not stand without challenges. These challenges have opened 
new opportunities for informatics research. One of the challenges of EHR-based research 
is to accurately find cases and controls for a phenotype of interest (Carroll et al., 2011). 
This is called as cohort identification that has been widely used for various clinical and 
biomedical studies (Yadav et al., 2018). Cohort identification is an obstacle especially 
when phenotyping definitions are not readily available for performing clinical research 
studies (D. Li et al., 2012). Therefore, we have identified a gap, which is the absence of 
phenotyping definitions for some phenotypes of interest or sources that support its 
development. 
To generate or obtain a phenotyping definition, there are several approaches: low-
throughput or high-throughput approaches (R. L. Richesson et al., 2016). First, the low-
throughput phenotyping is highly reliant on expert domain knowledge and rule-based 
algorithms, such as decision trees and boolean logic (R. L. Richesson et al., 2016). These 
methods for cohort identification tend to be time-consuming and labor-intensive (D. Li et 
al., 2012; Park & Choi, 2014) due to the need of an expert involvement. A multidisciplinary 
team works on developing and designing a phenotyping definition in which manual review, 
multiple iterations, and validation are needed (Carroll et al., 2011). For example, generation 
of a new phenotyping definition, especially when it is derived based on the EHR data of 
that institution, does not mean it is portable across other institutions. Therefore, a validation 
step of a phenotyping definition across multiple institutions is important to ensure that it is 
performing well across different populations (Liao, Ananthakrishnan, et al., 2015; Overby 
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et al., 2013). Electronic Medical Records and Genomics (eMERGE) network has an effort 
to manually create, disseminate, and validate phenotyping definitions that they made them 
publicly available in Phenotype KnowledgeBase (PheKB)1 (Newton et al., 2013; R. L. 
Richesson et al., 2016). However, these are still lacking standardized representations. For 
example, these definitions are stored in Microsoft® Word, Excel files, or other formats 
with no specific template for easing human interpretation (Chute et al., 2011). Another 
challenge is the development of a phenotyping definition for clinical notes that requires 
knowledge in Natural Language Processing (NLP) and human involvement (Park & Choi, 
2014). Therefore, the development of expert-driven phenotyping definitions process is still 
very challenging, labor intensive, error-prone, and time-consuming (Lasko et al., 2013; 
Park & Choi, 2014; Xu et al., 2015). 
Second, recent efforts (V. Agarwal et al., 2016; Banda, Callahan, et al., 2016; 
Halpern, Choi, Horng, & Sontag, 2014) are moving toward high-throughput phenotyping 
that uses statistical, machine learning, and data-driven approaches (Halpern et al., 2014; R. 
L. Richesson et al., 2016). Unlike low-throughput phenotyping that can be time-consuming 
and require high-effort, high-throughput phenotyping can be scalable to high-dimensional 
adverse events (V. Agarwal et al., 2016; Halpern et al., 2014; R. L. Richesson et al., 2016). 
However, it require multiple sources to support its scalability (Zhang et al., 2018). Some 
efforts suggest the use of machine-learning approaches to automate the development of a 
phenotyping definition using EHR data (Lasko et al., 2013). Such definitions are developed 
on specific populations in which generalization of models and algorithms can be infeasible 
due to EHR natural challenges. Moreover, EHR data can be sparse across patient data. 
EHR data usually reflects patient who are very ill, which generates bias (Castro et al., 2014; 
Malinowski et al., 2014; W. Q. Wei et al., 2016). Moreover, EHR data can be inconsistent 
(Castro et al., 2014; Frey, Lenert, & Lopez-Campos, 2014; Malinowski et al., 2014; W. Q. 
Wei et al., 2016), incomplete (Frey et al., 2014; Pathak et al., 2013; W. Q. Wei et al., 2016), 
fragmented, (Daniel & Choquet, 2014; W. Q. Wei et al., 2016), inaccurate, complex 
(Daniel & Choquet, 2014; Frey et al., 2014; Pathak et al., 2013), formatted in free text, 
from unknown sources, and variable in granularity (Daniel & Choquet, 2014).  A challenge 




is the variability across institutions in EHR data, which generate problem when creating or 
applying phenotyping definitions. For example, each institution might have its own usage 
of ICD-9 codes and drugs’ brand names. This can affect the query of the definition that if 
generated in one institution would not work in another institution and will generate variable 
and inconsistent results (Chute et al., 2011). A study found that only half of the evaluated 
tools can be used portable among other EHRs that are different from where the phenotyping 
definition were originally developed (Xu et al., 2015). Therefore, these common issues can 
be problematic, especially when phenotyping definitions are derived from it. 
Several systematic reviews have been performed to harmonize, compare, and 
validate phenotyping definitions in the literature. These studies (Claire Barber et al., 2013; 
Fiest et al., 2014; Leong et al., 2013; Lui & Rudmik, 2015; Macdonald et al., 2016; Pace 
et al., 2017; Souri et al., 2017) have systematically reviewed several case definitions for a 
number of phenotypes, including ADEs. Their goal was to validate or to compare 
performance of different case definitions. Moreover, these studies reported several reasons 
for performing these systematic reviews, such as the lack of widely used or validated 
definitions (Claire Barber et al., 2013; Fiest et al., 2014; Leong et al., 2013; Lui & Rudmik, 
2015; Macdonald et al., 2016; Pace et al., 2017; Souri et al., 2017), and the need to improve 
reproducibility of observational studies (Fox et al., 2013). In addition to these efforts, the 
Observational Medical Outcomes Partnership (OMOP) (Fox et al., 2013), which is called 
today the Observational Health Data Sciences and Informatics (OHDSI), has developed a 
library source based on systematic literature review of a number of health outcomes of 
interest (HOIs) definitions for ADEs. Even though these efforts are very valuable in 
harmonization and validation of phenotyping definitions, the process of searching literature 
systematically for evidence-based phenotyping definitions lacks scalability, and can be 
difficult, slow, and time-consuming. 
To summarize, we have identified several gaps related to the development of a 
phenotyping case definitions: (1) The lack of phenotyping definitions for several 
phenotypes; (2) The current approaches are labor-intensive and not scalable; (3) The need 
for high-throughput phenotyping with minimum expert involvement; and (4) The need of 
utilizing large-scale literature for knowledge discovery of phenotyping definitions. 
Therefore, in this study, we identified biomedical literature as a potential resource for text-
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3.2.1 EHR phenotyping 
Large-scale EHR has become an enriched resource for secondary use research. In 
the United States, office-based physicians adoption of any EHRs (i.e. all or partially 
electronic records) has increased from 42% in 2008 to 87% in 2015 (C. Barber et al., 2013). 
The increase of EHR adoptions has led to an increase in EHRs longitudinal data providing 
new efficient and cost-effective resources for biomedical and clinical research. A number 
of other advantages of using EHRs data for research, such as big data, variety of data types, 
diverse populations, and real-world patterns of phenotypes. Moreover, EHRs enable new 
discoveries and hypothesis generations in areas like drug-adverse effect associations, 
phenotype-genetic associations, phenotype-disease associations, and comparing 
effectiveness of established therapies (Castro et al., 2014). Declerck et al. (Declerck et al., 
2015) hypothesized that using EHR data can support the drug-related adverse events 
discovery. Examples of EHR datatypes, are demographics, drug history, symptoms, and 
laboratory tests (Declerck et al., 2015). Large number of these EHR based studies are 
already published in the literature. 
As we introduced in Chapter 2 and this Chapter, the use of EHR requires an 
identification of cohort for a desired population with a data-driven approach called EHR 
phenotyping (Lasko et al., 2013; Park & Choi, 2014). EHR phenotyping is the process that 
involves the design, implementation, and execution of phenotyping algorithms for a 
phenotype of interest as well as the analysis of the queried results (Peterson & Pathak, 
2014). Furthermore, EHR phenotyping process includes engineering, identifying, 
quantifying, and automating cohort and phenotype selection in EHR. This process is 
primarily achieved by using EHR-driven data (Frey et al., 2014; Glueck et al., 2016; Lasko 
et al., 2013). EHRs data is large by nature, phenotyping process involves dealing with 
massive amount of practice-based daily routine clinical data, such as clinical narratives, 
billing codes, and medications, and patient-generated data that both can be imperfect 
(Roden & Denny, 2016; W. Q. Wei et al., 2016). Moreover, data within the EHR can be 
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structured, such as coded data (e.g. Logical Observation Identifiers Names and Codes 
(LOINC), Systematized Nomenclature of Medicine - Clinical Terms (SNOMED CT), and 
International classification of Diseases (ICD)) that can be used for billings and diagnosis 
(N. Alnazzawi et al., 2015; Ho et al., 2014). On the other hand, EHR data can be 
unstructured providing detailed information about clinical setting findings, vitals, 
symptoms, diagnosis, and signs (N. Alnazzawi et al., 2015), such as discharge summaries, 
radiology reports, and progress notes. However, with respect of phenotyping, there is a 
trade-off between the use of structured and unstructured data. Structured data can miss 
tremendous amount of clinical information about the patient, but it can be more 
interoperable, and machine-readable.  On contrary, unstructured data is enriched with 
detailed clinical information that derived more knowledge about diseases, but it is more 
difficult to manipulate, and it needs new computational approaches. 
 
3.2.2 Standardized terminologies for EHR phenotyping and literature mining 
One of the biggest challenges in EHR secondary use is data interoperability. In fact, 
efforts of developing phenotyping definitions are known to lack standardization and 
portability (Fort, Wilcox, & Weng, 2014; Simonett et al., 2015). As a result, inconsistency 
creates a difficulty in using these definitions across different EHR systems (Declerck et al., 
2015). In this section, a description of the common standardized terminologies is provided. 
There are many standard terminologies that are commonly used for different clinical 
purposes, such as Medical Dictionary for Regulatory Activities (MedDRA) for adverse 
events, and Systematized Nomenclature of Medicine - Clinical Terms (SNOMED CT) for 
clinical representation. Since we are using ADE as our example for phenotypes of interest, 
it is recommended to combine SNOMED CT, which is the most comprehensive 
terminology for clinical use, with MedDRA, which is used for adverse events but is not 
commonly used in clinical practice (Declerck et al., 2015). For literature uses, Medical 
Subject Headings (MeSH) terms were developed to index biomedical literature (S. T. Wu 
et al., 2012) which has been integrated in Merged disease vocabulary (MEDIC) (Davis, 
Wiegers, Rosenstein, & Mattingly, 2012). These terminologies are not only supportive for 
EHR phenotyping, but also for literature phenotyping and mining. Therefore, our 
dictionary integrates the above mentioned terminologies that are combined as a one 
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dictionary to serve our text mining tasks. Here, we provide a brief description for each of 
these terminologies: 
1. Medical Dictionary for Regulatory Activities (MedDRA) (Brown et al., 1999) is the 
international medical terminology developed under International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH). MedDRA has been widely used in classifying adverse events in 
clinical trials and event reporting systems (Reich, Ryan, Stang, & Rocca, 2012). 
MedDRA is characterized by its five levels hierarchy, which are System Organ Class 
(SOC), High Level Group Term (HLGT), High Level Term (HLT), Preferred Terms 
(PT), and Lowest Level Term (LLT). Furthermore, MedDRA covers pharmaceutical 
regulatory affairs terms, such as diagnoses, drug reactions, signs and symptoms, and 
procedures. Some of the advantages of using MedDRA is its completeness, accuracy, 
and flexibility (Brown et al., 1999). 
2. Systematized Nomenclature of Medicine - Clinical Terms (SNOMED CT) is 
maintained by the International Health Terminology Standards Organization 
(IHTSDO). IHTSDO is a non-profit organization that owns SNOMED CT and was 
founded in 2007. SNOMED CT is considered as the most comprehensive health 
terminology in the world for clinical documentation in EHR. One of the features of 
SNOMED CT is that it can be mapped to other terminologies, such as ICD9 and ICD 
10 codes. In fact, SNOMED CT is the largest resource that was developed specifically 
for clinical use (S. T. Wu et al., 2012). In addition, it supports data interoperability in 
healthcare settings. Therefore, mapping data from literature to SNOMED CT 
terminologies can be support for text mining tasks, particularly Named entity 
recognition (NER). 
3. International classification of diseases (ICD) is the standard for classifying diseases 
and conditions for clinical care use. ICD is the official coding system for coding 
procedures and diagnosis in the United States. ICD-9-CM is based on the World Health 
Organization’s Ninth Revision, International Classification of Diseases (ICD-9). For 
our dictionary, we will incorporate the available ICD-9 procedure terms to combine 
them with SNOMED CT procedure terms. 
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4. Comparative Toxicogenomics Database (CTD) is a publicly available database that 
provides manually curated information about diseases, genes, and chemical.  Merged 
disease vocabulary (MEDIC) (Davis et al., 2012) is a subset of diseases from the U.S. 
National Library of Medicine's Medical Subject Headings (MeSH) (Lipscomb, 2000), 
and a subset of genetic disorders from the Online Mendelian Inheritance in Man® 
(OMIM) database. MeSH vocabulary has been used to index MEDLINE/PubMed 
articles. On the other hand, OMIM has links of its diseases to many resources, such as 
MEDLINE. We believe that using MEDIC in our dictionary would enhance its 
coverage. 
 
3.2.3 Biomedical literature text mining 
Text mining was successful in several applications, such as protein-protein 
interaction, bio-entity tagging, normalization, and term extraction (Krallinger, Valencia, & 
Hirschman, 2008). Most of knowledge that requires analysis is represented in text. This 
knowledge provides a rich resource of scientific information (Fleuren & Alkema, 2015) 
that is mostly found within biomedical literature (Krallinger et al., 2008; Shatkay & 
Craven, 2012). For instance, PubMed offers over 24 million citations (Fleuren & Alkema, 
2015) and is the most accessible database for the biomedical literature with more than 5000 
biomedical journals, MeSH indexed, links to full text. Full texts can come in PDF or HTML 
formats where each of these possess its own challenges (Shatkay & Craven, 2012).  
Text mining, literature mining, and text data mining are terms that have been used 
with the goal of making an effective use of the biomedical text with the utilization of 
computational tools. Text mining implies mining of valuable information within text. Text 
mining is not a single-step process, but rather it is a multi-task process which involves, user 
needs, accessibility to text source, text representation (e.g. PDF and XML), tools, and 
evaluation (Shatkay & Craven, 2012). Text mining automates the process of discovering 
and extracting knowledge from unstructured text to represent knowledge in a concise 
format and to generate hypotheses (Ananiadou et al., 2006; Rebholz-Schuhmann et al., 
2012; Spasic et al., 2005). Most of text-mining tools consist of two major steps: information 
retrieval (retrieve relevant text and documents) and information extraction (extract 
information and knowledge from text) (Ananiadou et al., 2006; Rebholz-Schuhmann et al., 
 
51 
2012). Examples of the text-mining tasks and their descriptions (Shatkay & Craven, 2012), 
are:  
 The process of segmentation is to segment a document into smaller units, such as 
sections. Within these units, there are paragraphs and sentences. The paragraphs and/or 
sentences are further tokenized into smaller segments or tokens that can be either 
sentences or words. This process possesses some challenges such as the recognition of 
the end of a sentence. For example, a period can mean the end of a sentence or an 
abbreviation. In addition, recognizing token boundaries of biomedical text is another 
challenge. For this, medical dictionaries can be used as a solution for this, but there can 
be other solutions that are out of our scope. Therefore, the overall objective of the 
tokenizer is highly reliant on the used application. 
 Most of the literature documents are represented as PDF or HTML. Therefore, 
document conversion into free text is important but the structure of the final converted 
text is dependent on how the original format was presented. For example, PDF 
documents are more concerned on how the information look like rather than the 
structure of information. However, when converting PDF to text, the text might not 
presented in the correct order or characters. On the other hand, XML is more structured, 
but the structured can vary across publishers. 
 Normalization is one of the tasks. There are several normalization approaches, such as 
converting all letters to lowercase. Stemming is another approach where we trim the 
end of the word without the context involvement. On the other hand, lemmatization is 
a linguistic-oriented approach and it considers parts of speech, morphological rules, 
and lemmas. The used method/s is highly dependent on the application. 
 Chunking is the process of grouping words into phrases. 
 Parsing is the process of analyzing a sequence of words (Shatkay & Craven, 2012). 
In this work, we proposed building an automated text-mining approach to mine 
phenotyping definitions-related sentences in the biomedical literature. To achieve this goal, 
we performed several tasks. First, we build an annotated corpus for abstracts and full-text 
sentence-level (Chapter 2) and we used it to train and test machine learning algorithms. In 
these classifiers, we created features utilizing several text-mining approaches based on 
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analyzing patterns and contextual cues of a phenotyping definition. Second, we performed 
a large-scale information retrieval and extraction using the trained and validated classifiers. 
 
3.3 Methods 
We developed a text-mining pipeline for classifying abstracts and full texts on a 
sentence-level. First, the Abstract-level classifier to retrieve and classify abstracts with 
relevant content of observational studies. Second, Full-text sentence-level classifier to 
identify and extract method sections, and to classify positive sentences in full texts with 
evidence of a phenotyping definition. 
 
3.3.1 Building Lexica and Dictionary 
Our research group is primarily interested in adverse drug events (Duke et al., 2012; 
H. Y. Wu et al., 2017). In Chapter 2, we proposed a list of 279 ADEs as phenotypes for 
data collection. The primary list of 279 ADE terms (Appendix 1) are represented as 
MedDRA PT level (Brown et al., 1999). In order to develop a text-mining suite for 
extracting phenotyping related sentences, we developed a comprehensive terminology that 
assists in information retrieval (IR) and information extraction (IE) tasks from both 
literature and medical records. Our aim is to increase the coverage of terms. In addition to 
MedDRA, a number of terminologies are integrated: SNOMED CT) (Stearns, Price, 
Spackman, & Wang, 2001), MEDIC (Davis et al., 2012), ICD-9 procedures, and DrugBank 
(Wishart et al., 2006). For the task of IE NER, we created four dictionaries: 
This ADE dictionary is built by mapping our list of ADEs to all synonyms in 
MedDRA LLT, SNOMED CT, and MEDIC. The most recent version of SNOMED CT 
terms SNOMED CT was downloaded from Unified Medical Language System (UMLS) 
and MEDIC data were downloaded from CTD database. Within MEDIC, we used 
MeSH/OMIM terms, synonyms, and codes. SNOMED CT and MEDIC were mapped to 
MedDRA concepts (PT & LLT) using exact match method (Table 7). The clinical 
dictionary includes all clinical concepts excluding data from ADE dictionary for each of 
MedDRA (PT, LLT), SNOMED CT (diseases and disorders, body structure, clinical 
finding, clinical event, observable entity, organism, and the situation with explicit context), 
and MEDIC. The procedure dictionary is for procedures performed within a healthcare 
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setting. For this dictionary, we included procedures from SNOMED CT and ICD-9 
procedures. Finally, the drug dictionary is for drug terms from DrugBank1. 
 
Table 7 Mapping terms to ADE list of 279 phenotypes 
Source Number of mapped terms to ADE Number of unmapped to ADEs 
SNOMED CT 274 5 
MEDIC 140 139 
 
3.3.2 Corpus description 
In this work, we followed a similar approach to the manual or human-based process 
of reviewing literature-based medical knowledge by an abstract selection and full texts 
retrieval (Cohen et al., 2010). For the abstract selection, we manually reviewed abstracts 
for their relevance to observational-based studies in EHR. PubMed articles were searched 
for the 279 ADEs. We manually reviewed abstracts and decided on their relevance to 
observational studies using EHR data (See Chapter 2). The negative abstracts (n=1079) 
were selected randomly from PubMed foe years between 1995 and 2017. In constructing 
the full-text sentence-level corpus, a random subset from the positive abstracts in abstract 
corpus were selected. Their full texts were retrieved, and sentences in the method sections 
were extracted. More details about the annotation guidelines and performance as well as 
the annotated dimensions in Chapter 2 (annotation examples were shown in (Binkheder, 
Wu, Quinney, & Li, 2018) and Table 2). A summary description of the corpus is provided 
in Table 8. 
 
Table 8 Corpus summary 
Corpus Document type Class Number of documents Total 
Abstract-level Abstract Positive 799 
1878 Negative 1079 
Full-text sentence-level Sentence Positive 1923 
3971 Negative 2048 
 




The positive class, for either abstracts or sentence-level, means that they contain 
information about phenotype definitions. Sentences with a phenotype definition 
information can contain a description used for defining a phenotype or for building a cohort 
in an EHR that can include the inclusion and/or exclusion criteria or algorithmic criteria. 
Within an EHR context, “A phenotype is defined as a biochemical or physical trait of an 
organism, such as a disease, clinical or physical characteristics, or blood type” (Yadav et 
al., 2018). Several practices are used for defining phenotypes can be seen within the 
phenotyping definition descriptions, such as diagnostics terms or codes, clinical 
characteristics, laboratory tests values, use of medications, risk factors, use of standardized 
terminologies, and the use of NLP (e.g. list of keywords used) (Chute et al., 2011; R. 
Richesson et al.; Yadav et al., 2018). In addition, information about data sources (e.g. 
demographics, vitals, notes, electronic medical records) (Shivade et al., 2014) used in 
defining the phenotype can be potential for phenotyping, and it can appear in phenotype 
definitions-related sentences. 
On the other hand, the negative class, for either abstracts or sentence-level, means 
that they do not contain relevant information for phenotyping or defining a phenotype, such 
as financial information, location of the study, and computational and statistical analyses. 
An example of a negative sentence, 
 
“Since nearly everyone residing in the target ZIP code for the current study 
receives their health care through Marshfield Clinic, this record is 
considered comprehensive.” (PMID17456828). 
 
3.3.3 Information retrieval: the abstract-level classifier 
The abstract classifier is a binary with two categories: positive for abstracts that 
satisfied the criteria for observational studies, and negative for abstracts that were not 
(Table 2). The abstract corpus was implemented in Waikato Environment for Knowledge 
Analysis (WEKA) as string attributes where each contains a title and an abstract. 
“StringToWordVector” module in WEKA was used to represent each text document as a 




“NGramTokenizer (1-3 grams)”, “IDFTransform” (Inverse Document Frequency (IDF) 
Transformation), and “TFTransform” (Term frequency score (TF) Transformation). 
After pre-processing of text data and defining these input features, we tested several 
classification approaches and trained our classifier on the best algorithm, including 
sequential minimal optimization (SMO) (Platt, 1999), logistic regression (LR) (Quinlan, 
2014)), Naïve Bayes (NB) (John & Langley, 1995), and decision trees (C4.5 clone 
(Lecessie & Vanhouwelingen, 1992) called J48 in WEKA). All of the analyses were 
performed in WEKA software (Figure 4). 
 
 
Figure 4 Classifiers training and prediction flowchart 
NER: Named-entity recognition 
 
3.3.4 Information extraction: the full-text sentence-level classifier 
Document representation is a necessary pre-processing step for machine learning 
to represent text documents as vector of significant terms or patterns (Dalal & Zaveri, 2011; 
Khan, Baharudin, Lee, & Khan, 2010). There are several approaches that can be used for 
document representation utilizing different levels of linguistic processing, such as co-
occurrence, single term or token, and/or phrase approach (Khan et al., 2010). We used our 
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observations and intuitions to generate features (Kilicoglu, Rosemblat, Malicki, & ter Riet, 
2018) that were inspired by features from the annotation guidelines in Chapter 2. 
The sentence level classifier identifies phenotyping related sentences from full 
texts. This classifier is trained using full text sentence level corpus (Table 8). This corpus 
is a collection of documents (i.e. each document is a sentence from full texts’ methods 
sections. We constructed 339 features from this corpus and converted the corpus into a 
matrix of numerical attributes: binary (0, 1), count of terms in a sentence, or sum of values 
multiple attributes (i.e. sum of attribute values for specific set of features). After the text 
pre-processing and features extraction, we trained the sentence-level full-text on four 
algorithms, SMO (Platt, 1999), J48 Decision Tree (Quinlan, 2014), Logistic Regression 
(Lecessie & Vanhouwelingen, 1992), and Naïve Bayes (John & Langley, 1995). All the 
sentence classifier is trained for binary classification: positive and negative (Figure 4). 
Most of the extracted features used for representing each sentence in the corpus 
were based on Named-Entity Recognition (NER) technology. NER of medical terms for 
ADE, clinical, procedure, and drug entities (the dictionaries used for this task are shown in 
Table 10). For ADE entities, the 279 ADE phenotypes (listed in Appendix 1) were mapped 
to their exactly matched concepts and synonyms in other dictionaries which are Merged 
disease vocabulary (MEDIC) (Davis et al., 2012) and SNOMED-CT. With this, these 
ADEs terms and their synonyms were excluded from clinical and procedure entities’ 
dictionaries (Table 10). For clinical entities, SNOMED CT dictionary includes terms for 
body structure, finding, event, observable entity, organism, and situation. For drug entities, 
we used DrugBank. Other NER features used for recognizing phenotype definitions’ 
keywords (e.g. “defined as” and “identify”). These keywords were previously identified 
either manually during the annotation process, or using automated approaches such as n-
grams, term frequency (TF-transform), and inverse document frequency (IDF-Transform) 
(Binkheder et al., 2018). Overall, there we used two ways to represent these features, which 
are described below. 
Single-features refer to single term or pattern representations without rules. Several 
feature reduction techniques were used, such as word stemming (Dalal & Zaveri, 2011) 
and regular expression patterns. Regular expressions were used to capture some patterns, 
such as values of blood pressure, lab, age, height, weight, and body mass index (Appendix 
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6). NER of medical terms were used to represent single entities as single-features (Table 
10 and examples are shown in Appendix 7). In addition, NER of phenotype definitions’ 
keywords is used to represent phenotype definition-related information as one single 
feature. These definition keywords can be words or phrases, such as “defined", 
"definition", "classified", "defined as", "identification", "identified", "diagnosis of", 
"diagnostic criteria", and "case identification". For example, “Controls were patients 
without evidence of (definition keyword) PAD” (PMID20819866). In this sentence 
example, evidence of is recognized as a phenotype definition keyword and it can be 
represented as a single feature called “definition keywords”. 
Compound-features (c-features) refer to the co-occurrence of terms without any 
order or distance specifications between these terms. This approach was introduced by 
Figueiredo et al. (Figueiredo et al., 2011) who showed that combining c-features with other 
e.g. single-features improved the performance of classification. For example, 
 
“Confirmed adult-onset asthma (ADE entity) (AOA) cases were defined as 
(definition keywords) those potential cases with either new-onset asthma 
(ADE entity) or reactivated mild intermittent asthma (ADE entity) that had 
been quiescent for at least one year” (PMID12952547). 
 
In this example, asthma is recognized as an ADE entity, and defined as is 
recognized as a definition keyword. With this, the co-occurrence of ADE entity and 
definition keywords can be represented as one compound-feature indicates that this 
sentence has a phenotype definition for asthma. C-features can be also used, for instance, 
for the co-occurrence of “DRUG” entities with any of the medication-related terms, such 
as "initiat", "window", "dose", or "value". We hope that some c-features can represent 
important patterns of sentences in our corpus. Additional examples are shown in Appendix 
7. 
 
3.3.5 Classifiers performance evaluation 
For each of the abstract-level and full-text sentence-level classifiers, the full corpus 
was divided into 70% for training and 30% for testing. These algorithms were evaluated 
using 10-fold cross validation. The training and validation were performed in WEKA. To 
 
58 
assess the classifier performance, we used a number of matrices (Zaki, Meira Jr, & Meira, 
2014), which are: 
1. Recall (Sensitivity) The proportion of the correct predictions for the positive class, 










3. F-measure The F-measure is the trade-off between precision and recall where the 






3.3.6 Large-scale literature screening 
The large-scale screening of PubMed database is summarized into three major 
phases: large-scale screening of abstracts, full text data pre-processing, and large-scale 
screening of full-text sentence-level (Figure 5 & Figure 6). 
 
3.3.6.1 Phase 1—Large-scale screening of abstracts 
In this phase, we downloaded abstracts from PubMed database for years 1975-2018 
(1st Quarter). We selected the machine-learning algorithm with the highest performance 
(Table 8) in Weka software package. Using abstract-level classifier, PubMed abstracts that 





Figure 5 Flowchart for large-scale data processing 
 
3.3.6.2 Phase 2—Full text data pre-processing 
After the abstract-level retrieval, we retrieved full text articles in PDF or XML 
format. These files were pre-processed by converting them into text and then into GENIA 
format. The steps are as the following: 
1. Retrieve positive full text PDF and XML documents. Using our positive set of abstract 
PMIDs, their PDF and XML documents were downloaded from PubMed repository if 
they are open access articles or from the subscribed publisher by our institute. We 
excluded abstracts that were not human studies.  
2. Convert PDF format to text format. After retrieval of the PDF documents, they were 
converted to text format with pdftotext1 tool. In addition, sentences are tokenized and 
                                                 




their boundaries are defined (Dalal & Zaveri, 2011) using a package called 
Perl::Tokenizer. 
3. Convert from text format to GENIA XML format. GENIA format (J. D. Kim et al., 
2003) has been used for bio-text-mining of the literature. GENIA is an XML format in 
which each article is annotated with PMID, Title, and full text sentences (Figure 6). 
4. Extraction of method sections. Biomedical text in scientific papers are usually 
represented by four major sections; introduction, methods, results and discussion 
(IMRAD) (S. Agarwal & Yu, 2009). Using IMRAD keywords and rule-based methods, 
we were able to identify boundaries of the methods sections and extract them (Figure 
6). IMRAD is a standard format that was recommended by American National 
Standards Institute (ANSI) since 1979 (American National Standards Institute. & 
Council of National Library and Information Associations (U.S.), 1979), where it is the 
most used format in many research journals (Nair & Nair, 2014). We utilized rule-
based approach to extract these sections based on number of features (Figure 6). To 
automate extraction of method sections within the full texts according to IMRAD, we 
used “Baseline” classifier system which showed strong performance (S. Agarwal & 
Yu, 2009). “Baseline” system is a simple classifier that works by assigning each 
sentence IMRAD category to its original IMRAD section in structured full texts (S. 
Agarwal & Yu, 2009). Therefore, we developed a rule-based program that assigns 
sentences to IMRAD headings. We used two categories for our system: relevant section 
and irrelevant section (Table 9). For example, if a keyword “Methods” appears in a 
sentence all subsequent sentences were assigned to “Methods” until “Results” 
keywords appear. Specifically, features that implies heading were considered, such as 
capitalization of first letter of the keyword, the presence of “:” or “—” after the 
keyword, or the presence of capital letter after the keyword. Keywords and rules used 
are shown in Appendix 8. 
 
Table 9 Sections used for the “Baseline” extraction of full text articles 
Category Sections Reason 
Relevant 
section 
Methods Methods sentences are the sentences that we used for 





References, Other sections 
Sentences from these sections did not show a 






Figure 6 Full text processing (Phase 2 & 3 in Figure 5) 
 
3.3.6.3 Phase 3—Large-scale screening of full-text sentence-level 
After full text processing and method section extraction, we followed similar steps 
of feature definitions for the sentence classifier when it was trained in the corpus (Figure 5 
& Figure 6). First, NER was conducted to identify and normalize ADE/medical and drug 
terms (the dictionaries used for medical entities are described in 3.3.1 section). Second, 
sentences ware represented as a matrix. Each row represents one sentence, and each column 
represents a feature. This data matrix is ready for the sentence-level classification. We used 
our optimal full-text sentence-level classifier trained from our corpus for the prediction. It 
was conducted in in WEKA software package. Positive sentences, i.e. phenotyping related, 





3.4.1 The dictionary and lexica 
Table 10 shows the dictionary and lexica that we developed for text-mining tasks 
by combining multiple standard terminologies. These were used mainly for the IE full-text 
sentence-level classifier. For example, a sentence with any of ADE entities is represented 
as a feature in the matrix of phase 3 (Figure 5). Similarly for CLINICAL, Procedure, and 
Drug entities. 
 
Table 10 Dictionary for 279 adverse drug events (ADEs) and other medical terms used 
for extraction of full-text sentence-level features 
Entity & Dictionary Number of terms 
279 ADEs (100%) 5627 
        MedDRA PT (4.9%) 279 
        SNOMED-CT (62.5%) 3517 
        MEDIC (MESH) (32.5%) 1831 
CLINCAL (100%) 471979 
         SNOMED-CT (84.3%) 398077 
         MEDIC (MESH) (15.3%) 72167 
         MEDIC (OMIM) (0.4%) 1735 
Procedure (100%) 190399 
         SNOMED-CT (98.8%) 188031 
         ICD-9 Procedures (1.2%) 2368 
Drug (100%) 21752 
        DrugBank (100%) 21752 
Total 689751 
 
3.4.2 Optimal machine learning algorithms for classifying phenotyping 
related abstracts and full text sentences 
The abstract-level classifiers were built upon the positive and negative abstract 
training dataset in our corpus. Table 11 shows the performance of the abstract-level 
classifier for SMO, J48 Decision Tree, Logistic Regression, and Naïve Bayes. SMO and 
J48 Decision Tree outperform the other algorithms, and their recall, precision, and F-
measure are as high as 97%; while Naïve Bayes and logistic regression’s performances are 
slightly lower. 
Similarly, full-text sentence-level classifiers were developed under the positive and 
negative sentence training dataset in our corpus.  The classification performances of SMO, 
decision tree, logistic regression, and Naïve Bayes, are reported in Table 11. Overall, SMO 
and logistic regression showed the best performance, and their precision, recall, and F-
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measures reach as high as 0.84. Decision tree and Naïve Bayes’s performances were a bit 
lower. Similar to the abstract level classifiers, sentence level classifiers were trained under 
the 10-fold cross-validation in the training set. 
 
Table 11 Classifiers performance for abstract level classifiers and full sentence classifiers 
on 10-cross validation 
Classifier Algorithm Precision Recall F-Measure 
Abstract-level Classifier *SMO 0.972 0.972 0.972 
J48 Decision Tree 0.971 0.971 0.971 
Logistic Regression 0.953 0.953 0.953 
Naïve Bayes 0.924 0.908 0.909 
Full-text sentence-level Classifier 
 
SMO 0.846 0.844 0.843 
J48 Decision Tree 0.817 0.816 0.816 
*Logistic Regression 0.840 0.838 0.837 
Naïve Bayes 0.799 0.796 0.794 
*The selected algorithm for this classifier 
 
For the full-text sentence-level classifier, we optimized the performance for recall. 
The default threshold that is used in WEKA is 0.5 where the predicted probability should 
be higher than 0.5 to be predicted as ‘positive’. This threshold can be adjusted manually in 
Weka using “manualThresholdValue” for values between 0 and 1. Figure 7 shows the plot 
to visualize the threshold values of the predicted probability for logistic regression. Since 
we were interested in high recall, we selected 0.2 as our threshold for ‘positive’ category 





Figure 7 Full-text sentence-level classifier performance using logistic regression 
(threshold selector) 
 
Both the abstract-level and full-text sentence-level classifiers were further validated 
by a random subset of 30% of the corpus. Table 12 shows the number of documents for 
each of the training and testing dataset. Both abstract level classifier and sentence level 
classified have the comparable performance as in their training samples, and F-measures 
are 0.98 and 0.81 respectively. 
 
Table 12 Classifiers validation results on testing dataset (70% validation results) 
Classifier Training Testing Optimal 
Algorithm 
Class Performance measures 
Precision Recall F-Measure 
Abstract-
level 
1315 563 SMO Positive 0.97 0.98 0.98 
Negative 0.99 0.98 0.98 




2780 1191 Logistic 
Regression 
Positive 0.79 0.86 0.82 
Negative 0.85 0.77 0.81 




3.4.3 Literature large-scale prediction results 
For literature large-scale phenotyping case definitions discovery, we used our 
validated classifier for the automatic phenotype discovery (Table 11). PubMed abstracts 
were used for years between 1975 and first quarter of 2018. Using our abstract-level 
classifier (SMO machine-learning algorithm), the number of abstracts that were predicted 
as positive, i.e. phenotyping related, are 459,406 abstracts (the distribution of abstracts on 
years is shown in Appendix 9. For positive abstracts, we retrieved their full texts. Some 
filters were applied, such as institutional full text accessibility and exclusion of animal 
studies. We retrieved the full text only either as PDF or XML. Some scanned articles (i.e. 
pictures) cannot be converted into text file, and full texts with issues in either PDF and 
XML format were excluded. Therefore, the total number of the final set of full texts is 
120,868. Using these full text articles, 6,129,574 sentences were extracted from their 
methods sections. Using our full-text sentence-level classifier (logistic regression machine-
learning algorithm), the number of sentences that were predicted as positive were 
2,745,416. Table 13 shows a summary of the results. 
 
Table 13 Results for large-scale screening of abstracts and full texts sentences 
Abstracts (Abstract-level classifier) 
Number of predicted positive abstracts (1975-2018 “Mid-March”) 459,406 
Full-text Retrieval 
Number of full text retrieved (Filters: full text available, not animal studies) 141,511 
Number of full text after data processing 120,868 
Full-text sentence-level classifier 
Total number of sentences (Method section) 6,129,574 
Number of predicted positive sentences 2,745,416 
Number of predicted negative sentences 3,384,158 
 
3.5 Discussion 
This study proposed an automated approach to mine a phenotyping case definition 
in the biomedical literature. First, we built a dictionary that we used in text-mining tasks, 
such as NER. We used several standard terminologies to build dictionary has 689,752 terms 
for entities: ADEs, Clinical, procedure, and drug. Second, we built two classifiers and 
selected the optimal machine learning algorithms using our annotated corpus from Chapter 
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2, which are abstract-level and full-text sentence-level classifier with F-measures 0.98 and 
0.81, respectively. Third, we used our validated classifiers for large-scale information 
retrieval and extraction in the literature. We predicted 459,406 abstracts as positive that 
were used for further analysis after applying some further filters that includes abstracts 
with full texts and exclude abstracts for animal studies. We were able to include 120,868 
full texts, utilized their sentences within methods sections, and predicted 2,745,416 
classified as positive. Using these sentences, we aimed to support research for phenotyping 
by deriving literature scientific information with evidence of a phenotyping definition. 
 
3.5.1 Error analysis 
We performed an error analysis to identify sources of error. We randomly selected 
100 misclassified sentences and identified some possible reasons for the misclassifications 
of full-text sentence-level classifier. Table 14 shows examples of errors. These are 
challenges associated with text-mining. Ambiguity is one of the challenges where in some 
situations it is hard to correctly infer the meaning of character, symbol, or term. For 
example, periods can indicate the end of a sentence or a word abbreviation (Shatkay & 
Craven, 2012). An error we called as Negative atypical showed the highest number among 
others with 40% appeared in sentences. A possible reason is that we extracted features that 
focused on positive cues for evidence of a phenotyping definition. These sentences can be 
also very similar to positive sentences in features, but it is negative. On the other hand, 
positive atypical are sentences that shows no evidence for positive cues or few that were 
not sufficient to classify correctly them as positive. One of the reasons can be because these 
sentences are too short that few or no positive cues found, but they are still supportive for 
phenotyping. Clinical dictionary and keywords dictionary showed also percentages of 37% 
and 35%, respectively. Both of these errors are utilizing NER approaches. The difference 
is the clinical dictionary used clinical entities from standardized dictionaries, such as 
MedDRA. On the other hand, keywords dictionary are the terms that we derived from our 
corpus analysis for positive or/and negative cues that represent or does not represent a 
phenotyping definition. In addition, abbreviations were challenging. Even though we used 
general approaches of patterns recognition to recognize some of the abbreviations such as 
term length and preceded or succeeded terms, this was not one of the scope of this work. 
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Word boundary detection and semantic ambiguity were the lowest frequent errors among 
this subset of 100 sentences with 16% and 7%, respectively. 
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3.5.2 Limitations of the study 
This work does not stand without limitation. The annotated corpus might not be 
representative to all of the cases that either represent or does not represent a phenotyping 
case definition. However, based on the error analysis, these cases are not very problematic 
as we optimized the full-text sentence-level classifier for high recall for positive class. 
Another limitation is reliance on NER features for the automatic classification of sentence-
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level (S. N. Kim, Martinez, Cavedon, & Yencken, 2011). Our error analysis shows that 
some terms might not be correctly recognized or are not present in the dictionaries. 
Therefore, we note that these lexical-based methods require frequent updating of the 
dictionaries. Furthermore, hand-crafted features based on expert evaluations have also been 
used for sentence-level features, where it might not be optimal. We note that we utilized 
TF and TF-IDF for extracting some of these terms (Binkheder et al., 2018). Additional 
automatic representation and detection of features might be supportive in future studies 
(Kilicoglu et al., 2018) for better representation and performance. 
Most of the literature documents are represented as PDF or XML. For example, 
PDF documents are more concerned on how the information look like rather than the 
structure of information. On the other hand, XML are more structured, but the structured 
can vary across publishers (Shatkay & Craven, 2012). This creates a challenge as we found 
some of the PDFs were in image format and/or some of XML were without content. Due 
to the challenges associated with full texts, most of the studies have focused on abstracts 
because they are free, easy to download, concise, and less challenging to mine (Shatkay & 
Craven, 2012). Here, our goal was to use full texts as we found that they contain most of 
the information for representing a phenotyping definition. Overall, conversions of full texts 
from PDF to text generated several unwanted characters, especially when using this 
information in GENIA XML format. 
 
3.5.3 Future work 
We believe that our large-scale corpus of predicted positive sentences provides a 
potential source for further applications of mining phenotyping definitions, such as 
implementing an evidence-based best practices for cohort identification research studies 
(Yadav et al., 2018). Several of studies shows that relying only on ICD-9 codes is not 
sufficient in building cohorts, and it is critical to utilize other sources like clinical notes 
(Iyer et al., 2014). Most efforts of automating the development of phenotyping definitions 
used EHR data, such as billing and administrative data and clinical text (Yu et al., 2015) 
can be biased. Developing data-driven approaches and more structured definitions using 
literature-mining of phenotyping definitions is recommended. Based on the challenges of 
developing DILI algorithm, such as identification of patients with rare conditions, 
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incomplete knowledge about DILI and its translation to phenotyping definition 
expressions, and variations in interpretation of the definition, textual descriptions of 
definitions are still an issue (Overby et al., 2013). We believe that this is one of the steps 
towards standardization of phenotyping definitions. Literature showed that the differences 
across phenotyping definitions can affect their applications across studies as well as the 
interpretation of results (Chute et al., 2011) and standardization for better portability is still 
a challenge (Fort et al., 2014). There were some efforts in the standardization of the 
representation phenotyping definitions (Chute et al., 2011). Examples are eMERGE and 
OMOP where eMERGE supports portability (Ho et al., 2014). When a phenotyping 
definition is standardized, it can provide consistent inclusion and exclusion criteria to 
define a phenotype of interest across databases (R. Richesson et al.). Utilizing our collected 
sentences, future text-mining applications can be built for tasks, such as information 
extraction and text summarization. Furthermore, we believe that literature-based mining of 
a phenotyping definition supports future work of hypothesis generation to discover 
unknown and novel correlations and patterns for phenotypic associations hidden in text. 
In conclusion, we proposed an automated approach to extract sentences with 
information of a phenotyping case definition. Two classifiers were built: abstract-level and 
full-text sentence-level. Both classifiers showed good performance in predictions and were 
applied to large scale literature. Future efforts are needed to support areas of text mining 




CHAPTER FOUR: DISCOVERY STUDY TO REPRESENT AND VALIDATE 
LITERATURE-BASED PHENOTYPING DEFINITIONS 
 
In Chapters 2 and 3, we created corpora for abstracts and full texts’ sentences to 
retrieve and extract phenotyping definition-related information. In this chapter, we utilize 
our large-scale corpus of over two million sentences that were predicted as positive for 
phenotype definition-related sentences. Our goal is to perform information extraction and 
a knowledge discovery study for some phenotypes of interest, such as type 2 diabetes and 
myopathy. After that, we provide some evaluations of the used approaches in this study. 
 
4.1 Introduction 
A phenotyping definition is critical for clinical and pharmacovigilance research. 
World health organization (WHO) and the centers of Disease Control (CDC) developed 
case definitions for some conditions (Botsis & Ball, 2013), these are referred by low-
throughput or expert-driven definitions (R. L. Richesson et al., 2016) that we introduced in 
Chapter 3. Low-throughput or expert-driven has several challenges. For example, we 
introduced the PheKB example (in Chapter 2 & 3) that is capable of disseminating and 
validating definitions across institutions. However, they lack structured representation of a 
case definition (Chute et al., 2011). Low-throughput phenotyping is still a long process, 
labor-intensive not scalable, and does not cover all phenotypes of interest (Botsis & Ball, 
2013; Henderson et al., 2017). Therefore, the main drawbacks with such manual processes 
of developing (Botsis & Ball, 2013) and representing (Rosenman et al., 2014) a 
phenotyping definition is affecting the progress of several research areas and surveillance. 
Existing phenotyping definitions are useful to establish clinical study or to validate 
these definitions. However, existing definitions are more complete for some conditions, 
e.g. myocardial infarction, but less complete for others, e.g. osteoporosis (Rosenman et al., 
2014). Additionally, most of these definitions are not capable of handling complex models, 
such as the ones for unstructured data (Xu et al., 2015) that lack flexible phenotyping 
definitions (Thompson et al., 2012). In validation challenges, an increase in definition 
complexity means harder validation across different institutions, e.g. HTCP definitions 
lack of standardization across EHRs (Simonett et al., 2015). Therefore, there is a need of 
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informatics approaches to automate the general process of representing case definitions 
(Botsis & Ball, 2013). 
The current direction is towards developing automated approaches for high-
throughput phenotyping that uses data-driven approaches (Conway et al., 2011; R. L. 
Richesson et al., 2016). Machine learning algorithms are more capable of discovering 
unknown relationships because the prediction logic uses real-world data rather than prior 
knowledge. Phenotypes generated from such data-driven approaches are called 
computational phenotypes that can be rapidly generated in high volumes to scale up to the 
needs of high-throughput phenotyping (R. L. Richesson et al., 2016). However, current 
efforts of high-throughput phenotyping are mainly using EHR data to generate or derive 
computational phenotypes. The use of EHR data has several limitations. The nature of 
EHRs suffer from several issues, such as bias, confounding, missing/incomplete data, 
irregular data (Castro et al., 2014; Yadav et al., 2018), and more were discussed in Chapter 
3. Furthermore, structured data, e.g. ICD-9 codes, have shown limited results in 
phenotyping; in comparison, when combined with NLP it showed better performance 
(Kotfila & Uzuner, 2015; Liao, Cai, et al., 2015; Roden & Denny, 2016) to obtain cases. 
Limestone (Ho et al., 2014) is an example of an EHR-based effort that uses data-driven 
approaches for deriving candidate computational phenotypes without the need of human 
supervision. Limestone investigated the interactions between diagnoses and medications 
using “tensors (a generalization of metrics)”. They confirmed that 82% of the top 50 
candidate phenotypes are clinical meaningful. Some of the limitations of Limestone, are: 
did not address portability, relied on only one medical expert, not all candidate were 
clinically meaningful (generating novel), and did not use text notes (Ho et al., 2014). 
Therefore, we believe that using EHR data to generate candidate computational phenotypes 
is not sufficient and should be supported with other sources such as biomedical literature. 
There are several studies that used literature-based knowledge discovery. In 
“Automating case definitions using literature-based reasoning” (Botsis & Ball, 2013), 
Botsis and Ball used co-occurrence approach and network-graph to automate 
representation of “anaphylaxis” definitions from literature abstracts. Their aim is to replace 
the manual identification of synonyms and definitions by automation. They used case-
based reasoning that utilize existing knowledge and build sematic similarity framework 
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combined with machine learning approaches. Semantic relationships were used to build 
the graph network nodes and relationships in which semantically co-occurring terms with 
the term anaphylaxis. However, Botsis and Ball have only utilized abstracts rather than full 
texts that restricted the complete retrieval of information. They stated that generating a 
corpus of full text is time-consuming and expensive. In addition, their developed approach 
was for only one condition "anaphylaxis" where more generalization needs further 
research. Moreover, they did not consider all features of a phenotyping definitions where 
some features might not be necessary for anaphylaxis, such as laboratory values, but can 
be important for other conditions (Botsis & Ball, 2013). 
PheKnow-Cloud (Henderson et al., 2017) is another study that used knowledge-
discovery from literature. PheKnow-cloud leveraged clinical expertise from PubMed Open 
Access Subset by using the evidence of co-occurrence in sentences as an automatic 
validation. The user needs to specify candidate phenotypes that were derived from EHR 
data. Then, these candidate phenotypes can be validated by screening the literature as a 
validation tool. The phenotype significance metric called lift was used to measure the 
clinical significance of candidate phenotypes (Henderson et al., 2017). The limitation of 
this tool is the need to have a potential candidate generated from other source rather than 
generating potential candidates, which is our goal in this study. 
Identification of cohorts of chronic diseases, such as diabetes, has critical value for 
the “clinical quality, health improvement, and research” as well as the development of 
patients’ registries and research datasets (R. L. Richesson, Rusincovitch, et al., 2013). With 
the utilization of standard phenotyping definitions, it enables comparison and aggregate 
analysis of patients on several levels, including population characteristics, risk factors, and 
complications (R. L. Richesson, Rusincovitch, et al., 2013). Recent results support the 
evidence that a phenotype or disease, like asthma and heart failure, are not single entity, 
but rather a collection of phenotypes. Data-driven approaches are unbiased and able to 
reveal unknown knowledge. Such analysis tools supported with large datasets are capable 
of discovering, for example, unknown clinical sub-phenotypes of diseases (Lasko et al., 
2013). The hypothesis generation of risk factors involves the use of statistical models to 
“describe the relationship between a condition and phenotypic and clinical data” (Ouyang, 
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Apley, & Mehrotra, 2016). These methods are considered unsupervised methods with the 
goal of minimizing human involvement (Lasko et al., 2013). 
Text mining analysis, especially dictionary-based approaches, using literature text 
is well-studied in the biomedical field (Kilicoglu et al., 2018). One of the text mining tasks 
is the information extraction and knowledge discovery through development of an 
automated approaches for identification of co-occurrence concepts (Krenn, 2000). In the 
medical field, co-occurrence association measures have been used to identify similar 
diseases, predict disease-causing genes (Henry, McQuilkin, & McInnes, 2018), and 
perform literature-based discovery (Henry et al., 2018; Yetisgen-Yildiz & Pratt, 2006). 
Lexical-based approaches can be used to recognize co-occurrence of two biomedical 
concepts. Recurrent concept combinations are expected to contain co-occurrence 
candidates than low ranking combinations (Krenn, 2000). The association measures are 
used to evaluate the likelihood of significant pattern of co-occurrences between any two 
concepts. After that, networks can be built using co-occurrence information; for example, 
Davazdahemami and Delen (Davazdahemami & Delen, 2018) used literature to build a 
network for drug-ADE associations. They reported that when this approach if replicated 
on a larger scale it can generate better results (Davazdahemami & Delen, 2018). 
 
4.2 Background 
4.2.1 Phenotypes in EHRs 
Phenotype is an observable property that result from interaction of an organism’s 
characteristics and environmental factors (N. Alnazzawi et al., 2015; Frey et al., 2014). In 
the medical domain, clinical phenotypes can be defined as one or collection of observable 
and measurable patient’s characteristics within a population (Frey et al., 2014; Glueck et 
al., 2016). The current phenotyping definitions are phenotype-specific, and are composed 
of an application of decision logics using EHR-based features and specifications (Carroll 
et al., 2011; Lasko et al., 2013; Mo et al., 2015; Yu et al., 2015).  The phenotype features 
can come from EHR data, including structured data (coded data), occurrences of two coded 
temporal events, unstructured narrative text, occurrences of clinical concepts (Peterson & 
Pathak, 2014; Yu et al., 2015), or relations between events (Park & Choi, 2014). Some 
studies showed an improved accuracy when EHR phenotyping definitions are combining 
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coded and clinical narratives than using one of them (Liao, Cai, et al., 2015; Roden & 
Denny, 2016; Yu et al., 2015). While other studies showed that structured data can be more 
effective in retrieving cohort data (Denny, 2012). 
EHR phenotyping can be complex; for example, recent studies showed that heart 
failure or asthma are not composed of single entities, but rather a collection of phenotypes 
that can overlap with historical diseases (Lasko et al., 2013). Current technologies are not 
practical in deepen our understanding of phenotypes. Thus, one of the major challenges is 
the insufficient phenotype granularity, which can result in uncertainty during the process 
of EHR phenotyping (Glueck et al., 2016). Therefore, the analysis of EHR phenotypes 
requires a deep understanding of all aspects of phenotypes. Computational algorithms 
capable of dealing with massive amount of data are necessary to generate new discoveries 
from EHR data (Kotfila & Uzuner, 2015). 
An understanding of phenotype-disease associations helps in diagnosing of 
diseases, improving treatments, identification of disease’s etiology (N. Alnazzawi et al., 
2015; Glueck et al., 2016). A phenotype can appear as an abnormal observation of one or 
a combination of the following: physiological, behavior, genetic, and physical traits. In 
addition, other factors can play an important role in the origin phenotypes, such as 
ethnicity, gender, and environment. Therefore, spectrums of phenotypic abnormalities are 
highly considered to better understanding of the phenotype-disease associations (Glueck et 
al., 2016). The use of EHR data has facilitated “novel clinical decision support, biomedical 
association studies, auditing and EHR security, and the cost effectiveness of treatments” 
(Chen et al., 2015). The research on the EHR data enable conversion of this data into 
knowledge (Chen et al., 2015). 
Phenotype definitions are used for cohort identification utilizing risk factors, 
clinical or medical characteristics and complications (Yadav et al., 2018). For example, 
coronary artery disease (CAD) study on three cohorts discovered that the risk of CAD is 
63.68% lower in rheumatoid arthritis and inflammatory bowel disease than diabetes 
mellitus. They developed CAD algorithm to compare the risk factors across diseases. 
However, their use of EHR data affected its generalization. The authors stated that one of 
the major limitations of the study is generalization of the algorithm due to ascertainment 
and bias on recording risk factors in EHR data facilities.  They recognized the need to 
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identify risk factors across other population (Liao, Ananthakrishnan, et al., 2015). 
Therefore, we believe that our approach provides more generalized evidence that can be 
applied over different populations. 
 
4.2.2 Co-occurrence and graph-based representation 
In Natural Language Processing (NLP), words combinations or associations are an 
important source of information (Evert, 2005; Kolesnikova, 2016), such as knowledge 
generation, text analysis and generation, knowledge extraction, text summarization, and 
information retrieval (Kolesnikova, 2016). Such collection of co-occurrences of concepts 
derived from real-world data e.g. sentences from literature creates important source of 
knowledge. A database can be created to represent these collocations of co-occurrences 
(Krenn, 2000) where frequency information of co-occurrences, when interpreted, can 
indicate a statistical association (Evert, 2005). Section 4.2.3 provides a summary about 
these measures of associations. 
Lexical-based approaches are used for recognition of co-occurring concepts rather 
than semantics (Krenn, 2000). One of the advantages of this technique is that it does not 
involve complicated linguistic theories (Chung & Lee, 2001). Mainly, we used positional 
co-occurrence when the terms co-occur within a certain distance (Evert, 2005). For 
example, the distance that we used in this study is the co-occurrence of two terms within 
the same sentence, and we called it direct co-occurrence. The direct co-occurrence can be 
extended using the network graph approaches into indirect co-occurrences. 
 
4.2.3 Measures of associations 
Association measures are statistical tests that help to distinguish between random 
co-occurrences and true associations. These frequencies and measures are used for ranking 
of pairs and/or selection of cutoff threshold. Co-occurrences are called candidates until 
specified criteria is employed (Evert, 2005). There are several associations’ measures 
models. Frequency counts associations is the simplest co-occurrence measure for 
association. However, frequency performance is weak because it only considers positive 
co-occurrences and does not consider the frequency of single words/terms. On the other 
hand, statistical lexical-based co-occurrence approaches provides better results, such as 
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DICE coefficient (Krenn, 2000). Association coefficients, such as Jaccard’s and Dice’s, 
are also called similarity coefficients (Chung & Lee, 2001). 
Dice coefficient (Smadja, McKeown, & Hatzivassiloglou, 1996) is one of the 
simplest association measures that considers the significance of each combination of 
words. Dice coefficient sums up the conditional probabilities p(X|Y) and p(Y|X) with equal 
weights and it considers the significance of individual words. This lowers the bias when 
data frequency is relatively low (Krenn, 2000). The degree of an association between two 
words or linguistic elements can be measured by “coefficients of association strength from 
the observed data” (Kolesnikova, 2016). Dice coefficient outperformed other association 
measures as well as it showed better performance for dictionary-based co-occurrences 
(Kolesnikova, 2016). 
In this work, we aimed to build data-driven approaches and hypothesis-driven 
investigation for high-throughput phenotype representations. We utilized our large-scale 
corpus data predicted from literature mining of full text sentences. The aim for our work is 
to use the corpus of sentences (from Chapter 3) with evidence of phenotyping information 
to identify potential set of computational phenotype candidates. Biomedical concepts were 
used for statistical identification of co-occurrences within the sentences. Reducing terms 
to their preferred terms is one approach for the identification of recurrent concepts with the 
aim to increase co-occurrences (Krenn, 2000). Co-occurrence approaches and association 
measures were used for extraction and ranking of the biomedical and procedure concepts. 




4.3.1 Co-occurrence analysis of phenotypes 
Co-occurrence analysis is a functional relationship and occurrence of two medical 
terms within a sentence (Evert, 2005; Fleuren & Alkema, 2015). Table 15 shows the 
dictionary used to recognize medical entities in sentences. After that, co-occurrences of the 





Table 15 Dictionary used to extract co-occurrence and MedDRA normalization 
 
Terminology 
Number of terms in 
the dictionary 
Percent of terminology 
in the dictionary 
Normalization to MedDRA 
Preferred terms 
Mapped Not mapped 
MedDRA LLT 69955 9.5% 69955 0 
SNOMED CT 580580 79.2% 15062 565518 
MEDIC (MESH) 78650 10.7% 44100 34550 
MEDIC (OMIM) 1643 0.2% 67 1576 
ICD9 Procedure 2354 0.3% 0 2354 





After the extraction of co-occurrence terms, they were represented as a document-
term matrix (DTM). DTM is a matrix that the rows are the sentences and the columns are 
the terms. This was further converted into co-occurrence matrix (n x n); n is the total 
number of terms. The matrix has the frequency of co-occurring phenotypes in columns and 
rows (Figure 8). After that, all terms were normalized by mapping them to MedDRA 
preferred terms. 
 
4.3.2 DICE scores for ranking phenotypes 
DICE coefficient is one of the statistical methods used in measuring the degree of 
the association between words x and y in an observed dataset (Evert, 2005). Olga 
Kolesnikova study (Evert, 2005) showed that DICE coefficient outperformed other 




 F(x) Number of occurrences of x (StartTerm) 
 F(y) Number of occurrences of comparison term y 
 F(xy) Number of joint occurrences of x (StartTerm) and y 
To calculate DICE coefficient, we start with an ADE or phenotype of interest which 
we called StartTerm and calculated its associations. All terms with zero DICE scores were 
eliminated as these indicate that they appeared in the corpus but did not co-occur with 
StartTerm. Terms were ranked in descending order where the highest means more 
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significant associations. Directly co-occurred terms are terms that co-occurred with 
StartTerm in the same sentence. Indirectly co-occurred terms are terms that did not co-
occurred with StartTerm in the same sentence. Indirectly co-occurred terms were derived 
by finding the co-occurred terms for the top-ranked 5% directly co-occurred terms with 
StartTerm. The 5% is our selected threshold, but this can be changed. The relation here is 
when A is related to B and B is related to C, so A is related to C. Both direct and indirect 
terms were utilized in building the network graph of the starting term. NER and term 
extraction were performed in Python and Perl. The co-occurrence analysis and DICE 
ranking (sections 4.3.1 & 4.3.2) were performed in R1 (Wiedemann & Niekler). 
 
4.3.3 Network graphs 
To visualize the co-occurrence results, we used DICE coefficient scores for a 
selection of significant phenotype terms with the StartTerm (Figure 8). Terms were 
normalized to MedDRA PT (Table 15) to facilitate the generation of the network. Both 
direct and in-direct terms were used to generate the co-occurrence network. Network 
graphs were evaluated and visualized in Cytoscape (Shannon et al., 2003). 
 
                                                 
1 The code and R packages can be found in “Tutorial 5: Co-occurrence analysis by 









4.3.4 Evaluation of literature-based co-occurrence results 
To validate and evaluate the phenotypes generated from co-occurrence analysis, we 
performed some further analysis. The goal is to compare the phenotype terms from 
literature with existing sources for terminologies, phenotyping definitions, and clinical 
guidelines. 
 
4.3.4.1 Evaluation of derived co-occurrences with 50/50 sample split of articles 
To evaluate if the co-occurrences are reproducible when derived from two 
independent sets of articles, we randomly divided the dataset into two subsets based on the 
number of articles per set. We used “Myopathy” as the StartTerm. The co-occurrence 
analysis and DICE ranking were performed on each of the datasets separately. Paired T-
test in R was used to compare the co-occurred terms with “Myopathy” in the two samples. 
 
4.3.4.2 Comparing T2DM concepts with existing sources for standard 
terminologies 
The goal is to compare phenotypes representations between our literature-based 
results and other existing terminology systems. We used the significant co-occurrence 
terms for “Myopathy” extracted from the full dataset. For comparison, we selected two 
terminology systems, MedDRA and SNOMED-CT. We compared our co-occurring 
myopathy terms to the myopathy related terms in two different terminology systems. 
 
4.3.4.3 Comparing with existing sources phenotyping definitions and clinical 
guidelines 
A number of existing sources are available providing information for case 
definitions or clinical guidelines. Here we selected PheKB1 and UpToDate2. PheKB is a 
“collaborative environment to building and validating electronic algorithms to identify 
characteristics of patients within health data.”  On the other hand, UpToDate is “an 
evidence-based, physician-authored clinical decision support resource which clinicians 
trust to make the right point-of-care decisions.” Documents from both sources were 
                                                 
1 https://phekb.org/ (accessed on September-October 2018) 
2 https://www.uptodate.com (accessed on September-October 2018) 
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converted into raw text, and terms were extracted using our dictionary and lexica (Table 
15). All of the extracted terms were compared across the three sources literature-based 
results, PheKB, and UpToDate. Our phenotypes selection for comparison was based on the 
overlap between our list of ADEs (in Chapter 2) and phenotypes that have case definitions 
available in PheKB. We evaluated 10 phenotypes that were existed in the three sources, 
which are: Diabetes Mellitus Type 2 (T2DM), acute coronary syndrome, aneurysm, 
arthritis, cardiac failure, cough, dementia, High-Density Lipoprotein (HDL) decreased, 
hypercholesterolaemia, hypothyroidism. 
 
4.3.4.4 Manual analysis of Type 2 Diabetes Mellitus (T2DM) co-occurred terms 
In this analysis, we utilized the terms for T2DM as a case study that were extracted 
from literature-based results, PheKB, and UpToDate. We manually evaluated all the terms 
for their clinical significance. For each source, we manually evaluate the phenotype by 
utilizing text documents that were used to extract the terms. For literature-based results, 
we used DICE scores of the T2DM significant terms to rank all positive sentences in our 
dataset. After that, articles were ranked in descending order using the sum of DICE score 
of sentences within that article. All of the text documents were used for manual 









4.4.1 Co-occurrence analysis results 
We used the 2,745,416 positive sentences (Chapter 3) to extract the co-occurrences 
terms. The number of sentences with co-occurrence terms is 1,414,380. The number of co-
occurrences is 12,616,465 and the number unique terms is 19,423 (Table 16). These 
phenotypes are shown in Figure 10 as a word cloud based on their frequency of unique 
terms in our dataset. 
 
Table 16 Co-occurrence analysis results 
Co-occurrence analysis 
Number of sentences with co-occurrences 1,414,380 
Number of co-occurrences 12,616,465 





Figure 10 Word cloud based on the frequency of unique concepts (Table 16) 
 
4.4.2 DICE ranking and network graphs of co-occurred terms 
For each StartTerm (a phenotype of interest), we calculated the frequencies of co-
occurrences with the StartTerm and DICE coefficient. If the DICE coefficient is 0, we 
eliminated these terms as they are not significant. For example, Table 17 shows the top 20 
terms when using “Myopathy” as StartTerm. “Rhabdomyolysis” showed the highest score 
(DICE = 0.1948) to co-occur with “Myopathy”. The number of significantly co-occurred 
terms to “Myopathy” is 573. These terms are directly co-occurred in the same sentence. 
We further extended to indirect terms by utilizing the top 5% of the direct co-occurred 
terms, and it led to additional indirect 29 terms. Table 17 shows the top 20 co-occurred 
terms for Myopathy. 
Co-occurred terms are visualized in network graphs. For example, Figure 11 shows 
the network for “Myopathy” that includes both direct and indirect phenotypes. For 
visualization purposes, we selected the top 69 co-occurred terms with “Myopathy”. 
Further, for the top 5% (n=29) indirect terms, we selected their top 10 co-occurred terms. 
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The largest node with the red color is the StartTerm, “Myopathy”. The bigger nodes have 
more edges than smaller nodes. For T2DM, Appendix 10 shows the top 20 co-occurred 
terms with T2DM and Appendix 11 shows T2DM network. 
 
 








Table 17 Top 20 terms for co-occurred terms with Myopathy in the two divided datasets (50/50) and combined (full dataset) 
Rank Myopathy (Sample 1) Myopathy (Sample 2) Myopathy (Combined) 
Concept Dice Frequency Concept Dice Frequency Concept DICE Frequency 
1 Rhabdomyolysis 0.2188 36 Rhabdomyolysis 0.1640 21 Rhabdomyolysis 0.1948 57 
2 Myalgia 0.0842 20 Myositis 0.0642 9 Myositis 0.0719 21 
3 Myositis 0.0789 12 Myalgia 0.0456 9 Myalgia 0.0667 29 
4 Muscular dystrophy 0.0592 8 Proximal muscle 
weakness 
0.0370 3 Muscular 
dystrophy 
0.0337 8 
5 SAMS 0.0555 6 Electromyography 0.0246 3 SAMS 0.0315 6 
6 Muscular weakness 0.0306 6 Dystonia 0.0238 3 Muscle 0.0268 43 
7 Muscle 0.0297 25 Muscle 0.0236 18 Muscular weakness 0.0227 8 
8 Critical illness 
polyneuropathy 
0.0295 3 Cardiomyopathy 
alcoholic 





0.0294 3 Ophthalmoplegia 0.0235 2 Polyneuropathy 
alcoholic 
0.0217 4 
10 Neuropathy peripheral 0.0259 17 Syringomyelia 0.0229 2 Proximal muscle 
weakness 
0.0217 4 
11 Systemic sclerosis 0.0259 4 Rare disease 0.0218 3 Systemic sclerosis 0.0213 6 
12 Polyneuropathy 0.0258 4 Electromyogram 0.0208 2 Cardiomyopathy 
alcoholic 
0.0209 4 
13 Motor end plate 0.0195 2 Torticollis 0.0208 2 Neuropathy 
peripheral 
0.018 24 
14 Myoglobinuria 0.0193 2 Meningitis cryptococcal 0.0206 2 Myoglobinuria 0.0163 3 
15 Cardiomyopathy 
alcoholic 
0.0188 2 Enuresis 0.0173 2 Polymyositis 0.0162 4 
16 Liver injury 0.0164 3 Polymyositis 0.0170 2 Dystonia 0.0157 4 
17 Polymyositis 0.0155 2 Systemic sclerosis 0.0156 2 Syringomyelia 0.0153 3 
18 Liver disorder 0.0152 3 Ataxia 0.0155 2 Polyneuropathy 0.0143 4 
19 Hepatotoxicity 0.0143 2 Pericarditis 0.0150 2 Cardiomyopathy 0.0122 10 




4.4.3 Evaluation and validation analysis of literature-based co-occurred 
phenotypes 
To better demonstrate the clinical significance of the extracted terms, we performed 
following validation analyses. We compared the performance of co-occurrence approach 
for “Myopathy” by splitting the dataset into two 50/50 samples based on the number of 
PMIDs randomly. “Myopathy” co-occurred terms in each of the two samples were matched 
and we conducted Paired t-test to compare their DICE coefficient scores. The results 
showed no significant difference (t =1.036, df =566, p-value=0.301, 95% CI: -0.0003 - 
0.0009) between the first and the second sample (mean of the difference = 0.0003). This 
suggests the consistency of results in smaller subsets of full-text articles. Three terms 
appeared in the first sample but not in the second: “Electromyogram abnormal” 
(DICE=0.01), “History of hepatocellular carcinoma” (DICE=0.009), and “MPD1” 
(DICE=0.009). On the other hand, three terms appeared in the second sample only: 
“Inclusion body myositis” (DICE=0.01), “able to run” (DICE=0.01), and “unable to run” 
(DICE=0.01). All of these 6 terms have co-occurred with “Myopathy” only one time, 
which explains why they did not appear in both subsets. Table 17 shows the top 20 terms 
in each sample. 
In the second analysis, we compared the co-occurred terms with myopathy to the 
existing sources of terminologies, MedDRA and SNOMED-CT. Figure 12 (A & B) shows 
the representation of terms for “Myopathy” in MedDRA and SNOMED-CT, respectively. 
In MedDRA, for example, “Myopathy” is one of the preferred terms for (“Myopathies”, 
MedDRA HLT). On a lower level, “Myopathy” has 14 LLT terms that serve are synonyms 
for it. On the other hand, in SNOMED-CT, “Myopathy” is considered as the root term, 
which has around seven synonym terms. SNOMED-CT describes relationships where in 
Figure 12 B “Myopathy” is also described as “Is a” “Disorder of muscle” and “Is a” 
“Skeletal muscle (body structure)”. This example illustrates the classification structure for 
“Myopathy” in each standard. We note that in our NER tasks for recognizing terms, we 
used both dictionaries. Overall, these terms are already extended to the same levels as the 
examples in Figure 12. Literature-based phenotypes adds concepts associations (direct and 









The third analysis was to compare our literature-based co-occurred phenotypes to 
the phenotypes in PheKB and UpToDate. Table 18 shows the total count of terms for each 
phenotype in each of the sources. If we treat the total terms from three databases as total 
information, our literature based co-occurred phenotypes always possess the most the 
information, i.e. they have much more terms than the other two phenotype definition 
sources. For each of these ADEs, we provide the Venn diagram (Figure 13) for the three 
sources, the top terms for each ADE, and the network graph. 
 
Table 18 The number of terms from text sources (Literature, PheKB, UpToDate) in ten 
selected phenotypes 
Phenotypes of Interest Total count of terms Total 
combined Literature (%) PheKB (%) UpToDate (%) 
Diabetes Mellitus Type 2 
(T2DM) 
508 (63.8%) 106 (13.3%) 498 (62.6%) 796 
Acute coronary syndrome 1203 (96.5%) 36 (2.9%) 197 (15.8%) 1247 
Aneurysm 1487 (89.4%) 120 (7.2%) 432 (26.0%) 1664 
Arthritis 2776 (93.9%) 169 (5.7%) 539 (18.2%) 2956 
Cardiac failure 412 (58.0%) 119 (16.8%) 406 (57.2%) 710 
Cough 2299 (93.9%) 31 (1.3%) 526 (21.5%) 2449 
Dementia 2484 (90.5%) 38 (1.4%) 793 (28.9%) 2744 
High-Density Lipoprotein 
(HDL) decreased 
405 (78.9%) 33 (6.4%) 197 (38.4%) 513 
Hypercholesterolaemia 1307 (87.7%) 340 (22.8%) 147 (9.9%) 1491 
Hypothyroidism 1418 (81.8%) 137 (7.9%) 678 (39.1%) 1733 
 
Finally, we manually compared T2DM phenotypes among literature-based 
discovery, PheKB and UpToDate. Figure 9 shows the data processing steps. All of the 
terms were extracted using our lexica (Table 15) and NER method. For literature-based, 
we used the DICE scores for T2DM co-occurred terms and their synonyms to recognize all 
sentences with presence of these terms. The DICE scores for each article’s sentences were 
summed. The total number of articles that showed DICE score more than zero was 36,172 
articles with a total of 903,120 sentences (Figure 9). Articles with higher DICE scores 
suggest that they contain more relevant T2DM definition-related sentences. For PheKB 
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and UpToDate, the relevant T2DM texts were extracted and relevant terms were 
recognized using NER method. 
Figure 13 shows a Venn diagram for the overlap of T2DM terms across the three 
sources. There were around 59 terms overlapped across the three sources. The overlap 
between Literature-based and PheKB was on 78 terms. Therefore, the literature-based 
T2DM covered 73.6% (n= 78 out of 106) of the PheKB terms. Then, we further looked 
into all of the terms (n = 796) from three sources combined. We evaluated each of the terms 
manually and assigned a category for it. Table 19 shows the categories, their counts in each 
of the sources, and examples for some overlapped terms. 
Examples of risk factors that we found in our literature-based discovery, but not in 
PheKB and UpToDate are in Appendix 12. All of these concepts were direct relationship 
with T2DM, which means that they appeared in the same sentence. Appendix 12 shows 
examples of sentences for some T2DM risk factors or complications that appeared only in 
literature-based definitions. These sentences were selected from our dataset for illustration 
and might not have T2DM terms within the same sentence. However, these terms provide 
sentences with phenotyping definition information for phenotypes with relation to T2DM. 
Each of these concepts was mapped to its MedDRA PT. 
 






Table 19 Categories of candidate phenotypes for Type 2 Diabetes Mellitus in the three sources 






Terms appeared in the three sources 






Refers to an illness, 
condition, disease, 
disorder, or clinical 
features that describes 
patient’s status to establish 
a clinical diagnosis. It can 
be also other related 
conditions, such as co-
morbidities. 
68 (13.4%) 11 (10.4%) 83 (16.6%) 6 (10.2%) Type 2 diabetes 
mellitus 
0 
Type 1 diabetes 
mellitus 
1 (0.23267) 
Diabetes type 4 (0.01513) 
Hyperglycaemia 15 (0.00949) 
Diabetes mellitus 19 (0.00812) 
Glycosuria Indirect relationship 
(T2DM | Gestational 
diabetes | Glycosuria) 
Risk factor or 
complication 
Factors that increase the 
risk of diabetes and reduce 




41 (38.7%) 199 
(39.9%) 










Family history 49 (0.00399) 




Female 200 (0.00195) 














Pregnancy 314 (0.00085) 
Hypertension 355 (0.00064) 
Weight 366 (0.00057) 
Kidney 371 (0.00052) 
Smoking 374 (0.00052) 
Fall 401 (0.00043) 
Ethnicity 432 (0.00032) 
Race 435 (0.00031) 
Gender 439 (0.00029) 
Birth 449 (0.00023) 
Polycystic ovaries Indirect relationship 
(T2DM | Gestational 




Refers to the terms for 
clinical measurements, or 
laboratory tests or results. 
38 (7.5%) 14 (13.2%) 58 (11.6%) 9 (15.2%) Blood insulin 6 (0.0137) 
Drug tolerance 22 (0.0067) 




Fasting 122 (0.0029) 
Body mass index 289 (0.0010) 
Haemoglobin 316 (0.0008) 




(T2DM | Tolerance | 
Glucose tolerance test) 
Procedure Refers to the procedures 
that are performed as a part 
of a healthcare delivery, 
such as surgery. 




Definition criteria Terms that describe the 
medical entity within the 
phenotype definition, but 
not specific enough to be 
categorized as a diagnosis 
or a procedure 
15 (3%) 8 (7.5%) 8 (1.6%) 6 (10.2%) Diagnosis 266 (0.00131) 
Problem 319 (0.00082) 
History 359 (0.00062) 
Screening 370 (0.00054) 
Included 393 (0.00045) 





General / remove Terms that are either too 
general for describing a 
phenotype or disease, or 
can be a noise. 
128 
(25.2%) 
28 (26.4%) 135 
(27.1%) 
13 (22%) Mass 165 (0.00233) 
Syndrome 177 (0.00222) 
Concentration 312 (0.00089) 
Related 324 (0.00079) 
Management 334 (0.00076) 
Education 341 (0.00073) 
Disease 346 (0.00068) 
Euphoric mood 384 (0.00049) 
Will 386 (0.00048) 
Single 434 (0.00032) 
Observation 442 (0.00025) 
Counseling Indirect relationship 
(T2DM | supervision | 
counseling) 
Ovary Indirect relationship 
(T2DM | Gestational 
diabetes | ovary) 








Terms with ranking are the terms that have direct relationship with T2DM. On the other hand, terms without ranking are the indirect 







4.5.1 Primary findings 
The corpus of sentences predicted as positive (from Chapter 3) with evidence of 
phenotyping information were used for further discovery. Using these sentences, we used 
lexical-based named entity recognition to extract co-occurrences (n=12,616,465) and 
identify unique phenotypes (n=19,423). The statistical co-occurrence approach called 
DICE coefficient was used to rank co-occurrence concepts for a phenotype of interest. We 
used several approaches to validate the co-occurrences. First, for myopathy phenotype, we 
divided the dataset into 50/50 randomly, extracted co-occurrences concepts for each half 
with “Myopathy”. We applied paired t-test on the co-occurrence concepts and it showed 
no significant difference between the two datasets. Second, we compared the co-occurrence 
concepts with myopathy from the whole dataset with other existing terminologies, such as 
MedDRA and SNOMED CT. According to our observations, existing terminologies do not 
provide the relationships that were observed in our literature-based phenotypes. We believe 
that literature-based concepts would generate unknown relationships for a phenotype of 
interest and serve better for the task of phenotyping and cohort identification. Third, 
literature-based phenotypes were further compared to phenotypes in other existing data 
sources: PheKB and UpToDate. When considering the total terms from three data sources 
combined as total information, literature-based co-occurred phenotypes always showed the 
most information across the ten tested phenotypes. Furthermore, we showed that T2DM 
concepts that were derived from literature-based co-occurrence analysis covered terms 
with 73.6% of PheKB. Finally, we manually evaluated T2DM concepts using raw text or 
online searches. 
PheKB provides phenotyping definitions for several phenotypes through 
collaboration between institutions. The process of building these definitions are still 
manual, and relied on experts and multidisciplinary teams from several institutions. Since 
PheKB has expert-driven phenotype definitions, we further explored the missing terms by 
our method. For T2DM, we found 28 terms appeared in PheKB, but not in our literature 
concepts. We note that we are looking for exact concept match. Upon further manual 
assessment of the 28 terms contained within PheKB T2DM definition (Table 20), we found 





our literature concepts, we found that all of terms co-occurred with T2DM as direct 
relationships as single terms except one terms, which is “Diabetes with Hyperosmolarity” 
co-occurred as indirect relationship. The indirect relationship between T2DM and 
“Hyperosmolarity” means that they did not co-occur in the same sentence. Instead, T2DM 
co-occurred directly with a complication called “Ketoacidosis”, “Ketoacidosis” co-
occurred directly with “Hyperosmolarity”, and the final indirect relationship is “T2DM| 
Ketoacidosis| Hyperosmolarity”. For the 17 terms that co-occurred with T2DM as direct 
relationships, these terms appeared as single terms.  For example, “Cataract diabetic” 
appeared as “Cataract” and “Diabetic coma” appeared as “Coma” in which both terms in 
this example co-occurred with T2DM. For the 17 terms that co-occurred with T2DM as 
direct relationships, these terms appeared as single terms.  For example, “Cataract diabetic” 
appeared as “Cataract” and “Diabetic coma” appeared as “Coma” in which both terms in 
this example co-occurred with T2DM. For the term “Diabetes mellitus uncontrolled”, even 
though its exact match is not in our literature-based terms, we found diabetic complications 
that can be caused by uncontrolled diabetes as single concepts. According to the American 
Diabetes Association (ADA)1, uncontrolled diabetes can lead to several complications 
including foot complications, (Ketoacidosis) & Ketones, Kidney Disease (Nephropathy), 
High Blood Pressure, Stroke, and infections. These conditions appeared as single terms in 
our literature-based concepts that co-occurred with T2DM. 
On the other hand, 7 terms were found in PheKB were not relevant directly to 
T2DM phenotyping definition, such as “Blue” and “Circling”. We found that these terms 
appeared out of context of T2DM definition such as a description of using blue highlight 
pen during the manual extraction process. Lastly, we found that “American Indian” 
appeared as a datatype in PheKB for manual data collection. “American Indian” did not 
appear in neither directly or indirectly co-occurred terms with T2DM in literature. Instead, 
we found the term “Race” co-occurred with T2DM, which is more generalized term. 
Overall, we found that most them co-occurred with T2DM as single terms. This shows that 
the concepts contained within T2DM phenotyping definitions-related sentences overlapped 
with most concepts contained within T2DM PheKB definition excluding the 7 terms (Table 






10) that are not relevant to phenotyping definitions as well as “Chart review”. Table 10 
shows the 28 concepts with their assessment for their presentation in PheKB. Table 20 
shows the 28 concepts with their assessment for their presentation in PheKB. 
 
Table 20 Missing terms in our literature-based concepts and existed in PheKB 
T2DM terms in PheKB, but 
not in literature-based co-
occurrences 
The presence of the 
term within PheKB 
phenotype 
definition 
Reasons for missing the terms in T2DM 
literature-based co-occurrences 
1. Cataract diabetic 
2. Diabetes self management 
3. Diabetes with 
hyperosmolarity 
4. Diabetic arthropathy 
5. Diabetic coma 
6. Diabetic nephropathy 
7. Diabetic neuropathy 
8. Glycosylated hemoglobin 
measurement 
9. Macular oedema 
10. Neurological symptom 
11. Familial risk factor 
12. Family history of 
13. Glucose measurement 
14. Impaired fasting glucose 
15. History of 
16. Random blood glucose 
17. Screening for diabetes 




These terms are presented in the literature as 
single terms that co-occurred with T2DM as 
either direct (n=17) or indirect relationship 
(n=1): 
 “Cataract diabetic” appeared as 
“Cataract” 
 “Diabetes self management” appeared 
as "Diabetes self-management" 
 “Diabetes with hyperosmolarity” 
appeared as indirect relationship 
“T2DM | Ketoacidosis | 
hyperosmolarity”. 
 “Diabetic arthropathy” appeared as 
“Arthropathy” 
 “Diabetic coma” appeared as “coma” 
 “Diabetic nephropathy” appeared as 
“Nephropathy” 
 “Diabetic neuropathy” appeared as 
“Neuropathy peripheral” 
 “Glycosylated hemoglobin 
measurement” appeared as 
“Glycosylated haemoglobin” and 
“measurement” 
 “Macular oedema” appeared as 
“Oedema” 
 “Neurological symptom” appeared as 
“Neuropathy peripheral” 
 “Familial risk factor” appeared as 
“family history” and “family medical 
history” 
 “Family history of” appeared as “family 
history” and “family medical history” 
 “Glucose measurement” appeared as 
“measurement” and “Blood glucose” 
 “Impaired fasting glucose” appeared as 
“Fasting” and “Blood glucose” 
 “History of” appeared as “history" and 
"family history 
 “Random blood glucose” appeared as 
“Blood glucose” 






 “Tolerance test” appeared as “Glucose 
tolerance test” 





“Diabetes mellitus uncontrolled” is not in 
literature-based concepts, but terms for 
diabetes complications are present. 
20. American Indian Presented with 
datatypes used for 




“American Indiana” appeared in PheKB 
T2DM datatypes for extraction of patient’s 
data. In our literature, we found more 
generalized terms, such as “Ethnicity” and 
“Race, co-occurred with T2DM. 






“Chart review” is not in our literature terms. 
This term is usually appear within 










other text. These 
terms are not 
contained within 
T2DM definition. 
These terms were either noise or not relevant 
to T2DM phenotyping definition itself. In 
our manual evaluation, these terms were 
categorized as “general/remove”. 
 
4.5.2 Limitations of the study 
One limitation is the manual process of assigning categories for T2DM co-occurred 
concepts. T2DM was selected for manual validation of the co-occurred phenotypes because 
both PheKB and UpToDate provide sufficient information. For each candidate phenotype 
for T2DM, we manually reviewed the original text in each of the three sources.  We 
identified six categories, and each of them was assigned to a concept. These concepts 
include diagnosis and/or symptom, risk factor, laboratory, procedure, definition criteria, 
and general and/or remove. We note that false associations, i.e. noise, we called it “general 
and/or remove” in literature-based and UpToDate is higher than in PheKB. A possible 
reason is that literature and UpToDate sources have more textual information than PheKB 
that has finalized & post-processed T2DM definition information. Besides, when some of 
the phenotype candidates were still ambitious, we consulted a physician with specialization 
in diabetes. She reviewed the co-occurred T2DM concepts, confirmed the clinical 






Another limitation is the NER matching that it may match shorter terms rather than 
longer ones (e.g. one word rather than two). It has been reported that vocabulary mapping 
can generate some error in creating cohorts (Hripcsak, Levine, Shang, & Ryan, 2018), such 
as mapping to preferred terms or string matching. There is no standard or agreement on the 
best method for normalization, but dictionary-based methods are the best (Botsis & Ball, 
2013). However, for example, we found that the preferred term ‘Drug tolerance’ is the 
MedDRA PT for the term 'Tolerance' (see Figure 14). In this example, the correct matched 
concept is “oral glucose tolerance test”. The normalization of terms helped in increasing 
the weight of some of the co-occurrences by extending the synonyms of a phenotype. There 
are still some other challenges when using lexicon based methods such as describing the 
occurrence of hypokalemia or hyperglycemia in quantitative terms, such as changes in 
potassium or sugar levels (Iyer et al., 2014). Our network graphs helped to improve our 
understanding about the relations between concepts. It also helps in observing the patterns 
and clusters of phenotypes and the in-direct phenotypes, which provides a vision of 
unknown relationships. This was a more technical issue that can be addressed with 
advanced NLP approaches such as dependency approaches (Abacha & Zweigenbaum, 







Figure 14 Named-entity recognition for “Tolerance” and examples from literature 
sentences 
 
4.5.3 Impact and future work 
One of the major goals of this work is to decrease the need for human involvement 
during the process of developing a phenotyping definition. We used literature to derive 
evidence that supports information extraction of these definitions. We showed that we were 
able to decrease the expert involvement during this process. A researcher or an expert role 
can come later by either selecting a subset of candidate phenotypes or using all of them. 
This replaces the need to manually search for this information to define these terms in 
literature and medical guidelines sources. Besides, our data-driven approach provides less 
bias criteria for selection of phenotypes in comparison to expert involvement that their 
prior knowledge and experience might reflect their selection. We believe that utilizing this 





definition information helped in generating more accurate co-occurrence concepts. Such 
evidences were not built on a single definition, but on a large-scale set of data. We were 
able to extract over 12 million co-occurrences that the more recurrence of a co-occurrence 
means the highest its significance (Krenn, 2000). This provides research-based evidence to 
promote certain science and to derive consistent and generalizable findings built across 
several studies (Greenhalgh). We believe that our approach will support the generation and 
advancement of phenotyping definitions that were not represented previously in other 
sources, such as PheKB. In addition, it will support developing machine learning 
algorithms for automatic identification of cohorts of patients. With this, the goal is to help 
to transform the data to answer different research questions because different studies 
require different questions, and consequently designs (Yadav et al., 2018). 
One of the advantages of utilizing literature-based definitions is the availability of 
definitions that were already used in research studies; in comparison, UpToDate is only 
providing diagnosis descriptions and guidelines developed primarily for clinical use. In 
addition, PheKB did a great achievement in creating a collaborative environment for 
developing, disseminating, and validating phenotyping definitions; however, it does not 
provide the definitions for all phenotypes of interest. In fact, the already existing definitions 
might not be efficient on all research purposes (R. Richesson et al.)1. Moreover, the 
designation of medical knowledge mapping, such as co-occurrences of terms extended to 
common dictionaries, can support phenotyping. For example, a patient with rheumatoid 
arthritis with an elevated liver function test might indicate either an ADE or a result of viral 
infection, heart failure, sepsis, or other causes (Mo et al., 2015). In this example, single 
phenotypes are not sufficient to understand or identify the cohort, but rather evidence from 
other supportive sources is required to define a phenotype. The terms contained within 
literature-based phenotyping definitions is capable of providing not only phenotype 
synonyms, but also other terms with some correlation evidence in the literature, such as 
risk factors and complications. These provide more flexibility for the user in designing the 
study of interest. For example, infectious disease is one of the candidate phenotypes with 
T2DM, but not in other sources (PheKB and UpToDate). Studies showed that there are 






associations between infectious diseases and diabetes (Casqueiro, Casqueiro, & Alves, 
2012; Shah & Hux, 2003). Furthermore, the procedure of splenectomy is also shown in our 
phenotypes, but not in other sources. We found that there is literature-evidence that 
splenectomy has an association with diabetes (S. C. Wu, Fu, Muo, & Chang, 2014). More 
examples are shown in Appendix 12. 
In conclusion, data-driven approaches were used for extracting and ranking 
candidate phenotypes, including co-occurrence and network graphs, named-entity 
recognition, and DICE coefficients. Our main contribution is to decrease the human effort 
and involvement during the process of deriving phenotyping information from literature. 
Furthermore, our candidate concepts offer potential resource to support phenotyping and 
hypothesis generations, and open opportunities for EHR-based studies and validation. 







CHAPTER FIVE: DISCUSSION AND CONCLUSION 
 
This dissertation presents an innovative informatics approach for mining 
phenotyping definitions in biomedical literature. Phenotyping definitions are often not 
available for many phenotypes of interest, especially when performing high-throughput 
phenotyping. A phenotyping case definition helps in the identification of cohorts of patients 
(Q. Li et al., 2014). We further discussed current approaches to develop a phenotyping 
definition including low-throughput phenotyping (expert-driven) and high-throughput 
phenotyping (data-driven). These methods can be time-consuming, labor-intensive, biased, 
and not scalable. Therefore, we developed a text-mining pipeline combining rule-based 
and machine-learning methods to automate retrieval, classification, and extraction of 
phenotyping definitions-related sentences from literature. To our knowledge, there is no 
existing work for mining literature-based phenotyping definitions using full texts on a large 
scale. We proposed three Aims to build our text mining and knowledge discovery approach 
for mining literature-based phenotyping definitions. In this chapter, we summarize major 
findings in each Aim of this dissertation, limitations of the study, and future work. 
In Aim 1, we developed two corpora, abstracts and sentence-level full texts, as a 
first step for building a text-mining pipeline. Our selected phenotypes of interest were 
based on our research group’s interests in adverse drug reaction phenotypes, and 279 
phenotypes were selected. The list of phenotypes was used for several tasks, including data 
collection and lexica construction. For abstract-level corpus construction, two searching 
criteria were performed to retrieve abstracts relevant to EHR-based studies. A random set 
of these abstracts were selected that consists of 86 abstracts to build the full text corpus. 
Top phenotypes in these 86 abstracts are diabetes, hypertension, and heart failure. We 
downloaded their full texts, tokenized text into sentence tokens, and extracted sentences 
within methods sections boundaries. We proposed a new generalizable approach that 
serves as foundational basis for sentence-level annotations. The annotation guidelines 
aimed to annotate sentences that show contextual cues of a phenotyping definition (Botsis 
& Ball, 2013; Kirby et al., 2016; Shivade et al., 2014; Yadav et al., 2018)  and PheKB 
modalities (Kirby et al., 2016), such as laboratories and standard codes. To our knowledge, 





medication entities were not studied previously. Two annotators with degrees in 
biomedical informatics have annotated the corpus. Several inter-annotator agreement 
measurements were used to assess the reliability of the annotations and guidelines. These 
measurements are overall sentence-level percent agreement (inspired by Wilbur et al. 
(Wilbur et al., 2006)), percent agreement, and Kappa. 3971 sentences were annotated. The 
overall sentence-level percent agreement was as high as 97.8%. 
In Aim 2, we constructed a text-mining approach to automate extraction of 
phenotyping definitions’ information. Two tasks were performed to accomplish this goal: 
information retrieval of abstracts and information extraction of sentences from methods 
sections of full texts. First, we used the 279 ADEs from Aim 1 to build our lexica and 
dictionary composed of 689,752 concepts that were used in several text-mining tasks. 
Second, we trained and validated two classifiers: abstract-level and full-text sentence-level. 
These classifiers utilized informatics approaches of text-mining, machine learning, and 
rule-based. For building the abstract-level classifier, we utilized a corpus of 799 positive 
abstracts (manually reviewed from Aim 1) and 1079 negative abstracts (randomly selected 
from PubMed between 1995 and 2017). We used WEKA to test and train the abstract-level 
classifier on several classification algorithms including sequential minimal optimization 
(SMO) (Platt, 1999), logistic regression (LR) (Quinlan, 2014)), Naïve Bayes (NB) (John 
& Langley, 1995), and J48 Decision Tree (Lecessie & Vanhouwelingen, 1992). The SMO 
and J48 Decision Tree algorithms outperformed the others, and their recall, precision, and 
F-measure were as high as 97%. For building the full-text sentence-level classifier, we used 
the corpus of 3971 sentences from Aim 1. NER and feature extraction (n=339) were 
performed followed by training and testing the classifier on SMO, LR, NB, and J48 
Decision Tree algorithms. SMO and logistic regression showed the best performance, and 
their recall, precision, and F-measures were 84%. Both classifiers, the abstract-level (SMO 
algorithm) and the full-text sentence-level (LR algorithm), were used for predictions on 
large-scale literature text data. After optimizing the classifiers, we performed a large-scale 
screening of PubMed for years between 1975 to early March 2018. Using the abstract-level 
classifier, we predicted 459,406 abstracts as relevant to phenotyping. We retrieved their 
full texts, and our final set of full texts is 120,868. We processed the documents that were 





extracted for predictions (n=6,129,574). We used the full-text sentence-level classifier on 
these sentences and were able to predict 2,745,416 sentences to be relevant to phenotyping. 
We believe that these sentences provide important phenotyping information, and were used 
for further knowledge discovery in Aim 3. 
In Aim 3, we performed a discovery-based study to evaluate and validate literature-
based phenotyping case definitions of selected phenotypes. We utilized sentences with 
phenotyping information from Aim 2 (n=2,745,416). Using lexical-based approaches we 
extracted concepts (n=19,423) and their co-occurrences in the same sentence 
(n=12,616,465). We used DICE coefficient scores to rank associated concepts with a 
phenotype of interest from the most significant to the least. We showed examples for 
myopathy and Type 2 Diabetes Mellitus (T2DM). Furthermore, we performed several 
validation tests. First, we compared the performance of co-occurrence approach for 
“Myopathy” by dividing the PMIDs into two subsets randomly. From each of the two 
subsets “Myopathy” co-occurred terms were extracted. We performed a paired t-test to 
compare the DICE coefficient scores between the two subsets, and the results showed no 
significant difference between them (p-value=0.301). Second, we compared candidate 
concepts for myopathy with concepts in MedDRA and SNOMED CT. We found that our 
candidate concepts provide additional information about myopathy phenotype such as risk 
factors and comorbidities. We note that we used both MedDRA and SNOMED CT for 
recognizing concepts in sentences. Third, we compared the candidate concepts for ten 
phenotypes in three resources: our literature-based results, PheKB, and UpToDate. We 
found that our literature-based phenotypes generally generated the largest number of 
concepts. We further manually reviewed T2DM candidate concepts for their clinical 
significance. We identified six categories that were each assigned to a T2DM concept, 
diagnosis and/or symptom, risk factor, laboratory, procedure, definition criteria and general 
and/or remove. Literature and UpToDate provided the most information about the risk 
factor category phenotypes followed by the diagnosis and/or symptom category. The 
diagnosis and/or symptom category was the highest in PheKB followed by the risk factor 
category. 
In this work, we aimed to provide a scalable approach that is capable of deriving 





need to experts’ involvement. We were able to collect large number of sentences containing 
phenotyping definitions information using text-mining and machine learning classifiers. 
The collection of sentences, if collected manually, can be time-consuming and labor-
intensive. With this, we were able to extract over 2 million sentences that were predicted 
to contain phenotype definitions information. This collection of sentences can be used for 
several tasks, in future work, including information extraction and text summarization. 
We utilized these sentences for extracting knowledge relevant to phenotyping 
definitions that uses data-driven approach. Unlike traditional methods, data mining and 
data-driven approaches provide new opportunities to use several data sources for 
knowledge discovery and identification of significant associations (R. Harpaz et al., 2012). 
We compared our data-driven approach to PheKB, which their phenotype definitions are 
considered expert-driven. Expert-driven approach, as we mentioned previously, requires, 
in many cases, experts collaboration and multidisciplinary teams involvement from one or 
multiple institutions. In addition, generating new definitions in PheKB is still a long 
process. To date, PheKB contains definitions for less than 65 phenotypes, which does not 
cover all phenotypes or ADEs of interest in high dimensions. Therefore, we identified the 
need of a more scalable approach that can accelerate the process of identifying concepts 
that are relevant to a phenotype. We further found that our literature results is capable of 
deriving most terms that were presented in PheKB. Additionally, our literature-based 
concepts are not limited to the expert knowledge, which can be sometimes bias, but are 
derived from evidence presented in literature supporting the goal of discovering unknown 
knowledge. Moreover, we believe that our literature-based concepts can provide 
phenotyping candidates in large numbers that supports high-dimensional research of ADEs 
and other phenotypes. This approach of extracting and ranking terms from full texts 
showed that we were able to present terms and concepts that are related to a phenotype or 
ADE of interest. The evidence used is the co-occurrence of the concepts within the same 
sentence that we called direct relationships. We further built and extended relationships of 
our network to the terms that did not co-occur within the same sentence and we called it 
indirect relationships. Our literature-based concepts included not only phenotypes, but also 
others such as procedures, definition criteria, and laboratories. With this, we are able to 





in our literature-based concepts. These phenotype candidates facilitate standardized 
development of definitions using common terminologies. In addition, they can provide 
potential lists of concepts and relationships that can be later filtered according to research 
needs. The corpus of sentences combined with our candidate concepts can provide potential 
data sources for supporting EHR-based phenotyping research. A summarized overview of 




Figure 15 Overview of literature-based phenotyping definitions mining and knowledge 
discovery of this dissertation 
 
This work does not stand without limitations. First, the annotation process is 
expensive, time-consuming, and labor-intensive. Therefore, only two annotators annotated 
the sentences of the corpus. Testing the guidelines on more annotators with clinical 





lexical-based approaches such as feature extraction and co-occurrence extraction tasks. 
Such lexical-based approaches require frequent updates of the used dictionaries. Third, 
challenges accompanied with processing full texts are more than with abstracts. For 
example, texts converted from PDF documents had some issues with structure and 
unreadable special characters. Fourth, the manual validation process of the T2DM requires 
time and effort as well as expertise in several clinical specialties. Fifth, we note that one of 
the limitation of this study in our annotation criteria and text-mining classifier is not 
addressing the differentiation between the inclusion and exclusion criteria of a phenotyping 
definition. At this level of work in this dissertation, our goal was to extract all sentences 
that contain phenotyping definitions information. Future work can include further 
categorization and negation handling (J. J. Kim, Zhang, Park, & Ng, 2006) in order to 
differentiate between inclusion and exclusion sentences and terms contained within these 
sentences. Here are examples of definitions with inclusion and exclusion criteria, 
consecutively: 
 
“Those with specific diagnoses were included based on the following 
criteria: PA: diagnosis confirmed by pathological SIT i.e., PAC > 140 
pmol/L post the infusion of 2 L of normal saline (0.9% NaCl) over 4 h” 
(PMID28924583), and “Patients with gestational diabetes mellitus, 
secondary diabetes (steroid-induced, cystic fibrosis, hemochromatosis, and 
chronic pancreatitis), or type 1 diabetes were excluded” (PMID25986070). 
 
There are several opportunities for future work. We developed a corpus that can 
serve as a gold standard for future text-mining applications. In addition, the annotation 
guidelines can serve as a foundational basis for mining a phenotyping case definition and 
can be tested on a bigger corpus with more annotators. Furthermore, we recommend 
annotating entities including biomedical and phenotyping modalities. Such annotations can 
assist in several text-mining tasks, such as information extraction and summarization. For 
co-occurrence analysis, the candidate associations need some further validation and testing 
in other data sources such as EHR. These candidate concepts support several future 
research opportunities within areas of EHR-based research. For a phenotype of interest, 
indirect associations contribute in hypothesis generation and knowledge discovery. 
Negative outcomes, such as drug-drug interactions (DDIs) and ADEs, have 





and outcomes at different levels (Zeng, Deng, Li, Naumann, & Luo, 2018). There are 
several data sources for mining ADEs such as literature, FAERS, social media, and EHR, 
that evaluation of ADEs can use more than one source (Tafti et al., 2017). Mining ADEs 
in EHR requires phenotyping definitions, especially when dealing with large number of 
ADE phenotypes. A phenotyping definition has several research applications, which 
include diagnosis categorization, novel phenotype discovery, clinical trial screening, 
pharmacogenomics, DDIs and ADEs, and genomic studies (Zeng et al., 2018). Therefore, 
our work has the potential to build a database for ADEs phenotyping definitions and their 
associated concepts that serve as dictionaries and potential related candidates. In addition, 
the collection of sentences can support the process of future text annotation and 
summarization of ADEs phenotype definitions from literature to build this database.  
Harmonization of the definitions in one source can help in a better understating of how an 
ADE has been defined previously across different studies in the literature. By creating such 
a source, ADEs phenotyping definitions information can be available to use for the EHR-
based drug discovery research. 
In conclusion, the contribution of this dissertation is in building specific corpus for 
mining a phenotyping definition and advancing knowledge about contextual cues 
surrounding these definitions. Abstract-level and full-text sentence-level classifiers were 
built to recall relevant sentences with phenotyping information. Furthermore, this work is 
different than previous work because it uses full texts rather than abstracts to represent co-
occurrences of phenotypes. In addition, it used literature rather than EHR that suffers from 
bias. Validation of the co-occurrence candidates were performed with several methods. For 
empirical validation, text from different sources was used that differs in origin and style. 
For statistical validation, a paired t-test was used for comparing the co-occurrences derived 
from two subsets of data and showed no significant difference. Finally, this work is an 
effort to build scalable data-driven approach to represent computational phenotypes that 










Phenotypes of interest: list of 279 potential adverse drug events (ADEs) 
ADE-related phenotypes (1-150) MedDRA 
PT 
ADE-related phenotypes (151-279) MedDRA 
PT 
Abscess 10000269 Insomnia 10022437 
Acne 10000496 Irritability 10022998 
Acute coronary syndrome 10051592 Ischaemia 10061255 
Affect lability 10054196 Ischaemic stroke 10061256 
Aggression 10001488 Jaundice 10023126 
Agitation 10001497 Lethargy 10024264 
Akathisia 10001540 Leukocytosis 10024378 
Alopecia 10001760 Leukocyturia 10050791 
Anaemia 10002034 Leukopenia 10024384 
Aneurysm 10002329 Lipoatrophy 10024604 
Angina pectoris 10002383 Lipodystrophy acquired 10049287 
Anxiety 10002855 Liver disorder 10024670 
Anxiety disorder 10057666 Liver injury 10067125 
Arrhythmia 10003119 Lung disorder 10025082 
Arteriosclerosis 10003210 Lymphocele 10048642 
Arthritis 10003246 Lymphoproliferative disorder 10061232 
Asthenia 10003549 Malaise 10025482 
Asthma 10003553 Mania 10026749 
Ataxia 10003591 Menorrhagia 10027313 
Atrial fibrillation 10003658 Methaemoglobinaemia 10027496 
Atrioventricular block 10003671 Miosis 10027646 
Atrioventricular block second degree 10003677 Mitochondrial toxicity 10053961 
Azotaemia 10003885 Multi-organ failure 10028154 
Back pain 10003988 Muscular weakness 10028372 
Bipolar disorder 10057667 Musculoskeletal pain 10028391 
Blood cholesterol increased 10005425 Musculoskeletal stiffness 10052904 
Blood creatinine increased 10005483 Mutism 10028403 
Blood pressure decreased 10005734 Myalgia 10028411 
Bone marrow failure 10065553 Myocardial infarction 10028596 
Bradycardia 10006093 Myocardial ischaemia 10028600 
Bundle branch block left 10006580 Myoclonus 10028622 
Cachexia 10006895 Myopathy 10028641 
Cardiac arrest 10007515 Myositis 10028653 





Cardiac failure congestive 10007559 Nephrolithiasis 10029148 
Cardiac fibrillation 10061592 Nephropathy 10029151 
Cardiomegaly 10007632 Nephropathy toxic 10029155 
Cardiotoxicity 10048610 Nephrotic syndrome 10029164 
Cerebrovascular accident 10008190 Nervousness 10029216 
Chest discomfort 10008469 Neuralgia 10029223 
Chills 10008531 Neuropathy peripheral 10029331 
Cholelithiasis 10008629 Neurotoxicity 10029350 
Cholestasis 10008635 Neutropenia 10029354 
Chronic allograft nephropathy 10063209 Nightmare 10029412 
Cognitive disorder 10057668 Obsessive-compulsive disorder 10029898 
Coma 10010071 Oedema 10030095 
Completed suicide 10010144 Oliguria 10030302 
Confusional state 10010305 Osteopenia 10049088 
Constipation 10010774 Overdose 10033295 
Convulsion 10010904 Pain 10033371 
Coronary artery disease 10011078 Palpitations 10033557 
Cough 10011224 Pancreatitis 10033645 
Crying 10011469 Pancytopenia 10033661 
Cyanosis 10011703 Panic attack 10033664 
Delirium 10012218 Panic disorder 10033666 
Delusion 10012239 Paraesthesia oral 10057372 
Dementia 10012267 Parkinsonism 10034010 
Depression 10012378 Peptic ulcer 10034341 
Dermatitis 10012431 Peripheral sensory neuropathy 10034620 
Diabetes mellitus 10012601 Peripheral vascular disorder 10034636 
Diarrhoea 10012735 Pharyngitis 10034835 
Dissociation 10013457 Poisoning 10061355 
Dizziness 10013573 Polyuria 10036142 
Drug intolerance 10061822 Poor quality sleep 10062519 
Drug tolerance 10052804 Pregnancy 10036556 
Drug tolerance decreased 10052805 Presyncope 10036653 
Dry mouth 10013781 Productive cough 10036790 
Duodenal ulcer 10013836 Proteinuria 10037032 
Dysarthria 10013887 Prothrombin time prolonged 10037063 
Dyslipidaemia 10058108 Pruritus 10037087 
Dysphagia 10013950 Psoriasis 10037153 
Dyspnoea 10013968 Psychosomatic disease 10049587 
Dystonia 10013983 Psychotic disorder 10061920 
Electrocardiogram qt interval 10014385 Pulmonary toxicity 10061924 





Electrocardiogram st segment 10014389 Rash 10037844 
Embolism 10061169 Renal failure 10038435 
Epistaxis 10015090 Renal failure chronic 10038444 
Erectile dysfunction 10061461 Renal impairment 10062237 
Erythema 10015150 Renal tubular necrosis 10038540 
Erythema multiforme 10015218 Restlessness 10038743 
Essential hypertension 10015488 Rhabdomyolysis 10039020 
Euphoric mood 10015535 Rhinitis 10039083 
Extrapyramidal disorder 10015832 Salivary hypersecretion 10039424 
Fatigue 10016256 Schizoaffective disorder 10039621 
Fluid retention 10016807 Schizophrenia 10039626 
Flushing 10016825 Sedation 10039897 
Formication 10017062 Serotonin syndrome 10040108 
Gait disturbance 10017577 Sexual dysfunction 10040477 
Gastric ulcer 10017822 Shock 10040560 
Gastrointestinal haemorrhage 10017955 Sinus bradycardia 10040741 
Gastrooesophageal reflux disease 10017885 Sinusitis 10040753 
Gingival hyperplasia 10018283 Skin toxicity 10059516 
Glomerulonephritis 10018364 Sleep disorder 10040984 
Glucose tolerance impaired 10018429 Social avoidant behaviour 10041243 
Glycosuria 10018473 Somnolence 10041349 
Gout 10018627 Stomatitis 10042128 
Graft dysfunction 10059677 Stress 10042209 
Graft loss 10048748 Sudden cardiac death 10049418 
Graft versus host disease 10018651 Sudden death 10042434 
Grand mal convulsion 10018659 Suicidal ideation 10042458 
Gynaecomastia 10018800 Suicide attempt 10042464 
Haematoma 10018852 Syncope 10042772 
Haematuria 10018867 Tachycardia 10043071 
Haemolysis 10018910 Tardive dyskinesia 10043118 
Haemorrhage 10055798 Tension 10043268 
Haemorrhagic diathesis 10062713 Thinking abnormal 10043431 
Hallucination 10019063 Thrombocytopenia 10043554 
Hemiparesis 10019465 Thrombosis 10043607 
Hemiplegia 10019468 Thrombotic thrombocytopenic purpura 10043648 
Hepatic cirrhosis 10019641 Torsade de pointes 10044066 
Hepatic encephalopathy 10019660 Transaminases increased 10054889 
Hepatic enzyme increased 10060795 Tremor 10044565 
Hepatic failure 10019663 Type 2 diabetes mellitus 10067585 
Hepatic function abnormal 10019670 Ulcer 10045285 





Hepatitis cholestatic 10019754 Urinary incontinence 10046543 
Hepatotoxicity 10019851 Urticaria 10046735 
High density lipoprotein decreased 10020060 Vasoconstriction 10047139 
Hostility 10020400 Ventricular arrhythmia 10047281 
Hot flush 10060800 Ventricular extrasystoles 10047289 
Hyperbilirubinaemia 10020578 Ventricular failure 10060953 
Hypercalcaemia 10020583 Ventricular fibrillation 10047290 
Hyperchlorhydria 10020601 Ventricular tachycardia 10047302 
Hypercholesterolaemia 10020603 Vision blurred 10047513 
Hyperglycaemia 10020635 Visual impairment 10047571 
Hyperhidrosis 10020642 Weight decreased 10047895 
Hyperkalaemia 10020646 Weight increased 10047899 























































































































Abstracts selected by using the other searching criteria (Not included Table 1 Abstract 
Inclusion-Exclusion criteria) 
PMID Search Criteria 
11388131 hypertension electronic medical record diagnosis guideline 





hypertension electronic medical record (code OR retrospective)  
15572716 
26116311 
myopathy electronic medical record 
15758007 
20655691 






diabetes electronic medical record 
17269833 electronic medical records adrenal cohort  
17567225 electronic medical records heart failure 
22466034 stroke electronic medical record (cohort* OR retrospective)  
27940627 (cardiotoxicity OR cyanosis OR "peripheral vascular disorder" OR shock OR 
vasoconstriction OR "hypertrophic cardiomyopathy" OR "acute coronary syndrome" OR 
"angina pectoris" OR "cardiac arrest" OR infarction OR ischaemia OR" myocardial 
infarction" OR "myocardial ischaemia" OR "sudden cardiac death" OR arteriosclerosis 
OR "coronary artery disease" OR arrhythmia OR "atrial fibrillation" OR 
"atrioventricular block" OR "atrioventricular block second degree" OR bradycardia OR 
"bundle branch block left" OR "cardiac fibrillation" OR "electrocardiogram st segment" 
OR palpitation* OR presyncope OR "sinus bradycardia" OR syncope OR tachycardia 
OR "ventricular arrhythmia" OR "ventricular extrasystoles" OR "ventricular failure" OR 
"ventricular fibrillation" OR "ventricular tachycardia" OR "torsade de pointes" OR 
electrocardiogram qt interval OR" electrocardiogram qt prolonged" OR "cardiac failure" 
OR cardiac failure congestive OR cardiomegaly OR "blood pressure decreased" OR 
"blood pressure increased" OR thrombotic thrombocytopenic purpura OR "sudden 
death")  electronic health record (cohort OR surveillance or case-control or 
epidemiological or Longitudinal Studies) (code or billing or algorithm)(code OR codes 
OR algorithm* or case definition) 
23781409 (Diabetes type II) AND ("Electronic Health record" OR "Electronic Medical Record" 
OR "Electronic Health records" OR "Electronic Medical Records") AND validation  
23968235 electronic health records and anemia  
24303267 (diabetes mellitus OR glucose tolerance impaired OR glycosuria OR hyperglycaemia 





(cohort OR surveillance or case-control or epidemiological or Longitudinal Studies) 
(code or billing or algorithm) (code OR codes OR algorithm* or case definition) 
24507049 renal failure electronic medical record 
25091637 myocardial infarction electronic medical record (retrospective OR cohort*)  
25933736 electronic medical record Arrhythmia cohort  
26221186 electronic medical record Arrhythmia algorithm  
26283069 electronic health records and anemia and validation  
27317850 (drug-induced OR "adverse events" OR "DDI" OR drug drug interaction OR "adverse 
reaction") electronic health record (cohort OR surveillance or case-control or 
epidemiological or Longitudinal Studies)  
26082655 (asthenia OR chest discomfort OR chills OR dry mouth OR dysphagia OR fluid 
retention OR flushing OR formication OR haematoma OR hot flush OR hypercalcaemia 
OR hyperkalaemia OR hypokalaemia OR hypomagnesaemia OR hyponatraemia OR 
hypophosphataemia OR mitochondrial toxicity OR multi-organ failure OR oedema OR 
overdose OR pain OR poisoning) electronic health record (cohort OR surveillance or 
case-control or epidemiological or Longitudinal Studies) (code or billing or 









Annotation guidelines to annotate a phenotyping definition in the literature 
 
Inclusion category (five dimensions) 
 
Inclusion dimension 1 – Biomedical & Procedure: 
Criteria 1: The sentence should include two entities: 
Rule for criteria 1: [Biomedical|Procedrue] AND [Definition criteria] 
A. [Biomedical|Procedrue]: any biomedical or procedure terms, or any of the following: disease stages, 
symptoms, outcome of interest, diseases, laboratory & vital tests, diagnosis, procedure, clinical 
observation, person-time, Bed rest, Height, race, comorbidity, weight, sex or gender (Males, 
females, women, woman, man, men), hospitalization, birth date, surgery, chronic condition, BMI, 
age, ADE(drug-induced side effect), medication adherence, drug intolerance, cell level 
(gene/allele/SNPs/ homozygotes/dna). 
B. [Definition criteria]: can be any of the following: 
- Verbs to define a phenotype: defined, identify, identified, included, excluded, calculate, having, 
undergoing, underwent, who had, documented, diagnosed, classified, consider, selected, 
counted, captured 
- Nouns to define a phenotype: inclusion, exclusion, definition, case identification, eligible, 
presence, criteria, Algorithm, diagnostic criteria, presence, absence, parameter, incident, sign, 
history, diagnosis, diagnoses, initiation, onset, occurrence, referral, guideline, category or 
categories, stage, outcome, outcome of interest, history, endpoint, examination, severity, 
adverse event, condition of interest 
- Phrase: “Patients/case/subject/child with”, “Patients/case/subject/child had”, 
“Patients/case/subject/child who”, “primary diagnosis”, “secondary diagnosis”, “primary 
procedure”, “secondary procedure”, “based on”, evidence of. 
 
Criteria 2: Definitions in table, figure, box, or appendix. The sentence provide evidence of a 
phenotyping definition information presented in other sources, rather than text, such as table, figure, 
box, or appendix: 
Rule for criteria 2: [Table terms] AND [Definition terms] 
A. [Table terms]: Table, figure, Box, appendix. 
B. [Definition terms]: inclusion, exclusion, definition, case identification, inclusion criteria, criteria, 
phenotyping algorithm, exclusion criteria. 
 
Examples for inclusion dimension 1: 
• “[identification] of [syndromic conditions]” (PMID17567225) – criteria 1 
• “Such phenocopies [include] several [vasculitides, Buerger’s disease, embolism, trauma to leg 
arteries and other rare arteriopathies].” (PMID20819866) – criteria 1 
• “We first [calculated] the prevalence of [prehypertension], [stage] 1 [hypertension], and stage 2 
[hypertension] in the cohort.” (PMID17712071) – criteria 1 with categories or stages 
•  “The [categories] of [race] were ‘white’, ‘black or African American’, ‘American Indian or 
Alaskan’, ‘Asian’, ‘other’, and ‘unknown’” (PMID20819866) – criteria 1 with categories or stages 
• “ Six comorbid disease conditions were selected and validated using the definitions reported in 





• “The diagnoses are presented in hierarchical order in the first column of the Table.” 
(PMID23449283) – criteria 2 
 
Inclusion dimension 2 – Standard Codes: 
Criteria 1: Mention of standard terms (e.g. International classification of diseases), such as ICD, CPT, 
UMLS, SNOMED, RxNorm, billing code, Read codes, diagnostic code¸ procedure code. Accepted 
formats: Short or long form (ICD or International Classification of Diseases) or list diagnostic or 
procedure codes. 
Criteria 2: able terms with evidence of diagnostic or procedure codes list/ code definitions/algorithms: 
Table, figure, Box, appendix 
 
Example for inclusion dimension 2: 
• “a primary or any secondary discharge diagnosis (International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9-CM] code) of myoglobinuria (791.3)” (PMID15572716) 
 
Inclusion dimension 3 – Medications: 
Criteria 1: Keywords describe medications: e.g. generic drug names, prescribing, medication regimens, 
recommended agent, medication prescribed, drug dosage, drug frequency, drug route, medications, 
prescriptions. 
 
Criteria 2: Drug name o-occurs with any of the following: medication, dose, treatment, therapy, drug, 
receiving, received, prescrib, using, use, use of, inclusion, include, exclusion, exclude, definition, case 
identification, identify, eligible, presence, criteria, presence, initiation, window, dose, guideline, history, 
started, agent(s), drug, medication, exposure, who had, treated with, indication, drug dosage, drug 
frequency, drug route, cohort. 
 
Criteria 3: Medication terms co-occur with table, figure, box, or appendix: Table terms with evidence of 
a list of medication terms (Table, figure, Box, appendix). 
 
Examples for inclusion dimension 3: 
• “Other risk factors and comorbidities were ascertained based on ICD-9-CM codes, medication use 
and laboratory data.” (PMID20819866) – criteria 1 
• “Prior antihypertensive therapy was defined as the use of any AHDs before the start of amlodipine, 
which were not discontinued on or before the start of amlodipine therapy.” (PMID15323063) – 
criteria 2 
• “Table 1 outlines the recommended agents for specific comorbid conditions, as stated in our 
guideline.” (PMID12952547)- criteria 3 
 
Inclusion dimension 4 – Laboratories: 
Criteria 1: The sentence should provide evidence of using clinical measurable values (i.e. laboratory 
values, vital values, procedures, clinical) combined with real values. The sentence should include 
[Clinical or procedure] AND [Measurable value]: 
A. [Clinical or procedure]: Clinical can be any of the following: disease stages, symptoms, outcome of 
interest, diseases, laboratory & vital tests, diagnosis, procedure, clinical observation, Height, weight, 
BMI, age. 
B.  [Measurable value]: Any of the following: 
- Terms or numbers indicate measurable values: >, <, ≥,  numerical values, more than, less than. 





- Other clue words combined with real values: value, measure, measurement, reference range, 
normal range, reading, level. 
 
Example for inclusion dimension 4: 
• “Achievement of lipid goals was defined as recommended by the National Cholesterol Education 
Program Adult Treatment Panel III guidelines16 as follows: LDL-C less than 100 mg/dL, 
triglyceride level less than 150 mg/dL, HDL-C greater than 40 mg/dL, and non–HDL-C less than 
130 mg/dL.” (PMID16765240) 
 
Inclusion dimension 5 – Use of Natural Language Processing (NLP): 
Criteria 1: The sentence provides evidence of using NLP in a phenotyping definition. 
Rule for criteria 1: [Phenotype, procedure, medication] AND [NLP terms] 
A. [Phenotype, procedure, medication]: Terms can be any of the following: disease stages, symptoms, 
outcome of interest, diseases, diagnosis, procedure, clinical observation, drugs, medications. Other 
terms can be considered: person-time, Bed rest, Height, race, comorbidity, weight, sex, birth date, 
surgery, diseases, signs/symptoms, anatomical sites, procedure, drug, medication. 
B. [NLP terms]: Natural Language processing, Natural language, nlp, text mining, "wildcard 
character", “bag of words”, parses, “named entity”, rule-based, NLP algorithm, n-grams, Regular 
Expression, tokenization, normalization, stemming, Lemmatization, named entity, named entity 
recognition (NER). 
 
Criteria 2: NLP evidence in a phenotyping definition and this information explained in a table, figure, 
box, or appendix. 
Rule for criteria 2: [NLP terms] AND [Table terms] 
A. [NLP terms]: Natural Language processing, Natural language, nlp, text mining, "wildcard 
character", “bag of words”, parses, “named entity”, rule-based, NLP algorithm, n-grams, Regular 
Expression, tokenization, normalization, stemming, Lemmatization, Named entity, synonym, 
Named entity recognition (NER). 
B. [Table terms]: Table, figure, Box, appendix. 
 
Examples for inclusion dimension 5: 
• “Example of a Clinical Note Represented as a “Bag of Words” . . .  HF status positive negative 
Covariate #1 "heart" 3 1 Covariate #2 "pulmonary"” (PMID17567225) – criteria 1 
• “Rule-based and machine learning techniques were applied to clinical narratives and smoking status 
was classified as ‘past’, ‘current’, ‘smoker’, ‘non-smoker’, or ‘unknown’.” (PMID20819866) – 
criteria 1 
• “Structuring free text into useable coded data Text mining techniques were used to code diagnoses 
and drug prescriptions into ICD10 and ATC classification systems, respectively.” (PMID26209741) 
– criteria 1 medications 
• “Details of text mining for identifying diagnoses are contained in a supplementary technical 
document” (PMID26209741) – criteria 2 
 
 
Intermediate category (two dimensions) 
 
Intermediate dimension 1 – Data sources: 





• Electronic health records keywords: Electronic health records, EHR, electronic medical record, 
EMR, database, registry, biobank, biospecimen, biorepositories 
 
Criteria 2: mention of datatypes/variables used in EHR/EMR. 
• Medical records keywords: progress notes, clinical notes/reports, laboratory records/data, radiology 
report/data, pharmacy records/data, administrative records/data, insurance claims/records/data, 
patient record, patient chart, hard copy report, medical chart, computerized charts. 
• Clinical data keywords: referral, encounter, immunization, consultation report, laboratory, dismissal 
summaries, Height measurement, weight measurement, genetic data, serological data, problem list, 
scanned image, free-text, diagnoses list 
• Procedure data keywords: claim, discharge, hospitalization, visit, admission, outpatient, inpatient, 
billing, hospital report, note. 
• Other data mentions with evidence in EHR/EMR: demographic, sociodemographic, patient 
characteristics, abnormal measurement, follow-up data/measurement., encounter identifier. 
 
Criteria 3: Any clinical or procedure followed with data keywords. 
Rule for criteria 3: [Biomedical|Procedrue] AND [Data keywords] 
A. [Biomedical|Procedrue]: any biomedical or procedure terms, or any of the following: disease 
stages, symptoms, outcome of interest, diseases, laboratory & vital tests, diagnosis, procedure, 
clinical observation, person-time, Bed rest, Height, race, comorbidity, weight, sex or gender 
(Males, females, women, woman, man, men), hospitalization, birth date, surgery, chronic 
condition, BMI, age, ADE(drug-induced side effect), medication adherence, drug intolerance, 
cell level (gene/allele/SNPs/ homozygotes/dna). 
B. [Data keywords]: data, measures, measurement, value, values, datamart, dataset. 
 
Examples for intermediate dimension 1: 
• “Computerized medical and pharmacy records were reviewed for patient demographics, 
antihypertensive medications, comorbid conditions, and BP readings.” (PMID11388131) – criteria 1 
& 2 
• “The data were all based on pharmacy claim records from the KP electronic prescription system.” 
(PMID17269833) – criteria 1 & 2 
•  “This detailed information includes medical history, clinical assessments, consultation reports, 
dismissal summaries, laboratory and radiology results, and correspondence.”  (PMID17162144) – 
criteria 2 
 
Intermediate dimension 2 – Study design or Institutional Review Board (IRB): 
Criteria 1: Institutional Review Board (IRB) or Study design. If any of the following is in the sentence: 
• Study design keywords:  Retrospective, observational study, longitudinal study, case-control study, 
“random/ly sample/d”, Inception cohorts, matched controls, matched cases, intervention group, 
control group, matched pairs, case-control pairs, cohort, negative cohort, positive cohort, pilot 
study, stratified, stratification, prospective, Surveillance Study, control. 
• Gold standard keywords: chart review, manual review, notes reviewed, records reviewed, manual 
abstraction, expert panel, validation study, gold standard, standardized abstraction, standardized 
protocol. 
• IRB keywords: IRB, Institutional Review Board, study protocol 
 
Criteria 2: Any of the following co-occurrences the same sentence: 





• “chart” and “review”, “record” and “review”, or similar. 
 
Examples for intermediate dimension 2s: 
• “IRB approval The Institutional Review Board (IRB) at the Birmingham VA Medical Center 
approved this study.” (PMID24377421) – criteria 1 
• “STUDY DESIGN: Retrospective chart review.” (PMID11388131) – criteria 1 
• “To establish the control group, all active patients in the practice for less than 12 months were 
excluded.” (PMID11388131) – criteria 1 
• “Chart review Confirmation of case status by manual review” (PMID12952547) – criteria 1 
 
 
Exclusion category (three dimensions) 
 
Exclusion dimension 1 – Irrelative evidence: 
Criteria 1: Evidence of information relevant to other components of the study that might not assist in 
phenotyping. Each of the following sub-dimensions shows examples of keywords: 
• Physical location (geographic) of the study only: information about the location (country, 
county, city, zip code, region, geographic). 
Note: We exclude from this criterion general location names because it can cause ambiguity 
with other institution names that are not physical location. Examples: institute, office, clinic, 
department…etc. In addition, we exclude from this criterion: if the state name is referring to the 
hospital. 
• Ethical: consent, ethics, patient approval, patient denial, HIPAA. 
• Financial: Funding, financial support, copayment, charged, sponsor, cost, insurance 
coverage, fee-per-service. 
• Patient direct contact or enrollment: The sentence that shows evidence of a direct contact 
or enrollment of patients in the study. Example keywords: Surveys, questionnaire, 
interviews, instructions, recruitment, recruit, enrollment, enroll patients, 9-item Patient 
Health Questionnaire (PHQ-9) 
• Providers & researchers: provider, physician, medical student, nurse, team, staff, clinician, 
fellow, --ologist, resident, general practitioner (GP), team, psychiatric, principal 
investigator, case manager. 
Note: We exclude from this criterion: author 
• Performance: performance evaluation, training, performance measure, CPOE intervention, 
human error 
• Quality of care: Quality of care, Quality Assurance, Quality Improvement 
 
Examples for exclusion dimension 1: 
• “Patients from the Department of Neurology, the Newborn Service, and the Neonatal Intensive Care 
Unit were excluded, as were patients receiving mechanical or pharmacologic prophylaxis.” 
(PMID15758007) – (Type: Location) 
• “Reasons for exclusion were as follows: 6 persons denied permission to use their medical records 
for research” (PMID17162144) – (Type: Ethical) 
• “All patients were members of the managed care system and incurred a significant financial 






•  “Patients overdue for specific screening services received personalized letters recommending the 
needed service (e.g., cholesterol testing or dilated eye examinations) on a quarterly basis.” 
(PMID16567608) – (Type: Patient direct contact or enrollment) 
• “Physicians received training on the use of the electronic medical record system and associated 
tools, such as reminders, from consultants working for the vendor company.” (PMID16567608) – 
(Type: Provider) 
• “Physicians received training on the use of the electronic medical record system and associated 
tools, such as reminders, from consultants working for the vendor company.” (PMID16567608) – 
(Type: Performance) 
• “Quality of care was determined by measuring the same parameters designed to measure the 
awareness, treatment, and control of hypertension.” (PMID12461305) – (Type: Quality of care) 
 
Exclusion dimension 2 – Computational and statistical evidence: 
Criteria 1: Evidence of information relevant to computational and statistical that might not assist in 
phenotyping. Each of the following sub-dimensions shows examples of keywords: 
• Alerts: computer alerts, reminders, intranet tracking, continuously updated, robust, automated 
• Software or tool: software, platform, plugin, computer, tool 
• Statistical methods (usually toward the end of the method section). Any of the following statistical 
terms (or similar):  
 Analysis of covariance (ANCOVA)  Measure (measured) - verb 
 Area under the receiver operating 
characteristic curves (AUC) 
 Model (modeled, modeling) 
 Bayes  Multiplication [ x ] 
 Bias  Multivariate 
 Bivariate  Normally distributed 
 Calculate (calculated, calculates, 
calculations) 
 Odds 
 Charlson’s comorbidity index  Over-fitting 
 Chisquare  P value 
 Chi-square  Package 
 Cluster  Permutation 
 Coefficient  Poisson distribution 
 Compute (computed, computes) - verb  Poisson regression 
 Confidence interval, CI  Predict 
 Correlation  Predicted 
 Covariance  Predictive value 
 Cox  Probability 
 Degrees of freedom  Propensity score 
 Descriptive statistics  R statistical language 
 Equation  
 Fisher exact test  Regression 
 Fisher’s exact  Relative risk (rr)  
 Fishers test  Risk score 
 General linear model  SAS 
 Goodness-of-fit  Sensitivity, specificity 
 Graphic  Simulation 
 Imputat  SPSS 





 Kaplan-meier  Statistics, statistical 
 Kolmogorov– smirnov  T-test 
 Likelihood  Two-tailed 
 Logistic  Univariate statistical analysis  
 Logistic regression  Variance 
 Mantel–Cox (log-rank)  Welch and Brown–Forsythe 
 Mean, median, mode  Weighted 
• Structured Query Language (SQL)  
 
Examples for exclusion dimension 2:  
• “We used logistic regression models with generalized estimating equations to adjust for race, year, 
race x year interactions, age, and sex.” (PMID16567608) – (Type: Statistics) 
• “We used the proportional-hazards model to estimate the relative hazard of clinical end points 
associated with the computer alert and obtained 95 percent confidence intervals from this model.” 
(PMID15758007) – (Type: Alerts) 
 
Exclusion dimension 3 – Insufficient evidence: 
Criteria 1: Sentences with insufficient evidence. We mean by insufficient evidence is a sentence that 
does not met any of the dimensions in all categories (inclusion, intermediate, exclusion 1 & 2). 
 
Example of exclusion dimension 3: 
• “BSA= beclomethasone-salmeterol; COPD= chronic obstructive pulmonary disease; FSA= 









Entities and terms in the 86 abstracts using PubTator annotation tool 
Entity Term Count of PMID 
Chemical 60 
 1RA 1 
 alcohol 1 
 aminosalicylates 1 
 amlodipine 1 
 amlodipine besylate 1 
 atorvastatin 1 
 beclomethasone 1 
 bilirubin 1 
 calcium 1 
 cerivastatin 1 
 cerivastatin-fibrate 1 
 chloride 1 
 cholesterol 6 
 creatinine 3 
 Cys 1 
 cystatin C 1 
 DVT 1 
 fatty acid 1 
 ferritin 1 
 fibrate 1 
 fluticasone 1 
 gabapentin 1 
 glucose 1 
 Hg 1 
 irbesartan 1 
 iron 2 
 lisinopril 1 
 losartan 1 
 N 1 
 Neurontin 1 
 olmesartan 1 
 PIO 1 
 potassium 1 
 PPV 2 
 pravastatin 1 





 SABA 1 
 salmeterol 1 
 serotonin 1 
 simvastatin 1 
 statin-fibrate 1 
 statins 1 
 steroid 1 
 TGL 1 
 thiopurines 1 
 triamcinolone acetonide 1 
 triglyceride 1 
 triheptanoin 1 
 uric acid 1 
 valsartan 1 
 venlafaxine 1 
Disease 264 
 AAA 1 
 abdominal aortic aneurysm 1 
 acute gout, chronic gout 1 
 acute kidney injury 1 
 acute liver failure 1 
 acute myocardial infarction 1 
 acute renal failure 2 
 adult-onset asthma 1 
 agranulocytosis 1 
 AHDs 1 
 ALD 1 
 allergic reaction 1 
 allergic reactions 1 
 allergies 2 
 allergy 1 
 AMI 1 
 anemia 1 
 aneurysm 1 
 anxiety 1 
 anxiety symptoms 1 
 AOA 1 
 AOA to infection 1 
 ARDS 1 
 ARF 1 





 arrhythmia 1 
 arthritis 1 
 ASCVD 1 
 aspiration 1 
 asthma 3 
 atherosclerotic 1 
 Atrial Fibrillation 1 
 beta-lactams 1 
 bipolar disorder 1 
 bleeding 3 
 BP reduction 1 
 breast cancer 1 
 CAD 1 
 cancer 3 
 cancers 1 
 cardiomyopathy 1 
 cardiovascular disease 1 
 Cardiovascular Health Study 1 
 CAS 1 
 catheter-directed thrombolysis 1 
 CDT 1 
 cellulitis 1 
 cerebrovascular disease 1 
 CHD 2 
 CHF 1 
 chronic disease 1 
 chronic diseases 1 
 chronic kidney disease 1 
 chronic obstructive pulmonary disease 1 
 CKD 3 
 CLIA 1 
 cognitive impairment 1 
 congestive heart failure 1 
 COPD 1 
 coronary heart disease 3 
 CRC 1 
 Crohn disease 1 
 CRT-D 1 
 CVD 1 
 death 2 





 deep-vein thrombosis 1 
 defined as high blood pressure 1 
 dementia 2 
 depression 1 
 Device failures 1 
 diabetes 16 
 diabetes care 1 
 diabetes mellitus 8 
 diabetic 3 
 diabetics 1 
 DM 4 
 DVT 1 
 ectopic pregnancies 1 
 epilepsy 1 
 GAD 1 
 generalized anxiety disorder 1 
 GI and other bleeding complications 1 
 GI bleeds 1 
 gout 2 
 gout flares 1 
 gout-related visits 1 
 heart disease 1 
 heart failure 7 
 Hemorrhage 1 
 HEP 1 
 Hepatic encephalopathy 1 
 hepatocellular carcinoma 1 
 HF 2 
 HH 1 
 hip fractures 1 
 HLD 1 
 HLMs 1 
 HSD 1 
 HTN 1 
 hyperkalemia 1 
 hypertension 11 
 hypertensive 3 
 hypertensives 1 
 hypoglycemia 1 
 hyporesponsive 1 





 IBD 1 
 ICD 2 
 ICS 1 
 IDA 1 
 IHD 1 
 iliofemoral DVT 1 
 incremental systolic BP reduction 1 
 infection 1 
 injury research 1 
 injury type definitions 1 
 injury types 1 
 ischaemic heart disease 1 
 LBBB 1 
 LE PAD 1 
 major bleeding 1 
 MB 1 
 MDD 2 
 MELD 1 
 mineral abnormalities 1 
 Model for End-Stage Liver Disease 1 
 myocardial infarction 2 
 nephrolithiasis 1 
 neutropenia 1 
 neutrophilia 1 
 NVAF 1 
 obese 1 
 obesity 3 
 osteoarthritis 3 
 PAD 2 
 pain 1 
 pancreatitis 1 
 parkinsonism 1 
 peripheral arterial disease 1 
 pneumonia 3 
 poisoning 1 
 postoperative complications 1 
 postoperative myocardial infarction 1 
 prehypertension 1 
 Preoperative anemia 1 
 pulmonary embolism 2 





 reduced kidney function 1 
 rhabdomyolysis 2 
 rheumatoid arthritis 2 
 right bundle branch block 2 
 rupture 1 
 SCD 1 
 Scotia 1 
 sepsis 2 
 SIRS 1 
 SSS 1 
 stroke 2 
 systemic inflammatory response 
syndrome 
1 
 T2D 2 
 TBI 1 
 TBI-related condition 1 
 thrombosis 1 
 thrombus 1 
 tophaceous gout 1 
 trauma 1 
 TSAT 2 
 tumor 1 
 type 3 
 type 2 diabetes 3 
 type of injury 1 
 UC 1 
 ulcer prophylaxis 1 
 Ulcerative Colitis 1 
 ULT 1 
 urate-lowering therapy 1 
 venous thromboembolism 1 
 weight loss 1 
 white-black disparity 1 
Gene 18 
 ACE 1 
 Angiotensin-converting enzyme 1 
 ARNO 1 
 CLNK 1 
 eGFR 1 
 Epoetin 1 
 HFE 1 





 K77 1 
 KCNH2 1 
 LDLR 1 
 RYR2 1 
 serotonin transporter 1 
 transferrin 3 
 zip 1 
 3/5/2019 1 
Mutation 3 
 Cys282Tyr 1 
 His63Asp 1 


























capture lab values 
“diabetes was diagnosed if a patient had fasting plasma 
glucose of 126 mg/dl or greater, or a random glucose 





“Height and weight were used to calculate BMI, with 





defin “Confirmed adult-onset asthma (AOA) cases were 
defined as those potential cases with either new-onset 
asthma or reactivated mild intermittent asthma that had 
been quiescent for at least one year.” (PMID12952547) 
code “Cerebrovascular disease was defined as the presence of 
ICD-9-CM diagnosis codes 430. X X -438. X X” 
(PMID20819866) 
history “Cerebrovascular disease was defined as the presence of 
ICD-9-CM diagnosis codes 430. X X -438. X X or a 
history of carotid stenting or endarterectomy (ICD-9-CM 
procedure codes 00.61, 00.63, 38.10).” (PMID20819866) 
Phrases Evidence of Controls were patients without evidence of PAD. 
(PMID20819866) 
Medical records “We retrospectively reviewed the medical records to 
collect the following data: patient age, sex, smoking 
history, previous and current antihypertensive 
medications, history of intolerance to antihypertensive 
agents, comorbid conditions, and BP.” (PMID11388131) 
Medical NER 
presence – (Medical 
entities features) 
ADE “patients for hyperkalemia: (1) potassium value &gt;5.5 
mmol/L; or (2) diagnosis code for hyperkalemia.” 
(PMID17712071) 
CLINICAL “Patient has heart disease diagnosis at any time.” 
(PMID23449283) 
Procedure “The primary endpoint was an asthma-related event 
(ARE), which was defined as (1) an emergency 
department (ED) visit or (2) hospital admission with a 
primary asthma diagnosis code ICD-9-CM code 493.xx.” 
(PMID17269833) 
 




Definition terms + 
Medical NER 
Presence 
“target BP was defined as systolic BP (CLINICAL)” 
(PMID11388131) 
Inclusion terms + 
Exclusion terms 
“the inclusion and exclusion criteria of the clinical 






Inclusion terms + 
Patient terms 
“Patients with the presence of at least one diagnosis of 
major depression determined . . . from the EMR for 






Patient terms + 
with + 
abbreviation 
“Patients with CAD (as defined by a history of 
myocardial infarction . . .” (PMID16765240) 
Co-occurrence of 




[diagno | event | 
disease | identif] 
“We used the confirmed SCD diagnosis from Michigan 













IMRAD keywords used and rules 
 






"Methodology", "METHODS", "Methods", "Method", "METHOD","DESIGN, SETTING, 
AND PATIENTS", "Design, Setting, and Participants", "Design", "DESIGN", 
"SETTING", "Setting", "SUBJECTS", "Materials and methods", "Materials and Methods", 
"Material and methods", "Patients and methods", "Participants and methods", 
"Experiment", "EXPERIMENT", "Subjects and methods", "Data source", "Research 




"Discussion", "DISCUSSION", "Findings", "Finding", "Result", "RESULT", "Results",  
"FINDING", "BACKGROUND", "Background", "Introduction", "INTRODUCTION", 
"IMPORTANCE", "Keywords", "Key Words:", "In conclusion", "Conclusion", 
"CONCLUSION", "REFERENCES", "COMMENT"] 
 
Examples of rules used 
 
•  A sentence starts with a keyword 
• "part 1: CHECK IF IT ENDS WITH S" 
• "part 2: CHECK IF IT FOLLWOED BY : OR ." 
• "part 3: CHECK IF IT FOLLWOED BY SPACE" 
• "part 4: CHECK IF IT ENDS WITH —" 
• Check if the following word is upper case or number 


















Top 20 terms for type 2 diabetes mellitus (T2DM) 
Rank Type 2 diabetes mellitus (T2DM) 
Concept DICE Frequency 
1 Type 1 diabetes mellitus 0.2326 94 
2 Glucose tolerance impaired 0.0171 17 
3 Hepatocyte 0.0152 5 
4 Diabetes type 0.0151 8 
5 Mitochondrial disease 0.0148 5 
6 Blood insulin 0.0137 113 
7 Cystic fibrosis 0.0134 9 
8 Ketoacidosis 0.0130 8 
9 Impaired glucose tolerance 0.0115 9 
10 Gestational diabetes 0.0109 12 
11 Haemochromatosis 0.0105 4 
12 Malnutrition 0.0103 10 
13 Mitochondrial myopathy 0.0097 3 
14 Shin 0.0096 4 
15 Hyperglycaemia 0.0094 15 
16 Pancreatic disease 0.0087 3 
17 Insulin resistance 0.0083 10 
18 Ketosis 0.0083 3 
19 Diabetes mellitus 0.0081 419 



























Infectious disease “Patients with inflammatory or infectious diseases, 
autoimmune and rheumatic diseases, cancer, 
haematological diseases and severe renal or liver 
failure, as well as those who were under treatment 






Rhinitis “Vasomotor and allergic rhinitis…ICD-10 





Pancreatic disease “we excluded patients with other kidney diseases 
such as … pancreatic disease, and psychopathy; 
with malignant tumors and secondary DM.” 
(PMID23691167) 
16.300 
Procedure Splenectomy “Patients older than 20 years with splenic injury 
who underwent splenectomy (ICD-9-OP 41.5)…” 
(PMID25738485). 
2.502 
Laboratory Microalbuminuria “Persistent microalbuminuria was defined as a 
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